Thiophene-2-carboxamides for use in treating cancers with kit mutations
Thiophene-2-carboxamide compounds are developed to inhibit KIT and PDGFRA mutations causing drug resistance, effectively treating cancers by targeting secondary and tertiary mutations with high potency, addressing the challenge of resistance to existing TKIs.
Patent Information
- Application Number
- PCT/US2026/027115
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-04-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
There is an unmet need for compounds that inhibit KIT and/or PDGFRA having clinically relevant mutations, particularly secondary and tertiary mutations resulting in acquired drug resistance to established tyrosine kinase inhibitors (TKIs) in the treatment of cancers with KIT and/or PDGFRA mutations.
The development of thiophene-2-carboxamide compounds that act as inhibitors of KIT and/or PDGFRA, effectively targeting mutations that cause resistance to existing TKIs, such as imatinib and sunitinib, by administering a therapeutically effective amount of these compounds to subjects with cancers like GIST, AML, CML, sinonasal natural killer/T-cell lymphoma, seminoma, or melanoma.
These compounds demonstrate potent inhibition of KIT and PDGFRA mutations with IC50 values less than 300 pM, providing therapeutic benefits in treating cancers by overcoming drug resistance and inhibiting kinase activity, thereby improving treatment outcomes for subjects with drug-resistant mutations.
Smart Images

Figure US2026027115_12112026_PF_FP_ABST
Abstract
Description
THIOPHENE-2-CARBOXAMIDES FOR USE IN TREATING CANCERS WITH KIT MUTATIONS BACKGROUNDField
[0001] The present disclosure provides KIT tyrosine kinase (KIT) inhibitors and platelet- derived growth factor receptor-alpha (PDGFRA) inhibitors. KIT and PDGFRA inhibitors are useful for treating cancers comprising one or more KIT and / or PDGFRA mutations, e.g., a gastrointestinal stromal tumor (GIST), when administered to a subject.Background
[0002] KIT is a tyrosine kinase growth factor receptor expressed in diverse cell types, including Cajal cells of the gastrointestinal tract, mast cells, and subsets of hematopoietic stem cells, germ cells, and melanocytes. Normally, activation of KIT via phosphorylation regulates apoptosis, differentiation, adhesion, motility, and proliferation. KIT deficiency due to nonsense / missense mutations leads to disruption of KIT-dependent functions such as erythropoiesis, sterility, skin pigmentation, and gastrointestinal motility. Conversely, activation of KIT via gain-of-function mutations leads to tumors of KIT-dependent cell types, such as Cajal cells (gastrointestinal stromal tumor [GIST]), mast cells, and germ cells.
[0003] Gastrointestinal stromal tumors are the most common mesenchymal tumors and soft tissue sarcomas of the gastrointestinal (GI) tract. They occur anywhere along the GI tract but are found most often in the stomach (60%) or small intestine (30%) and less frequently in the rectum, colon, or mesentery. The vast majority of GIST cases are sporadic, and older age is a recognized risk factor. Mutations in tyrosine kinase (KIT) and platelet-derived growth factor receptor-alpha (PDGFRA) are found in over 80% of all primary GISTs. Alterations in neurofibromatosis type 1 gene (NF1) and succinate dehydrogenase (SDH) complex (SDHC) genes as well as altered methylation of SDHC promoter have been described as oncogenic drivers in GIST without activating mutations in KIT or PDGFRA, and they have been linked to familial and heritable syndromes (NF1 and Camey-Stratakis syndrome).
[0004] Despite a wide variation in tumor size, location, and histologic subtypes (spindle cell, epithelioid cells, and mixed type), approximately 85% of all GISTs share oncogenic mutations in at least one of two tyrosine kinases (TKs): KIT or PDGFRA. Constitutive activation of either of these TKs plays a central role in the oncogenic behavior of GIST. The early characterization of GIST mutational status is important in both the localized and metastatic settings to identify drug-resistant mutations, for example imatinib-resistant mutations, such as some primary KIT exon 17 mutations or PDGFRA D842V, or mutations that require a higher dose of a kinase inhibitor drug, e.g., imatinib. Characterization of the mutational status can also be helpful to discriminate against other less frequent mutations that may be present in these subjects and drive GIST development, with the largest group represented by SDH-deficiency frequently associated with Carney or Camey-Stratakis- Syndrome. Other subtypes have mutations in NF1 (usually associated with neurofibromatosis type I) or in BRAF or KRAS. Casuistic cases of GIST-like tumors harboring NTRK translocations have further expanded the spectrum of molecular subtypes.
[0005] In the pre-tyrosine kinase inhibitor era, GISTs (often categorized as gastric leiomyosarcomas or leiomyoblastomas) were treated within the subtype of agnostic sarcoma trials and lacked an effective systemic therapy. However, a deeper understanding of the molecular pathogenesis and driving role of the protooncogenes KIT and PDGFRA has transformed the treatment of both localized and metastatic diseases. Localized and resectable tumors are treated surgically which remains the mainstay of curative therapy for localized disease. Resected high-risk GIST is typically treated with adjuvant imatinib, whereas low-risk GIST is managed with surgery alone. Intermediate-risk GIST is managed on a per-case basis. In an advanced / metastatic setting, the established and approved treatment is imatinib 400 mg daily, with dose escalation to 800 mg at the time of progression. Said treatment regimen has been shown to provide for dramatic increases in disease control. Imatinib-refractory subjects are currently treated with sunitinib as a second-line therapy and regorafenib as third-line therapy, the latter in particular in cases of resistance or intolerance to sunitinib.
[0006] At diagnosis, a mutation in the KIT gene is found in 80% of GISTs and usually occurs in exon 11 and less commonly in exon 9. Both mutations cause ligand-independent receptor activation, which leads to uncontrolled cell growth and transformation. Primary mutations are typically a gain-of-function mutation in the juxtamembrane (JM) domain andlead to a shift in equilibrium toward a Type I active or on-state conformation of KIT and away from a Type II inactive or off-state conformation of KIT. Exon 11 primary mutations are the ones most commonly seen in GISTs (around 70% of cases) and subjects derive significant benefit from treatment with imatinib in both the adjuvant and metastatic settings, achieving a 5-year overall survival of 89-100% (depending on type of exon 11 mutation) in the adjuvant setting, and a median event-free survival just under 2 years in the metastatic setting. Primary mutations (in treatment-naive subjects) in exon 9 affect the extracellular (EC) domain of KIT, mimicking conformational changes induced by ligand binding and triggering KIT receptor homodimerization. This dimerization leads to the activation of specific intracellular signaling pathways which can lead to cancer cell proliferation, survival, and resistance. Although less common than exon 11 mutations, exon 9 mutations (10% - 15% of newly diagnosed cases) are most commonly seen in GISTs arising from the small intestine. Unlike exon 11 mutations, they benefit less from imatinib in both the adjuvant and metastatic setting.
[0007] Despite significant improvement in outcomes compared with those in the pre- mutation-driven / tyrosine kinase inhibitor therapy era, response to imatinib is not experienced by all subjects, and most subjects with GIST will ultimately develop resistance to imatinib, most commonly due to the development of secondary mutations in KIT. Secondary resistance mutations usually arise in the catalytic domain of the kinase: 1) at the ATP -binding pocket, which typically occur in KIT exons 13 and 14 and impede drug binding by decreasing van der Waals interactions thereby reducing binding affinity or by steric repulsion due to the more demanding and lipophilic isoleucine; and 2) in the activation loop (AL) encoded by KIT exons 17 and 18 and PDGFRA 18. AL mutations act by shifting the kinase into an activated Type I or on-state conformation which precludes imatinib and sunitinib from occupying the binding pocket. In contrast, ripretinib can is highly effective to inhibit secondary KIT mutations involving the activation loop. Although uncommon in primary GIST (1% - 2% of newly diagnosed cases), mutations in exons 13, 14 and 17 are often responsible for acquired imatinib resistance, with exon 17 mutations alone accounting for as many as 50% of the acquired resistance cases to imatinib, and later to sunitinib.
[0008] A mechanism of late resistance has been described. As a consequence of effective inhibition of KIT AL mutations by ripretinib, compound mutations may emerge that consistof AL and AP mutations occurring on the same allele ("in cis"). These mutations are resistant to approved KIT inhibitors or experimental KIT inhibitors currently under clinical investigation. These may occur as triple-in-cis (primary KIT exon 11 mutations) or doublein-cis mutations (primary KIT exon 17 or PDGFRA exon 18 mutations) depending on the location of the primary mutation.
[0009] An unmet need exists for compounds that inhibit KIT and / or PDGFRA having clinically relevant mutations, particularly secondary and tertiary mutations resulting in acquired drug resistance to established tyrosine kinase inhibitors (TKIs), e.g., imatinib and sunitinib, in the treatment of cancers comprising one or more KIT and / or PDGFRA mutations.BRIEF SUMMARY
[0010] The existing demand for a compound that inhibits KIT having mutations and / or PDGFRA having mutations, e.g., clinically relevant mutations that cause resistance to existing TKIs, is met by the present disclosure and is based on the finding that the compounds disclosed herein are effective in inhibiting KIT and / or PDGFRA having accumulated mutations that commonly lead to escape from established treatment regimens.
[0011] In one aspect, the present disclosure provides a compound represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof, and compounds of Table 1, and the pharmaceutically acceptable salts and solvates thereof. These compounds, and the pharmaceutically acceptable salts and solvates thereof, are collectively referred to herein as "Compounds of the Disclosure" or individually as a "Compound of the Disclosure." Compounds of the Disclosure are inhibitors of KIT having mutations and / or PDGFRA having mutations and are thus useful in treating cancers comprising one or more KIT and / or PDGFRA mutations. In some embodiments, Compounds of the Disclosure inhibit both KIT having mutations and PDGFRA having mutations. In some embodiments, Compounds of the Disclosure inhibit both KIT having mutations and PDGFRA having mutations that cause resistance to existing TKIs.
[0012] In another aspect, the present disclosure provides a pharmaceutical composition comprising a Compound of the Disclosure and one or more pharmaceutically acceptable excipients.
[0013] In another aspect, the present disclosure provides a method of treating a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject. Cancers comprising one or more KIT and / or PDGFRA mutations include, but are not limited to, gastrointestinal stromal tumor (GIST), acute myeloid leukemia (AML), chronic myelogeneous leukemia (CML), sinonasal natural killer / T-cell lymphoma, seminoma, melanoma, or mastocytosis.
[0014] In another aspect, the present disclosure provides a Compound of the Disclosure for use in treating cancers comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0015] In another aspect, the present disclosure provides the use of a Compound of the Disclosure in the manufacture of a medicament for treating cancers comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0016] In another aspect, the present disclosure provides a method of inhibiting KIT in a cell of a subject, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject. In some aspects, the subject has a cancer comprising one or more KIT and / or PDGFRA mutations.
[0017] In another aspect, the present disclosure provides a method of inhibiting KIT having mutations, e.g., mutations that cause resistance to existing TKIs, in a cell of a subject, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject. In some aspects, the subject has GIST or another cancer comprising one or more KIT and / or PDGFRA mutations.
[0018] In another aspect, the present disclosure provides a method of inhibiting PDGFRA in a cell of a subject, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject. In some aspects, the subject has GIST or another cancer comprising one or more KIT and / or PDGFRA mutations.
[0019] In another aspect, the present disclosure provides a method of inhibiting PDGFRA having mutations, e.g., mutations that cause resistance to existing TKIs, in a cell of a subject, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject. In some aspects, the subject has GIST or another cancer comprising one or more KIT and / or PDGFRA mutations.
[0020] In another aspect, the present disclosure provides a method of inhibiting KIT and PDGFRA having mutations, e.g., mutations that cause resistance to existing TKIs, in a cell of a subject, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject. In some aspects, the subject has GIST or another cancer comprising one or more KIT and / or PDGFRA mutations.
[0021] In another aspect, the present disclosure provides kits for carrying out the methods of the present disclosure.
[0022] These and other aspects, embodiments, features, and advantages of the disclosure become apparent to the person skilled in the art in the following detailed description, claims and figures. Each feature from one aspect of the disclosure can be used in any other aspect of the disclosure. Furthermore, the examples contained herein are intended to describe and illustrate the disclosure, but do not restrict it. In particular, the disclosure is not limited to these examples.DETAILED DESCRIPTIONI. Compounds of the Disclosure
[0023] In one embodiment, the present disclosure provides a compound having Formula (I):R2(I),or a pharmaceutically acceptable salt thereof, wherein:
[0024] X is selected from the group consisting of O and S;
[0025] R1is selected from the group consisting of optionally substituted aryl and optionally substituted 5- to 10-membered heteroaryl;
[0026] R2is optionally substituted 4- to 8-membered heterocyclo;
[0027] A is selected from the group consisting of a bond, i.e., A is absent, -CH=CH-, and -C=C-; and
[0028] R3, R4a, R4b, and R5are hydrogen,
[0029] with the proviso that when A is a bond, then R2is substituted 4- to 8-membered heterocyclo.
[0030] In one embodiment, present disclosure provides a compound having Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a bond.
[0031] In one embodiment, present disclosure provides a compound having Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is - CMCH=CH-.
[0032] In one embodiment, present disclosure provides a compound having Formula (I), j . P Aor a pharmaceutically acceptable salt thereof, wherein A is -C=C-.
[0033] In another embodiment, the presentOV G - disclosure provides a compound having Formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is selected from any one or more of the compounds of Table 1.Table 1Cpd. No. Structure1oV-NH2HN2HN-VXX?° Ar°\H2N-^ II A )3HN— ZoCIHH
[0034] In another embodiment, the present disclosure provides any one or more of the following compounds, or a pharmaceutically acceptable salt or solvate thereof:
[0035] In another embodiment, the present disclosure provides any one or more of the following compounds, or a pharmaceutically acceptable salt or solvate thereof:
[0036] In another embodiment, the present disclosure provides any one or more of the following compounds, or a pharmaceutically acceptable salt or solvate thereof:
[0037] In another embodiment, the present disclosure provides any one or more of the following compounds, or a pharmaceutically acceptable salt or solvate thereof:
[0038] In another embodiment, the present disclosure provides any one or more of the following compounds, or a pharmaceutically acceptable salt or solvate thereof:
[0039] The compounds provided in this section, and the pharmaceutically acceptable salts and solvates thereof, are collectively referred to herein as "Compounds of the Disclosure" or individually as a "Compound of the Disclosure."II. Compositions of the Disclosure
[0040] The therapeutic methods and uses of the present disclosure can be accomplished by administering a Compound of the Disclosure as a neat compound or as a pharmaceutical composition to a subject. The present disclosure thus provides a pharmaceutical composition comprising (i) a Compound of the Disclosure; and (ii) one or more pharmaceutically acceptable carriers. In one embodiment, the pharmaceutical compositions of the present disclosure are sterile and contain no toxic, carcinogenic, or mutagenic compounds that would cause an adverse reaction when administered to a subject.
[0041] Pharmaceutically acceptable carriers include, but are not limited to, excipients, diluents, fillers, binders, buffers, stabilizers, solubilizers, disintegrants, lipids, stabilizers, suspension agents, viscosity agents, lubricants, glidants, or other materials known in the art for use in pharmaceutical compositions and formulations, as suited to the particular dosage form desired. General considerations in the formulation and / or manufacture of pharmaceutical compositions can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
[0042] These pharmaceutical compositions of the present disclosure can be manufactured, for example, by conventional mixing, dissolving, granulating, emulsifying, encapsulating, entrapping, or lyophilizing techniques. The particular formulation depends upon the route of administration chosen. When a Compound of the Disclosure is administered orally the composition may be, for example, in the form of a tablet, capsule, powder, solution, or suspension. When administered by intravenous or subcutaneous injection, the composition may be, for example, in the form of a pyrogen-free, parenterally acceptable aqueous solution.
[0043] Pharmaceutical compositions may of the present disclosure comprise about 0.1 wt / wt % to about 95 wt / wt % of a Compound of the Disclosure, e.g., about 1 wt / wt %, about 5 wt / wt %, about 10 wt / wt %, about 15 wt / wt %, about 20 wt / wt %, about 25 wt / wt %, about 30 wt / wt %, about 35 wt / wt %, about 40 wt / wt %, about 45 wt / wt %, about 50 wt / wt %, about 55 wt / wt %, about 60 wt / wt %, about 65 wt / wt %, about 70 wt / wt %, about 75 wt / wt %, about 80 wt / wt %, about 85 wt / wt %, about 90 wt / wt %, or about 95 wt / wt % of a Compound of the Disclosure.
[0044] The pharmaceutical compositions provided in this section are collectively referred to herein as "Compositions of the Disclosure" or individually as a "Composition of the Disclosure."III. Therapeutic Methods and Uses
[0045] Compounds of the Disclosure are useful for treating or preventing diseases, disorders, or conditions in a subject in need thereof. While not being limited to any specific theory or mechanism of action, Compounds of the Disclosure are particularly useful for treating or preventing a disease, disorder, or condition wherein inhibition of KIT and / orPDGFRA provides a therapeutic benefit. Foremost among these diseases, disorders, or conditions is a cancer comprising one or more KIT mutations and / or PDGFRA mutations. Exemplary non-limiting cancers comprising one or more KIT and / or PDGFRA mutations include GIST, acute myeloid leukemia (AML), chronic myelogeneous leukemia (CML), sinonasal natural killer / T-cell lymphoma, seminoma, melanoma, and mastocytosis.
[0046] Since Compounds of the Disclosure are KIT and / or PDGFRA inhibitors, diseases, disorders, or conditions mediated by these kinases can be treated or prevented by administering these compounds or pharmaceutical compositions comprising these compounds to a subject in need thereof. The present disclosure is thus directed generally to a method for treating or preventing a disease, disorder, or condition, e.g., cancer, responsive, directly or indirectly, to KIT and / or PDGFRA inhibition in a subject, e.g., an animal, e.g., a human, suffering from, or at risk of suffering from, the method comprising administering to the subject an effective amount of a Compound of the Disclosure.
[0047] Compounds of the Disclosure typically have IC50, e.g., the drug concentration that results in 50% KIT inhibition or 50% PDGFRA inhibition, values of less than 300 pM, e.g., less than 100 pM, less than 50 pM, less than 25 pM, and less than 5 pM, less than about 1 pM, less than about 0.5 pM, or less than about 0.1 pM. In some embodiments, Compounds of the Disclosure have IC50 values of less than about 0.1 pM. In some embodiments, Compounds of the Disclosure typically have IC50 values of less than about 0.5 pM. In some embodiments, Compounds of the Disclosure have IC50 values of less than about 0.01 pM.
[0048] In another embodiment, the present disclosure provides a method of treating or preventing a disease, disorder, or condition, wherein inhibition of KIT and / or PDGFRA provides a therapeutic benefit in a subject, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject.
[0049] In another embodiment, the present disclosure provides a method of treating a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject.
[0050] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is GIST.
[0051] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is acute myeloid leukemia (AML).
[0052] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is chronic myelogeneous leukemia (CML).
[0053] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is sinonasal natural killer / T-cell lymphoma.
[0054] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is seminoma.
[0055] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is melanoma, e.g., mucosal melanoma, cutaneous melanoma, or acral lentiginous melanoma.
[0056] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is mastocytosis.
[0057] In another embodiment, the KIT mutation is a gain-of-function mutation.
[0058] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a drug-resistant mutation.
[0059] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises an imatinib resistant mutation, sunitinib resistant mutation, regorafenib resistant mutation, ripretinib resistant mutation, avapritinib resistant mutation, or any combination thereof.
[0060] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, a KIT exon 18 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, or a PDGFRA exon 18 mutation, wherein optionally the mutation is a missense mutation, insertion mutation, a deletion mutation, or a combination thereof.
[0061] In another embodiment, the one or more KIT and / or PDGFRA mutations is a primary mutation.
[0062] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises: (i) a KIT exon 9 mutation selected from the group consisting of p.A502_Y503dup, p.Y503_F504insAY, andp.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream ofcodons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from K642E, V65A, and T670I; (iv) a KIT exon 17 mutation selected from mutations involving codons 809, 816, 820, 822, or 823; (v) a KIT exon 18 mutation selected from mutations involving codon 829; (vi) a PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.581S; and / or (vii) a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0063] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises one or more PDGFRA mutations selected from the group consisting of V598F, G605A, G652E, P653Q, V658A, N659K / T, T674R / I, E675G, Y676C, G680R / E, D842V, and I843_D846del.
[0064] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the PDGFRA mutation D842V.
[0065] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the PDGFRA mutation G680R.
[0066] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the PDGFRA mutation G652E.
[0067] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the PDGFRA mutation V658A.
[0068] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises one or more KIT mutations selected from the group consisting of S476I, F522C, K642E, V654A, N655K, T670E / I, D816A / E / G / H / N / V, D820A / E / G / H / V / Y, N822I / K / Y, Y823C / D, and A829P.
[0069] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the KIT mutation T670I.
[0070] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the KIT mutation V654A.
[0071] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the KIT mutation D816A.
[0072] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the KIT mutation D820A.
[0073] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the KIT mutation N822K.
[0074] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises the KIT mutation A829P.
[0075] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises at least one primary and at least one secondary mutation.
[0076] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary KIT exon 9 mutation and a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0077] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary KIT exon 11 mutation and a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary one or more KIT and / or PDGFRA mutations exon 17 mutation, or a secondary KIT exon 18 mutation.
[0078] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary KIT exon 13 mutation and a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0079] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary KIT exon 17 mutation and a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, or a secondary KIT exon 18 mutation.
[0080] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary PDGFRA exon 12 mutation and a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, a secondary PDGFRA exon 15 mutation, or a secondary PDGFRA exon 18 mutation.
[0081] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary PDGFRA exon 18 mutation and a secondary PDGFRA exon 12 mutation, a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, or a secondary PDGFRA exon 15 mutation.
[0082] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises compound mutations selected from double-in-cis mutations or triple-in-cis mutations.
[0083] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary KIT exon 9 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0084] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary KIT exon 9 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0085] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary KIT exon 11 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0086] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a primary KIT exon 11 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0087] In another embodiment, the subject is treated with a Compound of the Disclosure in combination with one or more kinase inhibitors known in the art.
[0088] In another embodiment, the subject was previously treated with one or more kinase inhibitors known in the art.
[0089] In another embodiment, the subject was previously treated with one or more kinase inhibitors selected from the group consisting of imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatlanib, crenolanib, ripretinib, nintedanib, ponatinib, nilotinib, axitinib, cabozantinib, pazopanib, pexidartinib, bezuclastinib, dasatinib, sorafenib, and avapritinib, or a pharmaceutically acceptable salt and solvate thereof.
[0090] In another embodiment, the subject was previously treated with imatinib, sunitinib, regorafenib, ripretinib and / or avapritinib.
[0091] In another embodiment, the subject was previously treated with imatinib.
[0092] In another embodiment, the subject was previously treated with sunitinib.
[0093] In another embodiment, the subject was previously treated with regorafenib.
[0094] In another embodiment, the subject was previously treated with ripretinib.
[0095] In another embodiment, the subject was previously treated with avapritinib.
[0096] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced form of the cancer that has progressed from, or the subject was intolerant to, administration of imatinib, administration of sunitinib, administration of regorafenib, administration of ripretinib and / or administration of avapritinib, or whereinthe subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib, ripretinib, and avapritinib.
[0097] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced form of the cancer that has progressed from, or the subject was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and an optional third line administration of regorafenib or ripretinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib and / or ripretinib.
[0098] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, or a KIT exon 18 mutation.
[0099] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises: (i) a KIT exon 9 mutation selected from the group consisting of p.A502_Y503dup, p.Y503_F504insAY, andp.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from K642E, V65A, and T670I; and / or (iv) a KIT exon 17 mutation selected from mutations involving codons 816, 820 or 823.
[0100] In another embodiment, the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced form of cancer that has progressed from, or the subject was intolerant to, administration of avapritinib, or wherein the subject has a documented intolerance to avapritinib.
[0101] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, or a PDGFRA exon 18 mutation.
[0102] In another embodiment, the one or more KIT and / or PDGFRA mutations comprises a PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.P581S; or a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0103] In methods of the present disclosure, a therapeutically effective amount of a Compound of the Disclosure, formulated in accordance with pharmaceutical practice,e.g., as a Composition of the Disclosure, is administered to a subject, e.g., a human cancer patient, in need thereof. Whether such a treatment is indicated depends on the individual case and is subject to medical assessment (diagnosis) that takes into consideration signs, symptoms, and / or malfunctions that are present, the risks of developing particular signs, symptoms and / or malfunctions, and other factors.
[0104] A Compound of the Disclosure can be administered by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, intracistemal or intrathecal through lumbar puncture, transurethral, nasal, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and / or surgical implantation at a particular site) administration. Parenteral administration can be accomplished using a needle and syringe or using a high-pressure technique. In one embodiment, a Compound of the Disclosure is orally administered to a subject. In another embodiment, a Compound of the Disclosure is parenterally administered, e.g., by injection or infusion.
[0105] The toxicity and therapeutic efficacy of the Compounds of the Disclosure can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the maximum tolerated dose (MTD) of a compound, which is defined as the highest dose that causes no toxicity in animals. The dose ratio between the maximum tolerated dose and therapeutic effects, e.g., inhibiting of tumor growth, is the therapeutic index. The dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
[0106] A therapeutically effective amount of a Compound of the Disclosure required for use in therapy varies with the nature of the disease being treated, the length of time that activity is desired, and the age and the disease of the subject, and ultimately is determined by the attendant physician. Dosage amounts and intervals can be adjusted individually to provide plasma levels of the inhibitor that are sufficient to maintain the desired therapeutic effects. In some embodiments, a total dose of about 0.005 to about 10000 milligrams of a Compound of the Disclosure is administered to the subject per day. The desired total dose can be administered to a subject in a single dose or as multiple doses administered atappropriate intervals, for example as two, three, four or more subdoses per day. Multiple subdoses per day may be desired or required.
[0107] The present disclosure provides the following particular embodiments with respect to a method of treating or preventing a cancer comprising one or more KIT and / or PDGFRA mutations in a subject with a Compound of the Disclosure or a Composition of the Disclosure.
[0108] Embodiment I. A method of treating or preventing a cancer with one or more KIT mutations and / or PDGFRA mutations, e.g., gastrointestinal stromal tumor (GIST), acute myeloid leukemia (AML), chronic myelogeneous leukemia (CML), sinonasal natural killer / T-cell lymphoma, seminoma, melanoma, or mastocytosis, in a subject in need thereof, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure or Composition of the Disclosure to the subject.
[0109] Embodiment II. The method of Embodiment I, wherein the one or more mutations comprises a drug-resistant mutation.
[0110] Embodiment III. The method of Embodiment II, wherein the one or more mutations comprises an imatinib resistant mutation, sunitinib resistant mutation, regorafenib resistant mutation, ripretinib resistant mutation, avapritinib resistant mutation, or a combination thereof.[oni] Embodiment IV. The method of any one of Embodiments I-III, wherein the one or more mutations comprises a gain-of-function KIT mutation.
[0112] Embodiment V. The method of any one of Embodiments I-IV, wherein the one or more mutations comprises a platelet-derived growth factor receptor-alpha (PDGFRA) mutation.
[0113] Embodiment VI. The method of any one of Embodiments I-V, wherein the one or more mutations comprises a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, a KIT exon 18 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, a PDGFRA exon 18 mutation, or a combination thereof.
[0114] Embodiment VII. The method of any one of Embodiments I- VI, wherein the one or more mutations comprises a missense mutation, insertion mutation, a deletion mutation, or a combination thereof.
[0115] Embodiment VIII. The method of any one of Embodiments I- VII, wherein the one or more mutations comprises is a primary mutation.
[0116] Embodiment IX. The method of any one of Embodiments I- VIII, wherein the one or more mutations comprises: (i) a KIT exon 9 mutation selected from the group consisting of p.A502_Y503dup, p.Y503_F504insAY, and p.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from the group consisting of K642E, V65A, and T670I; (iv) a KIT exon 17 mutation selected from the group consisting of mutations involving codons 809, 816, 820, 822, or 823; (v) a KIT exon 18 mutation selected from the group consisting of mutations involving codon 829; (vi) a PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.581S; or (vii) a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0117] Embodiment X. The method of any one of Embodiments I-IX, wherein the one or more mutations comprises one or more PDGFRA mutations selected from the group consisting of V598F, G605A, G652E, P653Q, V658A, N659K / T, T674R / I, E675G, Y676C, G680R / E, D842V, and I843_D846del.
[0118] Embodiment XI. The method of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation D842V.
[0119] Embodiment XII. The method of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation G680R.
[0120] Embodiment XIII. The method of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation G652E.
[0121] Embodiment XIV. The method of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation V658A.
[0122] Embodiment XV. The method of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation V658A and mutation G652E.
[0123] Embodiment XVI. The method of any one of Embodiments I-XV, wherein the one or more mutations comprises one or more KIT mutations selected from the group consisting of S476I, F522C, K642E, V654A, N655K, T670E / I, D816A / E / G / H / N / V, D820A / E / G / H / V / Y, N822I / K / Y, Y823C / D, and A829P.
[0124] Embodiment XVII. The method of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation T670I.
[0125] Embodiment XVIII. The method of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation V654A.
[0126] Embodiment XIX. The method of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation D816A.
[0127] Embodiment XX. The method of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation D820A.
[0128] Embodiment XXI. The method of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation N822K.
[0129] Embodiment XXII. The method of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation A829P.
[0130] Embodiment XXIII. The method of any one of Embodiments I-XXII, wherein the one or more mutations comprises at least one primary and at least one secondary mutation.
[0131] Embodiment XXIV. The method of Embodiment XXIII, wherein the one or more mutations comprises: (i) a primary KIT exon 9 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0132] Embodiment XXV. The method of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary KIT exon 11 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0133] Embodiment XXVI. The method of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary KIT exon 13 mutation; and (ii) a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0134] Embodiment XXVII. The method of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary KIT exon 17 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, or a secondary KIT exon 18 mutation.
[0135] Embodiment XXVIII. The method of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary PDGFRA exon 12 mutation; and (ii) a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, a secondary PDGFRA exon 15 mutation, or a secondary PDGFRA exon 18 mutation.
[0136] Embodiment XXIX. The method of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary PDGFRA exon 18 mutation; and (ii) a secondary PDGFRA exon 12 mutation, a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, or a secondary PDGFRA exon 15 mutation.
[0137] Embodiment XXX. The method of any one of Embodiments I-XXIX, wherein the one or more mutations comprises compound mutations selected from double-in-cis mutations or triple-in-cis mutations.
[0138] Embodiment XXXI. The method of Embodiment XXX, wherein the one or more mutations comprises a primary KIT exon 9 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0139] Embodiment XXXII. The method of Embodiment XXXI, wherein the one or more mutations comprises a primary KIT exon 9 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0140] Embodiment XXXIII. The method of Embodiment XXX, wherein the one or more mutations comprises a primary KIT exon 11 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0141] Embodiment XXXIV. The method of Embodiment XXXIII, wherein the one or more mutations comprises a primary KIT exon 11 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0142] Embodiment XXXV. The method of any one of Embodiments I-XXXIV, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatlanib, crenolanib, ripretinib, nintedanib, ponatinib, nilotinib, axitinib, cabozantinib, pazopanib, pexidartinib, bezuclastinib, dasatinib, sorafenib, and / or avapritinib, or a pharmaceutically acceptable salt and solvate thereof.
[0143] Embodiment XXXVI. The method of Embodiment XXXV, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, ripretinib and / or avapritinib.
[0144] Embodiment XXXVII. The method of Embodiments XXXV or XXXVI, wherein the subject was previously treated with imatinib.
[0145] Embodiment XXXVIII. The method of any one of Embodiments XXXV- XXXVII, wherein the subject was previously treated with sunitinib.
[0146] Embodiment XXXIX. The method of any one of Embodiments XXXV- XXXVIII, wherein the subject was previously treated with regorafenib.
[0147] Embodiment XL. The method of any one of Embodiments XXXV-XXXIX, wherein the subject was previously treated with ripretinib.
[0148] Embodiment XLI. The method of any one of Embodiments XXXV-XL, wherein the subject was previously treated with avapritinib.
[0149] Embodiment XLII. The method of any one of Embodiments I-XLI, wherein the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of imatinib, administration of sunitinib, administration of regorafenib, administration of ripretinib and / or administration of avapritinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib, ripretinib, and / or avapritinib.
[0150] Embodiment XLIII. The method of any one of Embodiments I-XLII, wherein the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and an optional third line administration of regorafenib or ripretinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib and / or ripretinib.
[0151] Embodiment XLIV. The method of Embodiment XLIII, wherein the one or more mutations comprises a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, or a KIT exon 18 mutation, wherein, the GIST comprises a KIT exon 9 mutation selected from the group consisting of: (i) p.A502_Y503dup, p.Y503_F504insAY, and p.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from K642E, V65A, and T670I; or (iv) a KIT exon 17 mutation selected from mutations involving codons 816, 820 or 823.
[0152] Embodiment XLV. The method of any one of Embodiments I-XLIV, wherein the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of avapritinib, or wherein the subject has a documented intolerance to avapritinib.
[0153] Embodiment XL VI. The method of Embodiment XLV, wherein the one or more mutations comprises a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, or a PDGFRA exon 18 mutation, wherein the PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.P581S; or a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0154] Embodiment XL VII. The method of any one of Embodiments I-XLVI, wherein the subject is a human subject.
[0155] Embodiment XL VIII. The method of any one of Embodiments I-XLVII, wherein the method is for treating a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0156] Embodiment XLIX. The method of any one of Embodiments I-XLVII, wherein the method is for preventing a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0157] Embodiment L. The method of any one of Embodiments I-XLIX, further comprising administering one or more additional therapeutic, e.g., anticancer, agents to the subject.
[0158] Embodiment LI. The method of Embodiment L, wherein the one or more additional therapeutic agents comprises topotecan.
[0159] Embodiment LIL The method of Embodiments L or LI, wherein the one or more additional therapeutic agents comprises an irinotecan drug product (IDP).
[0160] Embodiment LIII. The method of Embodiment LII, wherein the IDP comprises irinotecan.
[0161] Embodiment LIV. The method of Embodiment LII, wherein the IDP comprises irinotecan hydrochloride.
[0162] Embodiment LV. The method of Embodiment LII, wherein the IDP comprises irinotecan sucrosofate.
[0163] Embodiment LVI. The method Embodiment LII, wherein the IDP further comprises encequidar methanesulfonate.
[0164] Embodiment LVII. The method of any one of Embodiments L-LVI, wherein the one or more additional therapeutic agents comprises radiotherapy.
[0165] The present disclosure provides the following particular embodiments with respect to a Compound of the Disclosure or a Composition of the Disclosure for use in treating or preventing a cancer comprising one or more KIT and / or PDGFRA mutations in a subject.
[0166] Embodiment I . A Compound of the Disclosure or Composition of the Disclosure for use in treating or preventing a cancer comprising one or more KIT mutations and / or PDGFRA mutations, e.g., gastrointestinal stromal tumor (GIST), acute myeloid leukemia (AML), chronic myelogeneous leukemia (CML), sinonasal natural killer / T-cell lymphoma, seminoma, melanoma, or mastocytosis, in need thereof.
[0167] Embodiment II. The compound or composition for use of Embodiment I, wherein the one or more mutations comprises a drug-resistant mutation.
[0168] Embodiment III. The compound or composition for use of Embodiment II, wherein the one or more mutations comprises an imatinib resistant mutation, sunitinib resistant mutation, regorafenib resistant mutation, ripretinib resistant mutation, avapritinib resistant mutation, or a combination thereof.
[0169] Embodiment IV. The compound or composition for use of any one of Embodiments I-III, wherein the one or more mutations comprises a gain-of-function KIT mutation.
[0170] Embodiment V. The compound or composition for use of any one of Embodiments I-IV, wherein the one or more mutations comprises has a platelet-derived growth factor receptor-alpha (PDGFRA) mutation.
[0171] Embodiment VI. The compound or composition for use of any one of Embodiments I-V, wherein the one or more mutations comprises a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, a KIT exon 18 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, a PDGFRA exon 18 mutation, or a combination thereof.
[0172] Embodiment VII. The compound or composition for use of any one of Embodiments I- VI, wherein the one or more mutations comprises a missense mutation, insertion mutation, a deletion mutation, or a combination thereof.
[0173] Embodiment VIII. The compound or composition for use of any one of Embodiments I- VII, wherein the one or more mutations comprises is a primary mutation.
[0174] Embodiment IX. The compound or composition for use of any one of Embodiments I- VIII, wherein the one or more mutations comprises: (i) a KIT exon 9 mutation selected from the group consisting of p.A502_Y503dup, p.Y503_F504insAY, and p.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from the group consisting of K642E, V65A, and T670I; (iv) a KIT exon 17 mutation selected from the group consisting of mutations involving codons 809, 816, 820, 822, or 823; (v) a KIT exon 18 mutation selected from the group consisting of mutations involving codon 829; (vi) a PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.581S; or (vii) a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0175] Embodiment X. The compound or composition for use of any one of Embodiments I-IX, wherein the one or more mutations comprises one or more PDGFRA mutations selected from the group consisting of V598F, G605A, G652E, P653Q, V658A, N659K / T, T674R / I, E675G, Y676C, G680R / E, D842V, and I843_D846del.
[0176] Embodiment XI. The compound or composition for use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation D842V.
[0177] Embodiment XII. The compound or composition for use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation G680R.
[0178] Embodiment XIII. The compound or composition for use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation G652E.
[0179] Embodiment XIV. The compound or composition for use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation V658A.
[0180] Embodiment XV. The compound or composition for use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation V658A and mutation G652E.
[0181] Embodiment XVI. The compound or composition for use of any one of Embodiments I-XV, wherein the one or more mutations comprises one or more KIT mutations selected from the group consisting of S476I, F522C, K642E, V654A, N655K, T670E / I, D816A / E / G / H / N / V, D820A / E / G / H / V / Y, N822I / K / Y, Y823C / D, and A829P.
[0182] Embodiment XVII. The compound or composition for use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation T670I.
[0183] Embodiment XVIII. The compound or composition for use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation V654A.
[0184] Embodiment XIX. The compound or composition for use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation D816A.
[0185] Embodiment XX. The compound or composition for use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation D820A.
[0186] Embodiment XXI. The compound or composition for use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation N822K.
[0187] Embodiment XXII. The compound or composition for use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation A829P.
[0188] Embodiment XXIII. The compound or composition for use of any one of Embodiments I-XXII, wherein the one or more mutations comprises at least one primary and at least one secondary mutation.
[0189] Embodiment XXIV. The compound or composition for use of Embodiment XXIII, wherein the one or more mutations comprises: (i) a primary KIT exon 9 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0190] Embodiment XXV. The compound or composition for use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary KIT exon 11 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0191] Embodiment XXVI. The compound or composition for use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary KIT exon 13 mutation; and (ii) a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0192] Embodiment XXVII. The compound or composition for use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary KIT exon 17 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, or a secondary KIT exon 18 mutation.
[0193] Embodiment XXVIII. The compound or composition for use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary PDGFRA exon 12 mutation; and (ii) a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, a secondary PDGFRA exon 15 mutation, or a secondary PDGFRA exon 18 mutation.
[0194] Embodiment XXIX. The compound or composition for use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary PDGFRA exon 18 mutation; and (ii) a secondary PDGFRA exon 12 mutation, a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, or a secondary PDGFRA exon 15 mutation.
[0195] Embodiment XXX. The compound or composition for use of any one of Embodiments I-XXIX, wherein the one or more mutations comprises compound mutations selected from double-in-cis mutations or triple-in-cis mutations.
[0196] Embodiment XXXI. The compound or composition for use of Embodiment XXX, wherein the one or more mutations comprises a primary KIT exon 9 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0197] Embodiment XXXII. The compound or composition for use of Embodiment XXXI, wherein the one or more mutations comprises a primary KIT exon 9 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0198] Embodiment XXXIII. The compound or composition for use of Embodiment XXX, wherein the one or more mutations comprises a primary KIT exon 11 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0199] Embodiment XXXIV. The compound or composition for use of Embodiment XXXIII, wherein the one or more mutations comprises a primary KIT exon11 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0200] Embodiment XXXV. The compound or composition for use of any one of Embodiments I-XXXIV, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatlanib, crenolanib, ripretinib, nintedanib, ponatinib, nilotinib, axitinib, cabozantinib, pazopanib, pexidartinib, bezuclastinib, dasatinib, sorafenib, and / or avapritinib, or a pharmaceutically acceptable salt and solvate thereof.
[0201] Embodiment XXXVI. The compound or composition for use of Embodiment XXXV, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, ripretinib and / or avapritinib.
[0202] Embodiment XXXVII. The compound or composition for use of Embodiments XXXV or XXXVI, wherein the subject was previously treated with imatinib.
[0203] Embodiment XXXVIII. The compound or composition for use of any one of Embodiments XXXV-XXXVII, wherein the subject was previously treated with sunitinib.
[0204] Embodiment XXXIX. The compound or composition for use of any one of Embodiments XXXV-XXXVIII, wherein the subject was previously treated with regorafenib.
[0205] Embodiment XL. The compound or composition for use of any one of Embodiments XXXV-XXXIX, wherein the subject was previously treated with ripretinib.
[0206] Embodiment XLI. The compound or composition for use of any one of Embodiments XXXV-XL, wherein the subject was previously treated with avapritinib.
[0207] Embodiment XLII. The compound or composition for use of any one of Embodiments I-XLI, wherein the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of imatinib, administration of sunitinib, administration of regorafenib, administration of ripretinib and / or administration of avapritinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib, ripretinib, and / or avapritinib.
[0208] Embodiment XLIII. The compound or composition for use of any one of Embodiments I-XLII, wherein the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced gastrointestinal stromal tumor that has progressed from, or thesubj ect was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and an optional third line administration of regorafenib or ripretinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib and / or ripretinib.
[0209] Embodiment XLIV. The compound or composition for use of Embodiment XLIII, wherein the one or more mutations comprises a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, or a KIT exon 18 mutation, wherein, the GIST comprises a KIT exon 9 mutation selected from the group consisting of (i) p.A502_Y503dup, p.Y503_F504insAY, andp.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from K642E, V65A, and T670I; or (iv) a KIT exon 17 mutation selected from mutations involving codons 816, 820 or 823.
[0210] Embodiment XLV. The compound or composition for use of any one of Embodiments I-XLIV, wherein the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of avapritinib, or wherein the subject has a documented intolerance to avapritinib.
[0211] Embodiment XL VI. The compound or composition for use of Embodiment XLV, wherein the one or more mutations comprises a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, or a PDGFRA exon 18 mutation, wherein the PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.P581S; or a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0212] Embodiment XL VII. The compound or composition for use of any one of Embodiments I-XLVI, wherein the subject is a human subject.
[0213] Embodiment XL VIII. The compound or composition for use of any one of Embodiments I-XLVII, wherein the compound or composition is for treating a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0214] Embodiment XLIX. The compound or composition for use of any one of Embodiments I-XLVII, wherein the compound or composition is for preventing a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0215] Embodiment L. The compound or composition for use of any one of Embodiments I-XLIX, wherein the compound or composition is to be administered in combination with one or more additional therapeutic, e.g., anticancer, agents to the subject.
[0216] Embodiment LI. The compound or composition for use of Embodiment L, wherein the one or more additional therapeutic agents comprises topotecan.
[0217] Embodiment LIL The compound or composition for use of Embodiments L or LI, wherein the one or more additional therapeutic agents comprises an irinotecan drug product (IDP).
[0218] Embodiment LIII. The compound or composition for use of Embodiment LII, wherein the IDP comprises irinotecan.
[0219] Embodiment LIV. The compound or composition for use of Embodiment LII, wherein the IDP comprises irinotecan hydrochloride.
[0220] Embodiment LV. The compound or composition for use of Embodiment LII, wherein the IDP comprises irinotecan sucrosofate.
[0221] Embodiment LVI. The compound or composition for use Embodiment LII, wherein the IDP further comprises encequidar methanesulfonate.
[0222] Embodiment LVII. The compound or composition for use of any one of Embodiments L-LVI, wherein the one or more additional therapeutic agents comprises radiotherapy.
[0223] The present disclosure provides the following particular embodiments with respect to the use of a Compound of the Disclosure in the manufacture of a medicament for treating or preventing a cancer comprising one or more KIT and / or PDGFRA mutations in a subj ect.
[0224] Embodiment I. Use of a Compound of the Disclosure in the manufacture of a medicament for treating or preventing a cancer comprising one or more KIT and / or PDGFRA mutations, e.g., gastrointestinal stromal tumor (GIST), acute myeloid leukemia (AML), chronic myelogeneous leukemia (CML), sinonasal natural killer / T-cell lymphoma, seminoma, melanoma, or mastocytosis, in a subject in need thereof.
[0225] Embodiment II. The use of Embodiment I, wherein the one or more mutations comprises a drug-resistant mutation.
[0226] Embodiment III. The use of Embodiment II, wherein the one or more mutations comprises an imatinib resistant mutation, sunitinib resistant mutation, regorafenib resistant mutation, ripretinib resistant mutation, avapritinib resistant mutation, or a combination thereof.
[0227] Embodiment IV. The use of any one of Embodiments I-III, wherein the one or more mutations comprises a gain-of-function KIT mutation.
[0228] Embodiment V. The use of any one of Embodiments I-IV, wherein the one or more mutations comprises has a platelet-derived growth factor receptor-alpha (PDGFRA) mutation.
[0229] Embodiment VI. The use of any one of Embodiments I-V, wherein the one or more mutations comprises a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, a KIT exon 18 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, a PDGFRA exon 18 mutation, or a combination thereof.
[0230] Embodiment VII. The use of any one of Embodiments I- VI, wherein the one or more mutations comprises a missense mutation, insertion mutation, a deletion mutation, or a combination thereof.
[0231] Embodiment VIII. The use of any one of Embodiments I- VII, wherein the one or more mutations comprises is a primary mutation.
[0232] Embodiment IX. The use of any one of Embodiments I- VIII, wherein the one or more mutations comprises: (i) a KIT exon 9 mutation selected from the group consisting of p.A502_Y503dup, p.Y503_F504insAY, and p.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from the group consisting of K642E, V65A, and T670I; (iv) a KIT exon 17 mutation selected from the group consisting of mutations involving codons 809, 816, 820, 822, or 823; (v) a KIT exon 18 mutation selected from the group consisting of mutations involving codon 829; (vi) a PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.581S; or (vii) a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0233] Embodiment X. The use of any one of Embodiments I-IX, wherein the one or more mutations comprises one or more PDGFRA mutations selected from the group consisting of V598F, G605A, G652E, P653Q, V658A, N659K / T, T674R / I, E675G, Y676C, G680R / E, D842V, and I843_D846del.
[0234] Embodiment XI. The use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation D842V.
[0235] Embodiment XII. The use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation G680R.
[0236] Embodiment XIII. The use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation G652E.
[0237] Embodiment XIV. The use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation V658A.
[0238] Embodiment XV. The use of Embodiment X, wherein the one or more mutations comprises the PDGFRA mutation V658A and mutation G652E.
[0239] Embodiment XVI. The use of any one of Embodiments I-XV, wherein the one or more mutations comprises one or more KIT mutations selected from the group consisting of S476I, F522C, K642E, V654A, N655K, T670E / I, D816A / E / G / H / N / V, D820A / E / G / H / V / Y, N822I / K / Y, Y823C / D, and A829P.
[0240] Embodiment XVII. The use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation T670I.
[0241] Embodiment XVIII. The use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation V654A.
[0242] Embodiment XIX. The use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation D816A.
[0243] Embodiment XX. The use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation D820A.
[0244] Embodiment XXI. The use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation N822K.
[0245] Embodiment XXII. The use of Embodiment XVI, wherein the one or more mutations comprises the KIT mutation A829P.
[0246] Embodiment XXIII. The use of any one of Embodiments I-XXII, wherein the one or more mutations comprises at least one primary and at least one secondary mutation.
[0247] Embodiment XXIV. The use of Embodiment XXIII, wherein the one or more mutations comprises: (i) a primary KIT exon 9 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0248] Embodiment XXV. The use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary KIT exon 11 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0249] Embodiment XXVI. The use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary KIT exon 13 mutation; and (ii) a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0250] Embodiment XXVII. The use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary KIT exon 17 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, or a secondary KIT exon 18 mutation.
[0251] Embodiment XXVIII. The use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary PDGFRA exon 12 mutation; and (ii) a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, a secondary PDGFRA exon 15 mutation, or a secondary PDGFRA exon 18 mutation.
[0252] Embodiment XXIX. The use of Embodiment XXIII, wherein the one or more mutations comprises (i) a primary PDGFRA exon 18 mutation; and (ii) a secondary PDGFRA exon 12 mutation, a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, or a secondary PDGFRA exon 15 mutation.
[0253] Embodiment XXX. The use of any one of Embodiments I-XXIX, wherein the one or more mutations comprises compound mutations selected from double-in-cis mutations or triple-in-cis mutations.
[0254] Embodiment XXXI. The use of Embodiment XXX, wherein the one or more mutations comprises a primary KIT exon 9 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0255] Embodiment XXXII. The use of Embodiment XXXI, wherein the one or more mutations comprises a primary KIT exon 9 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0256] Embodiment XXXIII. The use of Embodiment XXX, wherein the one or more mutations comprises a primary KIT exon 11 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0257] Embodiment XXXIV. The use of Embodiment XXXIII, wherein the one or more mutations comprises a primary KIT exon 11 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0258] Embodiment XXXV. The use of any one of Embodiments I-XXXIV, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatlanib, crenolanib, ripretinib, nintedanib, ponatinib, nilotinib, axitinib, cabozantinib, pazopanib, pexidartinib, bezuclastinib, dasatinib, sorafenib, and / or avapritinib, or a pharmaceutically acceptable salt and solvate thereof.
[0259] Embodiment XXXVI. The use of Embodiment XXXV, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, ripretinib and / or avapritinib.
[0260] Embodiment XXXVII. The use of Embodiments XXXV or XXXVI, wherein the subject was previously treated with imatinib.
[0261] Embodiment XXXVIII. The use of any one of Embodiments XXXV- XXXVII, wherein the subject was previously treated with sunitinib.
[0262] Embodiment XXXIX. The use of any one of Embodiments XXXV- XXXVIII, wherein the subject was previously treated with regorafenib.
[0263] Embodiment XL. The use of any one of Embodiments XXXV-XXXIX, wherein the subject was previously treated with ripretinib.
[0264] Embodiment XLI. The use of any one of Embodiments XXXV-XL, wherein the subject was previously treated with avapritinib.
[0265] Embodiment XLII. The use of any one of Embodiments I-XLI, wherein the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of imatinib, administration of sunitinib, administration of regorafenib, administration of ripretinib and / or administration of avapritinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib, ripretinib, and / or avapritinib.
[0266] Embodiment XLIII. The use of any one of Embodiments I-XLII, wherein the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and an optional third line administration of regorafenib or ripretinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib and / or ripretinib.
[0267] Embodiment XLIV. The use of Embodiment XLIII, wherein the one or more mutations comprises a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, or a KIT exon 18 mutation, wherein, the GIST comprises a KIT exon 9 mutation selected from the group consisting of: (i) p.A502_Y503dup, p.Y503_F504insAY, and p.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from K642E, V65A, and T670I; or (iv) a KIT exon 17 mutation selected from mutations involving codons 816, 820 or 823.
[0268] Embodiment XLV. The use of any one of Embodiments I-XLIV, wherein the cancer comprising one or more KIT and / or PDGFRA mutations is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of avapritinib, or wherein the subject has a documented intolerance to avapritinib.
[0269] Embodiment XL VI. The use of Embodiment XLV, wherein the one or more mutations comprises a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, or a PDGFRA exon 18 mutation, wherein the PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.P581S; or a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0270] Embodiment XL VII. The use of any one of Embodiments I-XLVI, wherein the subject is a human subject.
[0271] Embodiment XL VIII. The use of any one of Embodiments I-XLVII, wherein the compound or composition is for treating a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0272] Embodiment XLIX. The use of any one of Embodiments I-XLVII, wherein the compound or composition is for preventing a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0273] Embodiment L. The use of any one of Embodiments I-XLIX, wherein the compound or composition is to be administered in combination with one or more additional therapeutic, e.g., anticancer, agents to the subject.
[0274] Embodiment LI. The use of Embodiment L, wherein the one or more additional therapeutic agents comprises topotecan.
[0275] Embodiment LII. The use of Embodiments L or LI, wherein the one or more additional therapeutic agents comprises an irinotecan drug product (IDP).
[0276] Embodiment LIII. The use of Embodiment LII, wherein the IDP comprises irinotecan.
[0277] Embodiment LIV. The use of Embodiment LII, wherein the IDP comprises irinotecan hydrochloride.
[0278] Embodiment LV. The use of Embodiment LII, wherein the IDP comprises irinotecan sucrosofate.
[0279] Embodiment LVI. The use Embodiment LII, wherein the IDP further comprises encequidar methanesulfonate.
[0280] Embodiment LVII. The use of any one of Embodiments L-LVI, wherein the one or more additional therapeutic agents comprises radiotherapyIV. Additional Therapeutic Agents
[0281] In one embodiment, a Compound of the Disclosure is administered as a single agent to treat or prevent a cancer comprising one or more KIT and / or PDGFRA mutations in a subject.
[0282] In another embodiment, a Compound of the Disclosure is administered in combination with one or more additional therapeutic agents, including radiotherapy, and / or surgery to treat or prevent a cancer comprising one or more KIT and / or PDGFRA mutations in a subject. A Compound of the Disclosure and the additional therapeutic agent(s) can be administered simultaneously or sequentially to achieve the desired effect. A Compound of the Disclosure and additional therapeutic agent(s) can also be administered as a single pharmaceutical composition or separate pharmaceutical compositions. In one embodiment, the Compound of the Disclosure and additional therapeutic agent(s) are administered asseparate pharmaceutical compositions. The goal of the combination therapy provided herein is to achieve better clinical outcomes, e.g., enhanced efficacy, reduced toxicity, or targeting different disease aspects, for the subject being treated than the individual active agents could achieve alone.
[0283] The one or more additional therapeutic agents is / are administered in an amount to provide the desired therapeutic effect. The effective dosage range for each additional therapeutic agent is generally known in the art, and the additional therapeutic agent(s) is / are administered to subject in need thereof within such established ranges. The effective dosage range of each additional therapeutic agent can also be lower, e.g., 5%, 10%, 15%, 20%, 25%, or more lower, than their established ranges to provide the desired therapeutic effect.
[0284] A Compound of the Disclosure and the additional therapeutic agent(s) can be administered together, e.g., as a single-unit dose or separately, e.g., as multi-unit doses. When administered as multi-unit doses the Compound of the Disclosure may be administered before the additional therapeutic agent(s) or vice versa. One or more doses of the Compound of the Disclosure and / or one or more doses of the additional therapeutic agent(s) can be administered.
[0285] In one embodiment, the one or more additional therapeutic agent comprises a tyrosine kinase inhibitor (TKI) other than a Compound of the Disclosure (referred to herein as a "second TKI"). Thus, in some embodiments, the present disclosure provides a method of treating a cancer comprising a KIT tyrosine kinase (KIT) mutation in a subject in need thereof, the method comprising administering a Compound of the Disclosure in combination with a second TKI in a therapeutically effective amount.
[0286] In another embodiment, the one or more additional therapeutic agents comprises imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatlanib, crenolanib, ripretinib, nintedanib, ponatinib, nilotinib, axitinib, cabozantinib, pazopanib, pexidartinib, bezuclastinib, dasatinib, sorafenib, or avapritinib.
[0287] When administered in combination, the Compound of the Disclosure and the second TKI can be independently administered by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, intracistemal or intrathecal through lumbar puncture, transurethral, nasal, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and / or surgicalimplantation at a particular site) administration. Parenteral administration of the second TKI can be accomplished using a needle and syringe or using a high-pressure technique. In one embodiment, a Compound of the Disclosure is orally administered to a subject in combination with the second TKI in a therapeutically effect amount. In another embodiment, a Compound of the Disclosure is parenterally administered to a subject in combination with the second TKI in a therapeutically effective amount.
[0288] In some embodiments, the Compound of the Disclosure and the second TKI are administered to the subject as a single pharmaceutical formulation, in any appropriate form and by any suitable route. In some embodiments, a single formulation comprising the Compound of the Disclosure and the second TKI is orally administered to the subject, e.g., as tablets or capsules. In some embodiments, a single formulation comprising the Compound of the Disclosure and the second TKI is parenterally administered to the subject, e.g., by injection or infusion.
[0289] In some embodiments, the Compound of the Disclosure and the second TKI are administered to the subject as separate pharmaceutical formulations, in any appropriate form and by any suitable route. In some embodiments, the Compound of the Disclosure and the second TKI are orally administered to the subject, e.g., as tablets or capsules. In some embodiments, a single formulation comprising the Compound of the Disclosure and the second TKI is parenterally administered to the subject, e.g., by injection or infusion.
[0290] In some embodiments, the Compound of the Disclosure is administered to the subject before administration of the second TKI. For example, the second TKI is administered 15 minutes to 24 hours, e.g., 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, or 12 hours before the administration of the second TKI to a subject.
[0291] In some embodiments, the Compound of the Disclosure and the second TKI are administered simultaneously, i.e., less than 10 minutes apart.
[0292] In some embodiments, the Compound of the Disclosure is administered to the subject after administration of the second TKI. For example, the Compound of the Disclosure is administered 15 minutes to 24 hours, e.g., 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, or 12 hours after the administration of the second TKI to a subject.
[0293] In some embodiments, the Compound of the Disclosure and the second TKI are administered to the subject about 1 minute to about 24 hours apart. For example, the Compound of the Disclosure and the second TKI are administered about 1 minute apart, 5 minutes apart, 10 minutes apart, 15 minutes apart, 30 minutes apart, 45 minutes apart, 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, or 11 hours to 12 hours apart.
[0294] In some embodiments, the one or more additional therapeutic agents comprises a DNA damaging agent. Thus, in some embodiments, the present disclosure provides a method of treating a cancer comprising a KIT mutation in a subject in need thereof, the method comprising administering a Compound of the Disclosure in combination with a DNA damaging agent in a therapeutically effective amount.
[0295] In some embodiments, the DNA damaging agent comprises topotecan. Thus, in some embodiments, the disclosure provides a method of treating cancer comprising a KIT mutation in a subject in need thereof, the method comprising administering a Compound of the Disclosure in combination with topotecan in a therapeutically effective amount.
[0296] In some embodiments, the DNA damaging agent comprises gemcitabine, cisplatin, carboplatin, oxaliplatin, capecitabine, 5 -fluorouracil, doxorubicin, danorubicin, methotrexate, mechlorethamine, bendamustine, melphalan, chlorambucil, ifosfamide, cyclophosphamide, carmustine, lomustine, semustine, dacarbazine, temozolomide, or a combination thereof.
[0297] In some embodiments, the DNA damaging agent comprises an irinotecan drug product (IDP). Thus, in some embodiments, the present disclosure provides a method of treating a cancer comprising a KIT mutation in a subject in need thereof, the method comprising administering a Compound of the Disclosure in combination with an IDP in a therapeutically effective amount.
[0298] In another embodiment, the IDP comprises irinotecan.
[0299] In another embodiment, the IDP comprises irinotecan hydrochloride.
[0300] In another embodiment, the IDP comprises irinotecan sucrosofate.
[0301] In another embodiment, the IDP further comprises encequidar methanesulfonate.
[0302] When administered in combination, the Compound of the Disclosure and the DNA damaging agent, e.g., topotecan or an IDP, can be independently administered by any suitable route, for example by oral, buccal, inhalation, sublingual, rectal, vaginal, intracistemal or intrathecal through lumbar puncture, transurethral, nasal, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and / or surgical implantation at a particular site) administration, and when the DNA damaging agent is radiotherapy, the radiotherapy can be administered, e.g., via a source of radiation is external to the subject. Parenteral administration of the topotecan or IDP can be accomplished using a needle and syringe or using a high-pressure technique. In one embodiment, a Compound of the Disclosure is orally administered to a subject in combination with the topotecan or IDP in a therapeutically effective amount. In another embodiment, a Compound of the Disclosure is parenterally administered to a subject in combination with the topotecan or IDP in a therapeutically effective amount.
[0303] In some embodiments, the Compound of the Disclosure and the DNA damaging agent, e.g., topotecan or an IDP, are administered to the subject as a single pharmaceutical formulation, in any appropriate form and by any suitable route. In some embodiments, a single formulation comprising the Compound of the Disclosure and the DNA damaging agent, e.g., topotecan or an IDP, is orally administered to the subject, e.g., as tablets or capsules. In some embodiments, a single formulation comprising the Compound of the Disclosure and the DNA damaging agent, e.g., topotecan or an IDP is parenterally administered to the subject, e.g., by injection or infusion.
[0304] In some embodiments, the Compound of the Disclosure and the DNA damaging agent, e.g., topotecan or an IDP, are administered to the subject as separate pharmaceutical formulations, in any appropriate form and by any suitable route. In some embodiments, the Compound of the Disclosure and the DNA damaging agent, e.g., topotecan or an IDP, are orally administered to the subject, e.g., as tablets or capsules. In some embodiments, a single formulation comprising the Compound of the Disclosure and the DNA damaging agent, e.g., topotecan or an IDP, is parenterally administered to the subject, e.g., by injection or infusion.
[0305] In some embodiments, the Compound of the Disclosure is administered to the subject before administration of the DNA damaging agent, e.g., topotecan or an IDP. For example, the Compound of the Disclosure is administered 15 minutes to 24 hours, e.g., 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, or 12 hours before the administration of the topotecan or IDP.
[0306] In some embodiments, the Compound of the Disclosure and the DNA damaging agent, e.g., topotecan or an IDP, are administered simultaneously, i.e., less than 10 minutes apart.
[0307] In some embodiments, the Compound of the Disclosure is administered to the subject after administration of the DNA damaging agent, e.g., topotecan or an IDP. For example, the Compound of the Disclosure is administered 15 minutes to 24 hours, e.g., 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, or 12 hours after the administration of the topotecan or IDP to a subject.
[0308] In some embodiments, the Compound of the Disclosure and the DNA damaging agent, e.g., topotecan or an IDP, are administered to the subject about 1 minute to about 24 hours apart. For example, the Compound of the Disclosure and the topotecan or IDP are administered about 1 minute apart, 5 minutes apart, 10 minutes apart, 15 minutes apart, 30 minutes apart, 45 minutes apart, 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, or 11 hours to 12 hours apart.
[0309] In some embodiments, the DNA damaging agent comprises radiotherapy. Thus, in some embodiments, the disclosure provides a method of treating cancer comprising a KIT mutation in a subject in need thereof, the method comprising administering a Compound of the Disclosure in combination with radiotherapy in a therapeutically effective amount.
[0310] In some embodiments, the methods disclosed herein comprise first administering a Compound of the Disclosure to the subject, then administering a radiotherapy to the subject.
[0311] In some embodiments, the methods disclosed herein comprise first administering the radiotherapy to the subject, then administering a Compound of the Disclosure to the subject.
[0312] In some embodiments, the methods disclosed herein comprise administering the radiotherapy and a Compound of the Disclosure to the subject substantially simultaneously,wherein the subject receives a Compound of the Disclosure while receiving the radiotherapy.
[0313] Any suitable method known in the art for delivering a therapeutic dose of radiation to a subject can be used in the methods of the present disclosure. Non-limiting exemplary methods for delivering radiotherapy include, but are not limited to, gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes, photon radiotherapy, particle beam radiation therapy, other types of radiotherapies, and combinations thereof. In some embodiments, the radiotherapy is delivered to the subject using a gamma knife. In some embodiments, the radiotherapy is delivered to the subject using a linear accelerator. In some embodiments, the radiotherapy uses an ionizing radiation. Non-limiting exemplary ionizing radiation relevant to cancer treatment include, but are not limited to, X-rays, gamma rays, and particulate radiation beams.
[0314] In some embodiments, the source of radiation is external to the subject. In some embodiments, the external radiation therapy includes directing a beam of high-energy radiation to a tumor site through the skin using, for instance, a linear accelerator. In some embodiments, the source of radiation is internal to the subject. In some embodiments, the internal radiation therapy includes implanting a radiation-emitting source, such as beads, wires, pellets, capsules, particles, and the like, inside the body at or near the tumor site, including the use of delivery systems that specifically target cancer cells, e.g., using particles attached to cancer cell binding ligands. Non-limiting exemplary internal radiation therapies include brachytherapy, interstitial irradiation, intracavity irradiation, radioimmunotherapy, and the like.
[0315] In some embodiments, the methods disclosed herein further comprise administering at least one radiosensitizer to the subject to enhance the killing of tumor cells. Non-limiting exemplary radiosensitizers include metronidazole, misonidazole, intra-arterial Budr, intravenous iododeoxyuridine (ludR), nitroimidazole, 5-substituted-4-nitroimidazoles, 2H- isoindolediones, [[(2-bromoethyl)-amino]methyl]-nitro-lH-imidazole-l-ethanol, nitroaniline derivatives, DNA-affinic hypoxia selective cytotoxins, halogenated DNA ligand, 1,2,4 benzotriazine oxides, 2-nitroimidazole derivatives, fluorine-containing nitroazole derivatives, benzamide, nicotinamide, acridine-intercalator, 5-thiotretrazole derivative, 3-nitro-l,2,4-triazole, 4,5-dinitroimidazole derivative, hydroxylated texaphrins,cisplatin, mitomycin, tiripazamine, nitrosourea, mercaptopurine, methotrexate, fluorouracil, bleomycin, vincristine, carboplatin, epirubicin, doxorubicin, cyclophosphamide, vindesine, etoposide, paclitaxel, and heat (hyperthermia).
[0316] In some embodiments, the methods disclosed herein further comprise administering at least one radioprotector to the subject to protect healthy tissue from the harmful effects of radiation. Non-limiting exemplary radioprotectors include cysteamine, aminoalkyl dihydrogen phosphorothioates, amifostine, IL-1, and IL-6.
[0317] In some embodiments, the methods disclosed herein includes administering a total dose of between about 1 Gray (Gy) and about 100 Gy radiation to the subject. In some embodiments, the methods disclosed herein includes administering a total dose of between about 1 Gy and about 75 Gy radiation to the subject, e.g., a total dose of about 10 Gy, about 15 Gy, about 20 Gy, about 25 Gy, about 30 Gy, about 35 Gy, about 40 Gy, about 45 Gy, about 50 Gy, about 55 Gy, about 60 Gy, about 65 Gy, or about 75 Gy to the subject.
[0318] In certain embodiments, the total dose of radiation is administered over the course of one day. In some embodiments, the total dose of radiation is fractionated to maximize target cell exposure and to reduce toxicity. In some embodiments, the total dose of radiation is fractionated and administered in between about 1 week and about 8 weeks. In some embodiments, the total dose of radiation is fractionated and administered in at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 10 days, at least about 14 days, at least about 17 days, at least about 21 days, at least about 24 days, at least about 28 days, at least about 31 days, at least about 35 days, at least about 38 days, at least about 42 days, at least about 45 days, at least about 49 days, at least about 52 days, or at least about 56 days.
[0319] In some embodiments, the radiotherapy is administered to the subject in a daily dose of between about 1 Gy and about 10 Gy, between about 1 Gy and about 8 Gy, between about 1 Gy and about 5 Gy, or between about 1 Gy and about 3Gy.
[0320] In some embodiments, the radiotherapy is administered to the subject in a daily dose of at least about 1 Gy, at least about 1.5 Gy, at least about 1.8 Gy, at least about 2 Gy, at least about 2.5 Gy, at least about 2.8 Gy, at least about 3 Gy, at least about 3.2 Gy, at least about 3.5 Gy, at least about 3.8 Gy, at least about 4 Gy, at least about 4.2 Gy, at least about 4.5 Gy, at least about 5 Gy, at least about 6 Gy, at least about 7 Gy, at least about 8 Gy, at least about 9 Gy, or at least about 10 Gy.
[0321] In some embodiments, the radiotherapy is administered to the subject in a daily dose of up to about 1 Gy, up to about 1.5 Gy, up to about 1.8 Gy, up to about 2 Gy, up to about 2.5 Gy, up to about 2.8 Gy, up to about 3 Gy, up to about 3.2 Gy, up to about 3.5 Gy, up to about 3.8 Gy, up to about 4 Gy, up to about 4.2 Gy, up to about 4.5 Gy, up to about 5 Gy, up to about 6 Gy, up to about 7 Gy, up to about 8 Gy, up to about 9 Gy, or up to about 5 Gy.
[0322] In some embodiments, the radiotherapy is administered to the subject in a daily dose of about 1 Gy, about 1.5 Gy, about 1.8 Gy, about 2 Gy, about 2.5 Gy, about 2.8 Gy, about 3 Gy, about 3.2 Gy, about 3.5 Gy, about 3.8 Gy, about 4 Gy, about 4.2 Gy, about 4.5 Gy, about 5 Gy, about 6 Gy, about 7 Gy, about 8 Gy, about 9 Gy, or about 10 Gy.
[0323] In some embodiments, the radiotherapy is administered cyclically. In some embodiments, the number of cycles is from about one to about 30 cycles. In some embodiments, the number of cycles is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. In some embodiments, the duration of each cycle is about 7 days, about 10 days, about 14 days, about 21 days, or about 28 days. In some embodiments, the duration of a cycle is about 7 days.
[0324] In some embodiments, each radiotherapy cycle includes a rest period, in which the radiation is not administered to the subject during the rest period. In some embodiments, the rest period is about 21 days, about 20 days, about 19 days, about 18 days, about 17 days, about 16 days, about 15 days, about 14 days, about 13 days, about 12 days, about 11 days, about 10 days, about 9 days, about 8 days, about 7 days, about 6 days, about 5 days, about 4 days, about 3 days, about 2 days, or about 1 day.
[0325] In some embodiments, the radiation is administered 5 days / cycle, where the duration of each cycle is 7 days, i.e., each cycle includes a 2-day rest period. In some embodiments, the radiation is administered on day 1, day 2, day 3, day 4, and day 5 of the 7-day cycle. The present disclosure allows for the frequency, number, and length of dosing cycles and rest period to be adjusted, depending on the responsiveness of the subject to the radiotherapy and the occurrence of the radiotherapy-associated side effect.
[0326] The radiotherapy can be initiated at any time during the Compound of the Disclosure treatment period. In some embodiments, for example, when a Compound of the Disclosure is administered on the same day as the radiotherapy, a Compound of the Disclosure is administered to the subject between about 1 hours and about 8 hours, e.g.,about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, or about 8 hours prior to the administration of the radiotherapy. In some embodiments, for example, when a Compound of the Disclosure is administered on the same day as the radiotherapy, a Compound of the Disclosure is administered to the subject between about 1 hours and about 8 hours, e.g., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, or about 8 hours after the administration of the radiotherapy. These exemplary dosing protocols are not intended, however, to limit the methods provided herein.V. Kits
[0327] In another embodiment, the disclosure provides a kit comprising a Compound of the Disclosure and a label with instructions for how to use the Compound of the Disclosure treat or prevent a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0328] In another embodiment, the disclosure provides a kit comprising Composition of the Disclosure and a label with instructions for how to use the Composition of the Disclosure treat or prevent a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0329] In another embodiment, the disclosure provides a kit for carrying out the methods of the present disclosure, the kit comprising a Compound of the Disclosure and a label with instructions for how to use the Compound of the Disclosure treat or prevent a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof.
[0330] In another embodiment, the label is approved by at least one regulatory health agency, e.g., the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), the China Food and Drug Administration (CFDA), or the Japanese Ministry of Health Labor and Welfare (MHLW).VI. Personalized Medicine
[0331] In another embodiment, the disclosure provides methods of personalized medicine for a subject having a cancer comprising one or more KIT and / or PDGFRA mutations, for example, by determining KIT and / or PDGFRA mutation status before administration of a Compound of the Disclosure to the subject. See, e.g., Oppelt et al., J Gastrointest Oncol 5( / 466-473 (2017).
[0332] In another embodiment, the disclosure provides a method of selecting a subject for treatment of a cancer comprising one or more KIT and / or PDGFRA mutations with a Compound of the Disclosure, comprising obtaining a biological sample, e.g., a tissue biopsy or blood sample, from the subject, and testing the biological sample from the subject for the presence of a pathogenic variant, i.e., a KIT and / or PDGFRA mutation, in the cancer. Mutations can be determined by immunohistochemistry and other techniques. This selection method may further comprise administering a therapeutically effective amount of a Compound of the Disclosure to the subject if the biological sample contains a pathogenic variant in the cancer, e.g., a KIT and / or PDGFRA mutation.
[0333] In another embodiment, the disclosure provides methods for predicting treatment outcomes in a subject having a cancer comprising one or more KIT and / or PDGFRA mutations, the method comprising obtaining a biological sample from the subject, testing the biological sample from the subj ect for the presence of a pathogenic variant in the cancer, wherein the detection of the pathogenic variant in the cancer indicates the subject will respond favorably to administration of a therapeutically effective amount of a Compound of the Disclosure. Favorable responses include, but are not limited to, tumor cell death, apoptosis, or prolonged cell stasis of cancer cells and / or eradication of tumor cells to the limit of detection and / or reduction of the volume of the tumor and / or inhibition of the new growth of the tumor.
[0334] In another embodiment, the disclosure provides methods of treating a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof, the method comprising administering a therapeutically effective amount of a Compound of the Disclosure to the subject, wherein the subject's cells contain a pathogenic variant in the cancer. In one embodiment, the subject is selected for treatment with a Compound of the Disclosure after the subject's cells have been determined to contain a pathogenic variant in the cancer.
[0335] In another embodiment, the method of treating a subject having a cancer comprising one or more KIT and / or PDGFRA mutations comprises obtaining a biological sample from the subject, e.g., a tumor biopsy, determining whether the biological sample contains a pathogenic variant in the cancer, and administering to the subject a therapeutically effective amount of a Compound of the Disclosure if the biological sample contains an elevated level or decreased level of the biomarker, i.e., pathogenic variant.
[0336] Mutations in KIT and / or PDGFRA can be determined by standard techniques including PCR and immunohistochemistry. Funasaka et al., Translational Oncology 13: 100848 (2020).
[0337] In another embodiment, the present disclosure provides the following particular embodiments with respect to personalized medicine for a subject having a cancer comprising one or more KIT and / or PDGFRA mutations.
[0338] Embodiment I. A method of treating a cancer comprising one or more KIT and / or PDGFRA mutations in a subject in need thereof, the method comprising: (i) determining whether the cancer comprises a KIT mutation and / or PDGFRA mutation, e.g., by obtaining and testing a biological sample from the subject; and (ii) administering a therapeutically effective amount of a Compound of the Disclosure to the subject if a KIT mutation and / or PDGFRA mutation is detected.
[0339] Embodiment II. A method, comprising administering a therapeutically effective amount of a Compound of the Disclosure to a subject in need thereof, wherein: (i) the subject has a cancer comprising one or more KIT and / or PDGFRA mutations; and (ii) a biological sample, e.g., tissue biopsy, obtained from the subject characterizes the cancer as comprising a KIT mutation and / or PDGFRA mutation.
[0340] Embodiment III. A method of identifying whether a subject having a cancer comprising one or more KIT and / or PDGFRA mutations is a candidate for treatment with a Compound of the Disclosure the method comprising: (i) determining whether the cancer comprises a KIT mutation and / or PDGFRA mutation; and (ii) identifying the subject as being a candidate for treatment if a KIT mutation and / or PDGFRA mutation is present; or (iii) identifying the subject as not being a candidate for treatment if a KIT mutation and / or PDGFRA mutation is absent.
[0341] Embodiment IV. A method of predicting treatment outcome in a subject having a cancer comprising one or more KIT and / or PDGFRA mutations, the method comprising determining whether the cancer comprises a KIT mutation and / or PDGFRA mutation, wherein: (i) the presence of a KIT mutation and / or PDGFRA mutation indicates that administering a Compound of the Disclosure to the subject will likely cause a positive therapeutic response, e.g., reduce tumor volume; and (ii) the absence of a KIT mutation and / or PDGFRA mutation indicates that administering a Compound of the Disclosure to the subject will likely cause little or no therapeutic response.
[0342] Embodiment V. The method of any one of Embodiments I-IV, wherein the cancer comprises a KIT mutation.
[0343] Embodiment VI. The method of any one of Embodiments I-V, wherein the cancer comprises has a PDGFRA mutation.
[0344] Embodiment VII. The method of any one of Embodiments I- VI, wherein the cancer comprises a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, a KIT exon 18 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, a PDGFRA exon 18 mutation, or a combination thereof.
[0345] Embodiment VIII. The method of any one of Embodiments I- VII, wherein the cancer comprises a missense mutation, insertion mutation, a deletion mutation, or a combination thereof.
[0346] Embodiment IX. The method of any one of Embodiments I- VIII, wherein the cancer comprises is a primary mutation.
[0347] Embodiment X. The method of any one of Embodiments I-IX, wherein the cancer comprises: (i) a KIT exon 9 mutation selected from the group consisting of p.A502_Y503dup, p.Y503_F504insAY, andp.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from the group consisting ofK642E, V65A, and T670I; (iv) a KIT exon 17 mutation selected from the group consisting of mutations involving codons 809, 816, 820, 822, or 823; (v) a KIT exon 18 mutation selected from the group consisting of mutations involving codon 829; (vi) a PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.581S; or (vii) a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0348] Embodiment XI. The method of any one of Embodiments I-X, wherein the cancer comprises one or more PDGFRA mutations selected from the group consisting of V598F, G605A, G652E, P653Q, V658A, N659K / T, T674R / I, E675G, Y676C, G680R / E, D842V, and I843_D846del.
[0349] Embodiment XII. The method of Embodiment XI, wherein the cancer comprises the PDGFRA mutation D842V.
[0350] Embodiment XIII. The method of Embodiment XI, wherein the cancer comprises the PDGFRA mutation G680R.
[0351] Embodiment XIV. The method of Embodiment XI, wherein the cancer comprises the PDGFRA mutation G652E.
[0352] Embodiment XV. The method of Embodiment XI, wherein the cancer comprises the PDGFRA mutation V658A.
[0353] Embodiment XVI. The method of Embodiment XI, wherein the cancer comprises the PDGFRA mutation V658A and mutation G652E.
[0354] Embodiment XVII. The method of any one of Embodiments I-XVI, wherein the cancer comprises one or more KIT mutations selected from the group consisting of S476I, F522C, K642E, V654A, N655K, T670E / I, D816A / E / G / H / N / V, D820A / E / G / H / V / Y, N822I / K / Y, Y823C / D, and A829P.
[0355] Embodiment XVIII. The method of Embodiment XVII, wherein the cancer comprises the KIT mutation T670I.
[0356] Embodiment XIX. The method of Embodiment XVII, wherein the cancer comprises the KIT mutation V654A.
[0357] Embodiment XX. The method of Embodiment XVII, wherein the cancer comprises the KIT mutation D816A.
[0358] Embodiment XXI. The method of Embodiment XVII, wherein the cancer comprises the KIT mutation D820A.
[0359] Embodiment XXII. The method of Embodiment XVII, wherein the cancer comprises the KIT mutation N822K.
[0360] Embodiment XXIII. The method of Embodiment XVII, wherein the cancer comprises the KIT mutation A829P.
[0361] Embodiment XXIV. The method of any one of Embodiments I-XXIII, wherein the cancer comprises at least one primary and at least one secondary mutation.
[0362] Embodiment XXV. The method of Embodiment XXIV, wherein the cancer comprises: (i) a primary KIT exon 9 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0363] Embodiment XXVI. The method of Embodiment XXIV, wherein the cancer comprises (i) a primary KIT exon 11 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0364] Embodiment XXVII. The method of Embodiment XXIV, wherein the cancer comprises (i) a primary KIT exon 13 mutation; and (ii) a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0365] Embodiment XXVIII. The method of Embodiment XXIV, wherein the cancer comprises (i) a primary KIT exon 17 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, or a secondary KIT exon 18 mutation.
[0366] Embodiment XXIX. The method of Embodiment XXIV, wherein the cancer comprises (i) a primary PDGFRA exon 12 mutation; and (ii) a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, a secondary PDGFRA exon 15 mutation, or a secondary PDGFRA exon 18 mutation.
[0367] Embodiment XXX. The method of Embodiment XXIV, wherein the cancer comprises (i) a primary PDGFRA exon 18 mutation; and (ii) a secondary PDGFRA exon 12 mutation, a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, or a secondary PDGFRA exon 15 mutation.
[0368] Embodiment XXXI. The method of any one of Embodiments I-XXX, wherein the cancer comprises compound mutations selected from double-in-cis mutations or triple-incis mutations.
[0369] Embodiment XXXII. The method of Embodiment XXXI, wherein the cancer comprises a primary KIT exon 9 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0370] Embodiment XXXIII. The method of Embodiment XXXII, wherein the cancer comprises a primary KIT exon 9 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0371] Embodiment XXXIV. The method of Embodiment XXXI, wherein the cancer comprises a primary KIT exon 11 mutation and at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0372] Embodiment XXXV. The method of Embodiment XXXIV, wherein the cancer comprises a primary KIT exon 11 mutation and at least one acquired mutation in KIT exon 13 or KIT exon 14 and at least one acquired mutation in KIT exon 17 or KIT exon 18.VII. Definitions
[0373] The phrase "DNA damaging agent" refers to a drug and / or radiotherapy that induces DNA damage. DNA damaging agents may induce DNA damage through mechanisms that include, but are not limited to, alkylation, oxidation, exposure to UV radiation, and crosslinking. Exemplary DNA damaging agents include, but are not limited to, topotecan, irinotecan, gemcitabine, fludarabine, cisplatin, carboplatin, oxaliplatin, capecitabine, 5- fluorouracil, tegafur, raltitrexed, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, danorubicin, methotrexate, cytosine arabinoside, hydroxyurea, adriamycin, bleomycin, mechlorethamine, bendamustine, melphalan, chlorambucil, busulphan, nitrosureas, ifosfamide, cyclophosphamide, nitrogen mustard, carmustine, lomustine, semustine, dacarbazine, temozolomide, amsacrine, camptothecin, belotecan, etoposide, or teniposide. DNA damaging agents include antibody-drug conjugates (ADCs), e.g., ADCs comprising a topoisomerase inhibitor or another class of DNA damaging agent, e.g., trastuzumab deruxtecan (Enhertu®), sacituzumab govitecan (Trodelvy®), loncastuximab tesirine (Zynlonta®), gemtuzumab ozogamicin (Mylotarg®), and inotuzumab ozogamicin (Besponsa®). In some embodiments, the DNA damaging agent is irinotecan. In some embodiments, the DNA damaging agent is an irinotecan drug product. In some embodiments, the DNA damaging agent is topotecan. In some embodiments, the DNA damaging agent is radiotherapy.
[0374] The phrase "irinotecan drug product" or "IDP" refers to a drug product containing irinotecan or a suitable salt or solvate thereof. Suitable salts and solvates of irinotecan include, but are not limited to, irinotecan hydrochloride, irinotecan sucrosofate (irinotecan liposome), irinotecan sulfate, irinotecan nitrate, irinotecan phosphate, irinotecan methanesulfonate, irinotecan citrate, irinotecan maleate, irinotecan succinate, irinotecan disulfate, irinotecan malate, irinotecan fumarate, irinotecan besylate, irinotecan camsylate, irinotecan edisylate, and irinotecan hydrochloride trihydrate. In some aspects, the irinotecan drug product can further comprise an agent to enhance bioavailability, such as, but not limited to, encequidar methanesulfonate.
[0375] The phrase "tyrosine kinase inhibitor" or "TKI" refers to a drug that inhibits tyrosine kinase, and the pharmaceutically acceptable salts thereof. Exemplary TKIs include, but are not limited to, (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2- carboxamide, imatinib, sunitinib, regorafenib, ripretinib, ponatinib, nilotinib, cabozantinib, bezuclastinib, dasatinib, avapritinib, bosutinib, lenvatinib, IDRX42 andNB003.
[0376] The term "topotecan" refers to (S)-10-((dimethylamino)methyl)-4-ethyl-4,9- dihydroxy-l,12-dihydro-14H-pyrano[3',4':6,7]indolizino[l,2-b]quinoline-3,14(4H)-dione:and the pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutically acceptable salt of topotecan is the hydrochloride salt.
[0377] The term "halo" as used herein by itself or as part of another group refers to a radical of the formula -Cl (chloro), -F (fluoro), -Br (bromo), or -I (iodo). In some embodiments the halo is -F. In some embodiments, the halo is -Cl. In some embodiments, the halo is -Br.
[0378] The term "nitro" as used herein by itself or as part of another group refers to a radical of the formula -NO2.
[0379] The term "cyano" as used herein by itself or as part of another group refers to a radical of the formula -CN.
[0380] The term "hydroxy" as herein used by itself or as part of another group refers to a radical of the formula -OH.
[0381] The term "amino" as used herein by itself or as part of another group refers to a radical of the formula -NRaRb, wherein Raand Rbare independently hydrogen, optionally substituted alkyl, e.g., haloalkyl, (hydroxy)C2-C4 alkyl, (alkoxy)C2-C4 alkyl, (amino)C2-C4 alkyl, (aryl)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, or (heteroaryl)alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, the amino is -NH2, i.e., an amino wherein Raand Rbare both hydrogen. In some embodiments, the amino is an "alkylamino," i.e., an amino wherein Rais Ci-Ce alkyl and Rbis hydrogen. In one embodiment, Rais Ci- C4 alkyl. Non-limiting exemplary alkylamino groups include -N(H)CH3 and -N(H)CH2CH3. In some embodiments, the amino is a "dialkylamino," i.e., an aminowherein Raand Rbare each independently Ci-Ce alkyl. In one embodiment, Raand Rbare each independently C1-C4 alkyl. Non-limiting exemplary dialkylamino groups include -N(CH3)2and -N(CH3)CH2CH(CH3)2.
[0382] The term "alkyl" as used herein by itself or as part of another group refers to a straight- or branched-chain unsubstituted aliphatic hydrocarbon radical containing one to twelve carbon atoms, i.e., a C1-C12 alkyl, or the number of carbon atoms designated, e.g., a Ci-C3alkyl such as methyl, ethyl, propyl, and isopropyl; a C1-C4 alkyl such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl; and so on. In some embodiments, the alkyl is a Ci-Ce alkyl. In some embodiments, the alkyl is a C1-C4 alkyl. In some embodiments, the alkyl is a Ci-C3alkyl. In some embodiments, the alkyl is a C2-C4 alkyl. Non-limiting exemplary C1-C12 alkyl groups include methyl, i.e., -CH3, ethyl, propyl, isopropyl, butyl, ec-butyl, tert-butyl, iso-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, and decyl.
[0383] The term "optionally substituted alkyl" as used herein by itself or as part of another group refers to an alkyl that is either unsubstituted or substituted with one or more, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroaryl sulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroaryl carbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)R>; -N(R‘)S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy,
[0384] wherein:
[0385] Rhis hydrogen or alkyl;
[0386] R1is hydrogen or alkyl;
[0387] R> is alkoxy, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl;
[0388] Rkis amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl; and
[0389] Rmis optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, optionally substituted heteroaryl, carboxamido, or carbonyl.
[0390] In some embodiments, the optionally substituted alkyl has four substituents. In some embodiments, the optionally substituted alkyl has three substituents. In some embodiments, the optionally substituted alkyl has two substituents. In some embodiments, the optionally substituted alkyl has one substituent. In some embodiments, the optionally substituted alkyl is unsubstituted. In some embodiments, the optionally substituted alkyl is an optionally substituted Ci-Ce alkyl. In some embodiments, the optionally substituted alkyl is an optionally substituted C1-C4 alkyl.
[0391] In some embodiments, the optionally substituted alkyl is a "(hydroxyl)alkyl," i.e., an alkyl substituted with one or two hydroxy groups. In some embodiments, the alkyl is a Ci-Ce alkyl and thus the resulting (hydroxy)alkyl is referred to as a "(hydroxy)Ci-C6 alkyl." In some embodiments, the alkyl is a C1-C4 alkyl and thus the resulting (hydroxy)alkyl is referred to as a "(hydroxy)Ci-C4 alkyl." In some embodiments, the hydroxyalkyl is a monohydroxyalkyl, e.g., a C1-C4 alkyl substituted with one hydroxy group. In some embodiments, the hydroxyalkyl is a dihydroxy alkyl, i.e., a C1-C4 substituted with two hydroxy groups. Non-limiting exemplary (hydroxyl)alkyl groups include hydroxymethyl, hydroxy ethyl, hydroxypropyl and hydroxybutyl groups, such as 1 -hydroxy ethyl, 2- hydroxy ethyl, 1,2-dihydroxy ethyl, 2-hydroxypropyl, 3 -hydroxypropyl, 3 -hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-l -methylpropyl, and l,3-dihydroxyprop-2-yl.
[0392] In some embodiments, the optionally substituted alkyl is a "haloalkyl," i.e., an alkyl substituted by one or more fluorine, chlorine, bromine, and / or iodine atoms. In some embodiments, the alkyl is substituted by one, two, or three fluorine and / or chlorine atoms. In some embodiments, the alkyl is substituted by one, two, or three fluorine atoms. In some embodiments, the alkyl is a C1-C4 alkyl and thus the resulting haloalkyl is thus referred to as a "C1-C4 haloalkyl." Non-limiting exemplary haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and tri chloromethyl.
[0393] In some embodiments, the optionally substituted alkyl is an "(amino)alkyl" i.e., an alkyl substituted with one amino group. In some embodiments, the amino group is -NH2. In some embodiments, the amino group is an alkylamino. In some embodiments, the amino group is a dialkylamino. In some embodiments, the alkyl is a Ci-Ce alkyl and thus the resulting (amino)alkyl is thus referred to as a "(amino)Ci-C6 alkyl." In some embodiments, the alkyl is a C1-C4 alkyl and thus the resulting (amino)alkyl is thus referred to as a "(amino)Ci-C4 alkyl." Non-limiting exemplary (amino)alkyl groups include -CH2NH2, -CH2CH2N(H)CH3, -CH2CH2N(CH3)2, CH2N(H)cyclopropyl, -CH2N(H)cyclobutyl, -CH2N(H)cyclohexyl, -CH2CH2CH2N(H)CH2Ph and -CH2CH2CH2N(H)CH2(4-CF3-Ph).
[0394] In some embodiments, the optionally substituted alkyl is an "(alkoxy)alkyl," i.e., an alkyl substituted with one alkoxy group. In some embodiments, the alkoxy group is a Ci-Ce alkoxy. In some embodiments, the alkoxy group is a C1-C4 alkoxy. In some embodiments, the alkyl group is a Ci-Ce alkyl. In some embodiments, the alkyl group is a C1-C4 alkyl. In some embodiments, the alkoxy is a C1-C4 alkoxy and the alkyl is a C1-C4 alkyl and thus the resulting (alkoxy)alkyl is referred to as a "(C1-C4 alkoxy)Ci-C4 alkyl." Non-limiting exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, isopropoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sec-butoxymethyl, and pentyloxymethyl.
[0395] In some embodiments, the optionally substituted alkyl is a "(cycloalkyl)alkyl," i.e., an alkyl substituted with one or two optionally substituted cycloalkyl groups. In some embodiments, the cycloalkyl is an optionally substituted C3-C6 cycloalkyl. In some embodiments, the alkyl is a Ci-Ce alkyl. In some embodiments, the alkyl is a C1-C4 alkyl. In some embodiments, the alkyl is a Ci or C2 alkyl. In some embodiments, the alkyl is substituted with one optionally substituted cycloalkyl group. In some embodiments, the alkyl is substituted with two optionally substituted cycloalkyl groups. Non-limiting exemplary (cycloalkyl)alkyl groups include:
[0396] In some embodiments, the optionally substituted alkyl is a "(heterocyclo)alkyl," i.e., an alkyl substituted with one, two, or three optionally substituted heterocyclo groups. In some embodiments, the alkyl is substituted with one optionally substituted 5- to8-membered heterocyclo group. In some embodiments, alkyl is a Ci-Ce alkyl. In some embodiments, alkyl is a C1-C4 alkyl. In some embodiments, alkyl is a C1-C3 alkyl. The optionally substituted heterocyclo group can be linked to the alkyl group through a carbon or nitrogen radical. Non-limiting exemplary (heterocyclo)alkyl groups include:
[0397] In some embodiments, the optionally substituted alkyl is an "(aryl)alkyl," i.e., an alkyl substituted with one, two, or three optionally substituted aryl groups. In some embodiments, the alkyl is substituted with one optionally substituted aryl group. In some embodiments, the alkyl is substituted with two optionally substituted aryl groups. In some embodiments, the aryl is an optionally substituted phenyl or optionally substituted naphthyl. In some embodiments, the aryl is an optionally substituted phenyl. In some embodiments, the alkyl is a Ci-Ce alkyl. In some embodiments, the alkyl is a C1-C4 alkyl. In some embodiments, the alkyl is a Ci or C2 alkyl. Non-limiting exemplary (aryl)alkyl groups include benzyl, phenethyl, -CHPI12, -C(H)CH3Ph and -CH(4-F-Ph)2.
[0398] In some embodiments, the optionally substituted alkyl is a "(heteroaryl)alkyl," i.e., an alkyl substituted with one or two optionally substituted heteroaryl groups. In one embodiment, the alkyl group is substituted with one optionally substituted 5- to 14-membered heteroaryl group. In some embodiments, the alkyl group is substituted with two optionally substituted 5- to 14-membered heteroaryl groups. In some embodiments, the alkyl group is substituted with one optionally substituted 5- to 9-membered heteroaryl group. In another embodiment, the alkyl group is substituted with two optionally substituted 5- to 9-membered heteroaryl groups. In some embodiments, the alkyl group is substituted with one optionally substituted 5- or 6-membered heteroaryl group. In some embodiments, the alkyl group is substituted with two optionally substituted 5- or 6-membered heteroaryl groups. In some embodiments, the alkyl group is a Ci-Ce alkyl. In some embodiments, the alkyl group is a C1-C4 alkyl. In some embodiments, the alkyl group is a Ci or C2 alkyl. Non-limiting exemplary (heteroaryl)alkyl groups include:
[0399] The term "heteroalkyl" as used herein by itself or part of another group refers to an unsubstituted straight- or branched-chain aliphatic hydrocarbon radical containing from three to sixteen chain atoms, i.e., 3- to 16-membered heteroalkyl, or the number of chain atoms designated, wherein at least one -CH2- is replaced with at least one of -O-, -N(H)-, -N(CI-C4 alkyl)-, or -S-. The -O-, -N(H)-, -N(CI-C4 alkyl)-, or -S- can independently be placed at any position of the aliphatic hydrocarbon chain so long as each -O-, -N(H)-, -N(CI-C4 alkyl)-, and -S- group is separated by at least two -CH2- groups. In some embodiments, one -CH2- group is replaced with one -O- group. In some embodiments, two -CH2- groups are replaced with two -O- groups. In some embodiments, three -CH2- groups are replaced with three -O- groups. In some embodiments, one -CH2- group is replaced with one -N(H)- group. In some embodiments, two -CH2- groups are replaced with two -N(H)- groups. Non-limiting exemplary heteroalkyl groups include -CH2OCH3, -CH2OCH2CH2CH3, -CH2CH2CH2OCH3, -CH2CH2OCH2CH2OCH2CH3, -CH2CH2OCH2CH2OCH2CH2OCH2CH3, and -CH2OCH2CH2OH.
[0400] The term "alkenyl" as used herein by itself or as part of another group refers to an alkyl group containing one, two, or three carbon-to-carbon double bonds. In some embodiments, the alkenyl group is a C2-C6 alkenyl group containing one or two carbon-to- carbon double bonds. In some embodiments, the alkenyl group is a C2-C4 alkenyl group containing one carbon-to-carbon double bond. Non-limiting exemplary alkenyl groups include ethenyl, i.e., -CH=CH2, propenyl, isopropenyl, butenyl, ec-butenyl, pentenyl, and hexenyl.
[0401] The term "optionally substituted alkenyl" as used herein by itself or as part of another refers to an alkenyl that is either unsubstituted or substituted with one or more, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroaryl sulfonyl; carbonyl, e.g.,alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroaryl carbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)R>; -N(R‘)S(=0)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, R>, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0402] In some embodiments, the optionally substituted alkenyl has four substituents. In some embodiments, the optionally substituted alkenyl has three substituents. In some embodiments, the optionally substituted alkenyl has two substituents. In some embodiments, the optionally substituted alkenyl has one substituent. In some embodiments, the optionally substituted alkenyl is unsubstituted. Non-limiting exemplary optionally substituted alkenyl groups include -CH=CHCH3 and -CH2CH=CHCH3.
[0403] In some embodiments, the optionally substituted alkenyl is an "(aryl)alkenyl," i.e., an alkenyl substituted with one, two, or three optionally substituted aryl groups. In some embodiments, the alkenyl is substituted with one optionally substituted aryl group. In some embodiments, the alkenyl is substituted with two optionally substituted aryl groups. In some embodiments, the aryl is an optionally substituted phenyl or optionally substituted naphthyl. In some embodiments, the aryl is an optionally substituted phenyl. In some embodiments, the alkenyl is a C2-C6 alkyl. In some embodiments, the alkenyl is a C2-C4 alkyl. In some embodiments, the alkenyl is a C2 alkyl. Non-limiting exemplary (aryl) alkenyl groups include -CH=CHPh.
[0404] The term "alkynyl" as used herein by itself or as part of another group refers to an alkyl containing one, two, or three carbon-to-carbon triple bonds. In some embodiments, the alkynyl is a C2-C6 alkynyl containing one or two carbon-to-carbon triple bonds. In some embodiments, the alkynyl is a C2-C4 alkynyl containing one carbon-to-carbon triple bond. Non-limiting exemplary alkynyl groups include ethynyl, i.e., -C=CH, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.
[0405] The term "optionally substituted alkynyl" as used herein by itself or as part of another group refers to an alkynyl that is either unsubstituted or substituted with one or more, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substitutedalkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroaryl sulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroaryl carbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)R>; -N(R‘)S(=0)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, R>, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0406] In some embodiments, the optionally substituted alkynyl has four substituents. In some embodiments, the optionally substituted alkynyl has three substituents. In some embodiments, the optionally substituted alkynyl has two substituents. In some embodiments, the optionally substituted alkynyl has one substituent. In some embodiments, the optionally substituted alkynyl is unsubstituted. Non-limiting exemplary optionally substituted alkynyl groups include -C=CPh and -CH(Ph)C=CH.
[0407] The term "cycloalkyl" as used herein by itself or as part of another group refers to a saturated and partially unsaturated, e.g., containing one or two double bonds, monocyclic, bicyclic, or tricyclic unsubstituted aliphatic hydrocarbon radical, that may include fused, bridged, or spirocyclic systems, containing three to twelve carbon atoms, i.e., a C3- C12 cycloalkyl, or the number of carbons designated. In some embodiments, the cycloalkyl is bicyclic, i.e., it has two rings. In some embodiments, the cycloalkyl is monocyclic, i.e., it has one ring. In some embodiments, the cycloalkyl is a C3-C8 cycloalkyl. In some embodiments, the cycloalkyl is a C3-C6 cycloalkyl, i.e., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Non-limiting exemplary C3-12 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbomyl, decalin, adamantyl, cyclohexenyl, and spiro[3.3]heptane.
[0408] The term "optionally substituted cycloalkyl" as used herein by itself or as part of another group refers to a cycloalkyl that is either unsubstituted or substituted with one or more, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionallysubstituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroaryl sulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroaryl carbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)R>; -N(R‘)S(=0)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, R>, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0409] In some embodiments, the optionally substituted cycloalkyl has three substituents.In some embodiments, the optionally substituted cycloalkyl has three substituents. In some embodiments, the optionally substituted cycloalkyl has two substituents. In some embodiments, the optionally substituted cycloalkyl has one substituent. In some embodiments, the optionally substituted cycloalkyl is unsubstituted. The term cycloalkyl includes groups wherein one or more -CH2- groups is replaced with one or more -C(=O)- groups. The term optionally substituted cycloalkyl also includes cycloalkyl groups having fused optionally substituted aryl groups or fused optionally substituted heteroaryl groups such as:
[0410] Non-limiting exemplary optionally substituted cycloalkyl groups include:
[0411] The term "heterocyclo" as used herein by itself or as part of another group refers to a saturated and partially unsaturated, e.g., containing one or two double bonds, monocyclic, bicyclic, or tricyclic radical, that may include fused, bridged, or spirocyclic systems, containing three to eighteen ring members, i.e., a 3- to 18-membered heterocyclo, comprising carbon atoms and one, two, three, or four heteroatoms. Each heteroatom is independently oxygen, sulfur, or nitrogen. Each sulfur atom is independently oxidized to give a sulfoxide or sulfone. The term heterocyclo includes groups wherein one or more -CH2- groups is replaced with one or more -C(=O)- groups, including cyclic ureido groups such as imidazolidinyl-2-one, cyclic amide groups such as pyrrolidin-2-one orpiperidin-2-one, and cyclic carbamate groups such as oxazolidinyl-2-one. The term heterocyclo also includes groups having fused optionally substituted aryl or optionally substituted heteroaryl groups such as indoline, indolin-2-one, 2,3-dihydro-lH-pyrrolo[2,3- c]pyridine, 2,3,4,5-tetrahydro-lH-benzo[d]azepine, or l,3,4,5-tetrahydro-2H- benzo[d]azepin-2-one.
[0412] In some embodiments, the heterocyclo is a 4- to 8-membered cyclic radical containing one ring and one or two oxygen atoms, e.g., tetrahydrofuran or tetrahydropyran, or one or two nitrogen atoms, e.g., pyrrolidine, piperidine, or piperazine, or one oxygen and one nitrogen atom, e.g., morpholine, and, optionally, one -CH2- group is replaced with one -C(=O)- group, e.g., pyrrolidin-2-one or piperazin-2-one. In some embodiments, the heterocyclo is a 5- to 8-membered cyclic radical containing one ring and one or two nitrogen atoms and, optionally, one -CH2- group is replaced with one -C(=O)- group. In some embodiments, the heterocyclo is a 5- or 6-membered cyclic radical containing one ring and one or two nitrogen atoms and, optionally, one -CH2- group is replaced with one -C(=O)- group. In some embodiments, the heterocyclo is a 8- to 12-membered cyclic radical containing two rings and one or two nitrogen atoms. The heterocyclo can be linked to the rest of the molecule through any available carbon or nitrogen radical. Non-limiting exemplary heterocyclo groups include:
[0413] The term "optionally substituted heterocyclo" as used herein by itself or part of another group refers to a heterocyclo that is either unsubstituted or substituted with one or more, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroaryl sulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroaryl carbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)R>; -N(R‘)S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or(aryl)alkyloxy, wherein Rh, R1, R>, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0414] In some embodiments, the optionally substituted heterocyclo has four substituents.In some embodiments, the optionally substituted heterocyclo has three substituents. In some embodiments, the optionally substituted heterocyclo has two substituents. In some embodiments, the optionally substituted heterocyclo has one substituent. In some embodiments, the optionally substituted heterocyclo is unsubstituted. Non-limiting exemplary optionally substituted heterocyclo groups include:
[0415] The term "aryl" as used herein by itself or as part of another group refers to an aromatic radical having six to fourteen carbon atoms, i.e., Ce-Cu aryl. Non-limiting exemplary aryl groups include phenyl (abbreviated as "Ph"), naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. In some embodiments, the aryl group is phenyl or naphthyl. In some embodiments, the aryl group is phenyl.
[0416] The term "optionally substituted aryl" as used herein by itself or as part of another group refers to aryl that is either unsubstituted or substituted with one, two, three, four, or five substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroaryl sulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroaryl carbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)R>; -N(R‘)S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, R>, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0417] In some embodiments, the optionally substituted aryl is an optionally substituted phenyl. In some embodiments, the optionally substituted phenyl has four substituents. In some embodiments, the optionally substituted phenyl has three substituents. In some embodiments, the optionally substituted phenyl has two substituents. In some embodiments, the optionally substituted phenyl has one substituent. Non-limiting exemplary optionally substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3 -methylphenyl, 3 -methoxyphenyl, 3- fluorophenyl, 3 -chlorophenyl, 4-m ethylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3 -methoxyphenyl, 2-ethyl, 3 -methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl, 3, 5 -dimethoxy, 4-methylphenyl, 2-fluoro-3 -chlorophenyl, 3-chloro- 4-fluorophenyl, and 2-phenylpropan-2-amine. The term optionally substituted aryl includes aryl groups having fused optionally substituted cycloalkyl groups or fused optionally substituted heterocyclo groups. Non-limiting exemplary fused aryl groups include:
[0418] The term "heteroaryl" as used herein by itself or as part of another group refers to a monocyclic and bicyclic aromatic radical having 5 to 14 fourteen ring members, i.e., a 5- to 14-membered heteroaryl, comprising one, two, three, or four heteroatoms. Each heteroatom is independently oxygen, sulfur, or nitrogen. In some embodiments, the heteroaryl has three heteroatoms. In some embodiments, the heteroaryl has two heteroatoms. In some embodiments, the heteroaryl has one heteroatom. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl has 5 ring atoms, e.g., thienyl, a 5-membered heteroaryl having four carbon atoms and one sulfur atom. In some embodiments, the heteroaryl has 6 ring atoms, e.g., pyridyl, a 6-membered heteroaryl having five carbon atoms and one nitrogen atom. Non-limiting exemplary heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2 / 7-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3 / 7-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4a7 / -carbazolyl, carbazolyl, P-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl,isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, and phenoxazinyl. In some embodiments, the heteroaryl is chosen from thienyl, e.g., thien-2-yl and thien-3-yl, furyl, e.g., 2-furyl and 3-furyl, pyrrolyl, e.g., lH-pyrrol-2-yl and lH-pyrrol-3-yl)„ imidazolyl, e.g., 2H-imidazol-2-yl and 2H-imidazol-4-yl, pyrazolyl, e.g., lH-pyrazol-3-yl, IH-pyrazol- 4-yl, and lH-pyrazol-5-yl, pyridyl, e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl, pyrimidinyl, e.g., pyrimidin-2-yl, pyrimidin-4-yl, and pyrimidin-5-yl, thiazolyl, e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl, isothiazolyl, e.g., isothiazol-3-yl, isothiazol-4- yl, and isothiazol-5-yl, oxazolyl, e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl, and isoxazolyl, e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl. The term heteroaryl also includes N-oxides. A non-limiting exemplary N-oxide is pyridyl N-oxide.
[0419] The term "optionally substituted heteroaryl" as used herein by itself or as part of another group refers to a heteroaryl that is either unsubstituted or substituted with one or more substituents, e.g., one, two, three, or four substituents, wherein each substituent is independently halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroaryl sulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroaryl carbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)R>; -N(R‘)S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy, wherein Rh, R1, R>, Rk, and Rmare as defined in connection with optionally substituted alkyl.
[0420] In some embodiments, the optionally substituted heteroaryl has three substituents.In some embodiments, the optionally substituted heteroaryl has three substituents. In some embodiments, the optionally substituted heteroaryl has two substituents. In some embodiments, the optionally substituted heteroaryl has one substituent. In some embodiments, the optionally substituted heteroaryl is unsubstituted. Any available carbon or nitrogen atom can be substituted. The term optionally substituted heteroaryl includes heteroaryl groups having fused optionally substituted cycloalkyl groups or fused optionallysubstituted heterocyclo groups. Non-limiting exemplary optionally substituted heteroaryl groups include:
[0421] The term "alkoxy" as used herein by itself or as part of another group refers to an alkyl attached to a terminal oxygen radical, i.e., a radical of the formula -ORm, wherein Rmis an alkyl. In some embodiments, the alkyl is a Ci-Ce alkyl, and thus the resulting alkoxy is referred to as a "Ci-Ce alkoxy." In some embodiments, the alkyl is a C1-C4 alkyl group and thus the resulting alkoxy is referred to as a "C1-C4 alkoxy." Non-limiting exemplary alkoxy groups include methoxy, ethoxy, and / c / 7-butoxy.
[0422] The term "haloalkoxy" as used herein by itself or as part of another group refers to a haloalkyl attached to a terminal oxygen radical, i.e., a radical of the formula -ORm, wherein Rmis a haloalkyl. In some embodiments, the haloalkyl is a Ci-Ce haloalkyl and thus the resulting haloalkoxy is referred to as a "Ci-Ce haloalkoxy." In some embodiments, the haloalkyl is a C1-C4 haloalkyl and thus the resulting haloalkoxy is referred to as a "Ci- C4 haloalkoxy." Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy.
[0423] The term "aryloxy" as used herein by itself or as part of another group refers to an optionally substituted aryl attached to a terminal oxygen radical, i.e., a radical of the formula -ORm, wherein Rmis an optionally substituted aryl. In some embodiments, the optionally substituted aryl is an optionally substituted phenyl. A non-limiting exemplary aryloxy group is PhO-.
[0424] The term "heteroaryloxy" as used herein by itself or as part of another group refers to an optionally substituted heteroaryl attached to a terminal oxygen radical, i.e., a radical of the formula -ORm, wherein Rmis an optionally substituted heteroaryl. In some embodiments, the optionally substituted heteroaryl is an optionally substituted 5- to 10- membered heteroaryl. A non-limiting exemplary aryloxy group is pyridyl-O-.
[0425] The term "(aryl)alkyloxy" as used herein by itself or as part of another group refers to an (aryl)alkyl attached to a terminal oxygen radical, i.e., a radical of the formula -ORm, wherein Rmis an (aryl)alkyl. In some embodiments, the aryl group is an optionally substituted phenyl. In some embodiments, the alkyl group is a C1-C4 alkyl and thus the resulting (aryl)alkyloxy is referred to as a "(aryl)Ci-C4 alkyloxy." Non-limiting exemplary aralkyloxy groups include PI1CH2O- and PI1CH2CH2-.
[0426] The term "alkylthio" as used herein by itself or as part of another group refers to an alkyl group or a haloalkyl group attached to a terminal sulfur radical. In some embodiments, the alkyl group is a C1-C4 lkyl group and thus the resulting alkylthio is referred to as a "Ci- C4 alkylthio." Non-limiting exemplary alkylthio groups include -SCH3, -SCF3, and -SCH2CH3.
[0427] The term "sulfonyl" as used herein by itself or as part of another group refers to refers to a radical of the formula -S(=O)2R°, wherein R° is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl.
[0428] In some embodiments, the sulfonyl is an "alkylsulfonyl," i.e., a -S(=O)2- group substituted with one optionally substituted alkyl group. In some embodiments, the sulfonyl group is substituted with a C1-C4 alkyl group and thus the resulting alkyl sulfonyl group is referred to as a "C1-C4 alkyl sulfonyl." A non-limiting exemplary alkylsulfonyl group is - S(=O)2CH3.
[0429] In some embodiments, the sulfonyl is a "cycloalkylsulfonyl," i.e., a -S(=O)2- group substituted with one optionally substituted cycloalkyl group. In some embodiments, the sulfonyl group is substituted with optionally substituted C3-C6 cycloalkyl group and thus the resulting cycloalkylsulfonyl group is referred to as a "C3-C6 cycloalkylsulfonyl." A non-limiting exemplary cycloalkylsulfonyl group is -S(=O)2-cyclohexyl.
[0430] In some embodiments, the sulfonyl is a "heterocyclosulfonyl," i.e., a -S(=O)2- group substituted with one optionally substituted heterocyclo group. In some embodiments, the sulfonyl group is substituted with an optionally substituted 4- to 8-membered heterocyclo group and thus the resulting heterocyclosulfonyl group is referred to as a "4- to 8-membered heterocyclosulfonyl." A non-limiting exemplary heterocyclosulfonyl group is:o o
[0431] In some embodiments, the sulfonyl is a "arylsulfonyl," i.e., a -S(=O)2- group substituted with one optionally substituted aryl group. In some embodiments, the sulfonyl group is substituted with one optionally substituted phenyl and thus the resulting arylsulfonyl is referred to as a "phenyl sulfonyl." A non-limiting exemplary arylsulfonyl group is -S(=O)2Ph.
[0432] In some embodiments, the sulfonyl is a "heteroarylsulfonyl," i.e., a -S(=O)2- group substituted with an optionally substituted heteroaryl group. In some embodiments, the sulfonyl group is substituted with an optionally substituted 5- to 10-membered heteroaryl group and thus the resulting heteroaryl sulfonyl is referred to as a "5- to 10-membered heteroaryl sulfonyl." A non-limiting exemplary heteroaryl sulfonyl group is:
[0433] The term "carbonyl" as used herein by itself or as part of another group refers to refers to a radical of the formula -C(=O)R°, wherein R° is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl.
[0434] In some embodiments, the carbonyl is an "alkylcarbonyl," i.e., a -C(=O)- group substituted with one optionally substituted alkyl group. In some embodiments, the carbonyl group is substituted with a C1-C4 alkyl group and thus the resulting alkylcarbonyl group is referred to as a "C1-C4 alkylcarbonyl." A non-limiting exemplary alkylcarbonyl group is - C(=O)CH3.
[0435] In some embodiments, the carbonyl is a "cycloalkylcarbonyl," i.e., a -C(=O)- group substituted with one optionally substituted cycloalkyl group. In some embodiments, the carbonyl group is substituted with optionally substituted C3-C6 cycloalkyl group and thus the resulting cycloalkylcarbonyl group is referred to as a "C3-C6 cycloalkylcarbonyl." A non-limiting exemplary cycloalkylcarbonyl group is -C(=O)cyclohexyl.
[0436] In some embodiments, the carbonyl is a "heterocyclocarbonyl," i.e., a -C(=O)- substituted with one optionally substituted heterocyclo group. In some embodiments, the carbonyl group is substituted with an optionally substituted 4- to 8-membered heterocyclogroup and thus the resulting heterocyclocarbonyl group is referred to as a "4- to 8- membered heterocyclocarbonyl." A non-limiting exemplary heterocyclocarbonyl group is:o
[0437] In some embodiments, the carbonyl is an "aryl carbonyl," i.e., a -C(=O)- group substituted with one optionally substituted aryl group. In some embodiments, the carbonyl group is substituted with one optionally substituted phenyl and thus the resulting arylcarbonyl is referred to as a "phenylcarbonyl." A non-limiting exemplary arylcarbonyl group is -C(=O)Ph.
[0438] In some embodiments, the carbonyl is a "heteroarylcarbonyl," i.e., a -C(=O)- group substituted with an optionally substituted heteroaryl group. In some embodiments, the carbonyl group is substituted with an optionally substituted 5- to 10-membered heteroaryl group and thus the resulting heteroarylcarbonyl is referred to as a "5- to 10-membered heteroaryl carbonyl." A non-limiting exemplary heteroaryl carbonyl group is:O
[0439] The term "carboxamido" as used herein by itself or as part of another group refers to a radical of formula -C(=O)NRcRd, wherein Rcand Rdare independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, and optionally substituted heteroaryl; or Rcand Rdtaken together with the nitrogen to which they are attached form an optionally substituted heterocyclo group. In some embodiments, Rcand Rdare each independently hydrogen, Ci-Ce alkyl, or optionally substituted aryl. Non-limiting exemplary carboxamido groups include -C(=O)NH2, -C(=O)N(H)CH3, and -C(=O)N(H)Ph.
[0440] The term "sulfonamido" as used herein by itself or as part of another group refers to a radical of the formula -S(=O)2NReRf, wherein Reand Rfare independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl; or Reand Rftaken together with the nitrogen to whichthey are attached from an optionally substituted heterocyclo group. Non-limiting exemplary sulfonamido groups include -S(=O)2NH2, -S(=O)2N(H)CH3, and -S(=O)2N(H)Ph.
[0441] The term "carboxyl" as used herein by itself or as part of another group refers to a radical of the formula -C(=O)ORg, wherein Rgis hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl.
[0442] The term "optionally substituted" as used herein means that substitution is optional and thus it is possible for the designated atom or group to be unsubstituted. In the event the designated atom or group is substituted then such substitution means that at least one hydrogen atom on the designated atom or group is replaced with at least one non-hydrogen atom, provided that the normal valency of the designated atom or group is not exceeded and the substitution results in a stable compound. Optional substituents may include, but are not limited to, the following atoms and groups, halo; cyano; nitro; hydroxy; amino; optionally substituted alkyl, e.g., (hydroxyl)alkyl, haloalkyl, (amino)alkyl, (alkoxy)alkyl, (cycloalkyl)alkyl, (heterocyclo)alkyl, (aryl)alkyl, or (heteroaryl)alkyl; heteroalkyl; optionally substituted alkenyl; optionally substituted alkynyl; optionally substituted cycloalkyl; optionally substituted heterocyclo; optionally substituted aryl; optionally substituted heteroaryl; alkylthio; sulfonyl, e.g., alkylsulfonyl, cycloalkylsulfonyl, heterocyclosulfonyl, arylsulfonyl, or heteroaryl sulfonyl; carbonyl, e.g., alkylcarbonyl, cycloalkylcarbonyl, heterocyclocarbonyl, arylcarbonyl, or heteroaryl carbonyl; carboxamido; sulfonamide; carboxyl; -N(Rh)C(=O)R>; -N(R‘)S(=O)2Rk; or -ORm, e.g., alkoxy, haloalkoxy, aryloxy, heteroaryloxy, or (aryl)alkyloxy,
[0443] wherein:
[0444] Rhis hydrogen or alkyl;
[0445] R1is hydrogen or alkyl;
[0446] R> is alkoxy, amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl;
[0447] Rkis amino, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, or optionally substituted heteroaryl; and
[0448] Rmis optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, optionally substituted aryl, optionally substituted heteroaryl, carboxamido, or carbonyl.
[0449] As used herein, the terms "treat," "treating," "treatment," and the like refer to eliminating, reducing, or ameliorating a disease, e.g., cancer, e.g. GIST, and / or symptoms associated therewith. Although not precluded, treating a disease does not require that the disease, or symptoms associated therewith be completely eliminated. The term "treat" and synonyms contemplate administering a therapeutically effective amount of a Compound of the Disclosure and optionally one more additional therapeutic agents to a subject need of such treatment. The treatment can be orientated symptomatically, for example, to suppress symptoms. It can be effected over a short period, be oriented over a medium term, or can be a long-term treatment, for example within the context of a maintenance therapy.
[0450] As used herein, the terms "prevent," "preventing," and "prevention" refer to a method of preventing the onset of a disease and / or its attendant symptoms or barring a subject from acquiring a disease. As used herein, "prevent," "preventing," and "prevention" also include delaying the onset of a disease and / or its attendant symptoms and reducing a subject's risk of acquiring a disease. The terms "prevent," "preventing" and "prevention" may include "prophylactic treatment," which refers to reducing the probability of redeveloping a disease, or of a recurrence of a previously-controlled disease, in a subject who does not have, but is at risk of or is susceptible to, redeveloping a disease or a recurrence of the disease.
[0451] A "subject" includes any human or nonhuman animal. The term "nonhuman animal" includes, but is not limited to, vertebrates such as nonhuman primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs. In some embodiments, the subject is a human. The terms, "subject" and "patient" are used interchangeably.
[0452] The term "therapeutically effective amount" and the like as used herein refers to an amount of a Compound of the Disclosure and, optionally, other active ingredient(s) that is / are sufficient, when administered according to a method of the present disclosure, to efficaciously deliver the active ingredient(s) for the treatment of a disease of interest, e.g., GIST, to a subject in need thereof. In the case of cancer, e.g., GIST, or other proliferation disorders, the therapeutically effective amount of the agent may reduce, e.g., retard to some extent or stop, unwanted cellular proliferation; reduce the number of cancer cells; reducethe tumor size, e.g., reduce tumor size by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% or more; inhibit, e.g., retard to some extent or stop, cancer cell infiltration into peripheral organs; inhibit, e.g., retard to some extent or stop, tumor metastasis; inhibit, to some extent, tumor growth; and / or relieve, to some extent, one or more of the symptoms associated with the cancer. To the extent the administered compound or composition prevents growth and / or kills existing cancer cells, it may be cytostatic and / or cytotoxic. In some embodiments, the methods and uses of the present disclosure induce cell death, apoptosis, or prolonged cell stasis of GIST cells and / or induce the eradication of tumor cells to the limit of detection and / or reduce the volume of the tumor and / or inhibit the new growth of the tumor.
[0453] The term "biological sample" as used herein refers to any tissue or fluid from a subject that is suitable for detecting a pathogenic variant in GIST. Examples of useful biological samples include, but are not limited to, tissue, e.g., tissue obtained from a tumor biopsy, blood, plasma, serous fluid, cerebrospinal fluid, saliva, urine, lymph, cerebral spinal fluid, and the like. Other suitable biological samples will be familiar to those of ordinary skill in the relevant arts. A biological sample can be analyzed for biomarker expression and / or mutation status using any technique known in the art and can be obtained using techniques that are well within the scope of ordinary knowledge of a clinical practitioner. In one embodiment of the disclosure, the biological sample is obtained by a tissue biopsy.
[0454] The term "container" means any receptacle and closure therefore suitable for storing, shipping, dispensing, and / or handling a pharmaceutical product.
[0455] The term "package insert" means information accompanying a pharmaceutical product that provides a description of how to formulate and / or administer the product, along with the safety and efficacy data required to allow the physician, pharmacist, and subject to make an informed decision regarding use of the product. The package insert generally is regarded as the "label" for a pharmaceutical product.
[0456] Concurrent administration," "administered in combination," "simultaneous administration," and similar phrases mean that two or more agents are administered concurrently to the subject being treated. By "concurrently," it is meant that each agent is administered either simultaneously or sequentially in any order at different points in time. However, if not administered simultaneously, it is meant that they are administered to asubject in a sequence and sufficiently close in time so as to provide the desired therapeutic effect and can act in concert. For example, a Compound of the Disclosure can be administered at the same time or sequentially in any order at different points in time as one or more additional therapeutic agents. A Compound of the Disclosure and an additional therapeutic agent can be administered separately, in any appropriate form and by any suitable route. When a Compound of the Disclosure and an additional therapeutic agent are not administered concurrently, it is understood that they can be administered in any order to a subject in need thereof. For example, a Compound of the Disclosure can be administered before, e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before, concomitantly with, or after, e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after, the administration of the additional therapeutic agent to the subject. In some embodiments, a Compound of the Disclosure and an additional therapeutic agent are administered less than 15 minutes apart, less than 30 minutes apart, less than 1 hour apart, less than 2 hours apart, less than 3 hours apart, less than 4 hours apart, less than 5 hours apart, less than 6 hours apart, less than 12 hours apart, less than 24 hours apart, or less than 48 hours apart. In some embodiment, the active agents of the combination therapy are administered at about 1 minute to about 24 hours apart.
[0457] The term "stable compound" refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture and formulation into an efficacious therapeutic agent.
[0458] The present disclosure encompasses any of the Compounds of the Disclosure being isotopically-labelled by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as2H (or deuterium (D)),3H,nC,13C,14C,15N,18O,170,31P,32P,35S,18F, and36C1, respectively, e.g.,3H,nC, and14C. In one embodiment, provided is a composition wherein substantially all of the atoms at a position within the Compound of the Disclosure are replaced by an atom having a different atomic mass or mass number. In another embodiment, provided is a composition wherein a portion of theatoms at a position within the Compound of the disclosure are replaced, i.e., the Compound of the Disclosure is enriched at a position with an atom having a different atomic mass or mass number. In some embodiments, one or more hydrogen atom are replaced with one or more deuterium atoms. Isotopically-labelled Compounds of the Disclosure can be prepared by methods known in the art.
[0459] Compounds of the Disclosure may contain one or more asymmetric carbon atoms and thus may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. The present disclosure encompasses the use of all such possible forms including racemic and resolved forms and mixtures thereof. Individual enantiomers of a chiral Compound of the Disclosure can be separated according to methods known in the art in view of the present disclosure. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers. All tautomers are also encompassed by the present disclosure.
[0460] As used herein, the term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes enantiomers and isomers of compounds with more than one chiral center that are not mirror images of one another (diastereomers).
[0461] The term "chiral center" or "asymmetric carbon atom" refers to a carbon atom to which four different groups are attached.
[0462] The terms "enantiomer" and "enantiomeric" refer to a molecule that cannot be superimposed on its mirror image and hence is optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image compound rotates the plane of polarized light in the opposite direction.
[0463] The term "racemic" refers to an optically inactive mixture of equal parts of enantiomers. In one embodiment, Compounds of the Disclosure are racemic.
[0464] The term "absolute configuration" refers to the spatial arrangement of the atoms of a chiral molecular entity (or group) and its stereochemical description, e.g., R or S.
[0465] The stereochemical terms and conventions used in the specification are meant to be consistent with those described in Pure & AppL Chem 68:2193 (1996), unless otherwise indicated.
[0466] The term "enantiomeric excess" or "ee" refers to a measure for how much of one enantiomer is present compared to the other. For a mixture of R and S enantiomers, the percent enantiomeric excess is defined as | R - S | *100, where R and S are the respective mole or weight fractions of enantiomers in a mixture such that R + S = 1 . With knowledge of the optical rotation of a chiral substance, the percent enantiomeric excess is defined as ([a]obs / [a]max)* 100, where [a]0bsis the optical rotation of the mixture of enantiomers and [a]max is the optical rotation of the pure enantiomer. Determination of enantiomeric excess is possible using a variety of analytical techniques, including NMR spectroscopy, chiral column chromatography, or optical polarimetry.
[0467] The term "wt / wt %" as used herein refers to the mass of one component in a composition, e.g., a pharmacutical composition comprising a Compound of the Disclosure and one or more one or more pharmaceutically acceptable carriers, divided by the combined mass of all components in the composition, times 100. For example, the wt / wt % of a Compound of the Disclosure in a composition comprising 1 kg of the compound, 1 kg hydroxypropyl methyl cellulose, and 2 kg of polyvinylpyrrolidone, is 25 wt / wt % (1 kg / 4 kg = 0.25 x 100 = 25 wt / wt %). The wt / wt % of a Compound of the Disclosure in a composition comprising 1 kg of the compound and 1 kg of methylcellulose is 50 wt / wt % (1 kg / 2 kg = 0.20 x 100 = 50 wt / wt %).
[0468] The term "pharmaceutically acceptable carrier" as used herein refers to a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic and thus acceptable for veterinary and / or human pharmaceutical or therapeutic use. Pharmaceutically acceptable carriers include, but are not limited to, any excipient, diluent, filler, binder, buffer, stabilizer, solubilizer, disintegrant, lipid, stabilizer, suspension agent, viscosity agent, lubricant, glidant, or other material well known in the art for use in pharmaceutical formulations.
[0469] The term "excipient" as used herein refers to any and all solvents, diluents or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. General considerations in formulation and / or manufacture can be found, for example, in Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and Remington: The Science and Practice of Pharmacy, 21st Edition (Lippincott Williams & Wilkins, 2005).
[0470] Non-limiting exemplary excipients include, but are not limited to, any non-toxic, inert solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as excipients include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; com oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as Tween 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. As would be appreciated by one of skill in this art, the excipients may be chosen based on what the composition is useful for. For example, with a pharmaceutical composition, the choice of the excipient will depend on the route of administration, the agent being delivered, time course of delivery of the agent, etc., and can be administered to a subject, e.g., humans and / or to animals, orally, rectally, parenterally, intraci stemally, intravaginally, intranasally, intraperitoneally, topically (as by powders, creams, ointments, or drops), buccally, or as an oral or nasal spray. In some embodiments, a Compound of the Disclosure administered orally or parenterally. In some embodiments, a Compound of the Disclosure administered orally.
[0471] Non-limiting exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.
[0472] Non-limiting exemplary granulating and / or dispersing agents include potato starch, com starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins,calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.
[0473] Non-limiting exemplary surface active agents and / or emulsifiers include natural emulsifiers, e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin, colloidal clays, e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate), long chain amino acid derivatives, high molecular weight alcohols, e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, and polyvinyl alcohol, carbomers, e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxy vinyl polymer, carrageenan, cellulosic derivatives, e.g., carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and methylcellulose, sorbitan fatty acid esters, e.g., polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan (Tween 60), polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60), sorbitan tristearate (Span 65), glyceryl monooleate, and sorbitan monooleate (Span 80), polyoxyethylene esters, e.g., polyoxyethylene monostearate (Myrj 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol, sucrose fatty acid esters, polyethylene glycol fatty acid esters, e.g., Cremophor, polyoxyethylene ethers, , e.g., polyoxyethylene lauryl ether (Brij 30), poly(vinyl-pyrrolidone), di ethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Pol oxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and / or combinations thereof. Exemplary binding agents include starch, , e.g., cornstarch and starch paste, gelatin, sugars, e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc., natural and synthetic gums, e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose,methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, polyvinylpyrrolidone, magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, etc., and / or combinations thereof.
[0474] Non-limiting exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.
[0475] Non-limiting exemplary antioxidants include alpha tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
[0476] Non-limiting exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof, e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like, citric acid and salts and hydrates thereof, e.g., citric acid monohydrate, fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
[0477] Non-limiting exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
[0478] Non-limiting exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.
[0479] Non-limiting exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid. Other preservatives include tocopherol, tocopherol acetate, deteroximemesylate, cetrimide, butylated hydroxyanisol (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, NeoIone, Kathon, and Euxyl. In certain embodiments, the preservative is an anti-oxidant. In other embodiments, the preservative is a chelating agent.
[0480] Non-limiting exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, etc., and combinations thereof.
[0481] Non-limiting exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behanate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.
[0482] A pharmaceutically acceptable composition of the present disclosure may further comprise a polymer. Non-limiting exemplary polymers include cellulosic polymers and copolymers, for example, cellulose ethers such as methylcellulose (MC), hydroxyethylcellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), methylhydroxyethylcellulose (MHEC), methylhydroxypropylcellulose (MHPC), carboxymethyl cellulose (CMC) and its various salts, including, e.g., the sodium salt, hydroxyethylcarboxymethylcellulose (HECMC) and its various salts, carboxymethylhydroxyethylcellulose (CMHEC) and its various salts, other polysaccharides and polysaccharide derivatives such as starch, dextran, dextran derivatives, chitosan, and alginic acid and its various salts, carageenan, varoius gums, including xanthangum, guar gum, gum arabic, gum karaya, gum ghatti, konjac and gum tragacanth, glycosaminoglycans and proteoglycans such as hyaluronic acid and its salts, proteins such as gelatin, collagen, albumin, and fibrin, other polymers, for example, polyhydroxyacids such as polylactide, polyglycolide, polyl(lactide-co-glycolide) and poly(epsilon- caprolactone-co-glycolide), carboxy vinyl polymers and their salts e.g., carbomer, polyvinylpyrrolidone (PVP), polyacrylic acid and its salts, polyacrylamide, polyacrylic acid / acrylamide copolymer, polyalkylene oxides such as polyethylene oxide, polypropylene oxide, polyethylene oxi de-propylene oxide), and a pluronic polymer, polyoxy ethylene (polyethylene glycol), polyanhydrides, polyvinylalchol, polyethyleneamine and polypyrridine, polyethylene glycol (PEG) polymers, such as PEGylated lipids, e.g., PEG-stearate, l,2-Distearoyl-sn-glycero-3-Phosphoethanolamine- N-(Methoxy(Polyethylene glycol)-1000], l,2-Distearoyl-sn-glycero-3- Phosphoethanolamine-N-(Methoxy(Poly ethylene glycol)-2000], and 1,2-Distearoyl-sn- glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethyleneglycol)-5000]), copolymers and salts thereof.
[0483] A pharmaceutically acceptable composition of the present disclosure may further comprise an emulsifying agent. Non-limiting exemplary emulsifying agents include a polyethylene glycol (PEG), a polypropylene glycol, a polyvinyl alcohol, a poly-N-vinyl pyrrolidone and copolymers thereof, poloxamer nonionic surfactants, neutral water-soluble polysaccharides, e.g., dextran, Ficoll, celluloses, non-cationic poly(meth)acrylates, noncationic polyacrylates, such as poly (meth) acrylic acid, and esters amide and hydroxy alkyl amides thereof, natural emulsifiers, e.g., acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin, colloidal clays, e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate), long chain amino acid derivatives, high molecular weight alcohols, e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, and polyvinyl alcohol, carbomers, e.g., carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxy vinyl polymer, carrageenan, cellulosic derivatives, e.g., carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and methylcellulose, sorbitan fatty acid ester, e.g., polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylenesorbitan (Tween 60), polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60), sorbitan tristearate (Span 65), glyceryl monooleate, sorbitan monooleate (Span 80), polyoxyethylene esters, e.g., polyoxyethylene monostearate (Myij 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol, sucrose fatty acid esters, polyethylene glycol fatty acid esters, e.g., Cremophor, polyoxyethylene ethers, e.g., polyoxyethylene lauryl ether (Brij 30), poly(vinyl-pyrrolidone), di ethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Pol oxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and / or combinations thereof. In certain embodiments, the emulsifying agent is cholesterol.
[0484] Pharmaceutically acceptable liquid compositions of the present disclosure may include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to a Compound of the Disclosure, the liquid composition may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, e.g., cottonseed, groundnut, com, germ, olive, castor, and sesame oils, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, stabilizers, thickening agents, colorants, sweetening, flavoring, and perfuming agents.
[0485] Pharmaceutically acceptable injectable compositions of the present disclosure may be, for example, injectable aqueous or oleaginous suspensions that may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be an injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents for pharmaceutical or cosmetic compositions that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid areused in the preparation of injectables. In certain embodiments, the particles are suspended in a carrier fluid comprising 1% (w / v) sodium carboxymethyl cellulose and 0.1% (v / v) Tween 80. The injectable composition can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0486] Pharmaceutically acceptable compositions of the present disclosure for rectal or vaginal administration may be, for example, in the form of suppositories which can be prepared by mixing the particles with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the particles.
[0487] Pharmaceutically acceptable solid compositions of the present disclosure may be, for example, capsules, tablets, pills, powders, and granules. In such solid compositions, the particles are mixed with at least one excipient and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0488] Tablets, capsules, pills, and granules comprising a Compound of the Disclosure can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples ofembedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0489] Pharmaceutically acceptable compositions for topical or transdermal administration include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The Compound of the Disclosure is admixed with an excipient and any needed preservatives or buffers as may be required. The ointments, pastes, creams, and gels may contain, in addition to the Compound of the Disclosure, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or mixtures thereof.
[0490] Pharmaceutically acceptable powders and sprays may contain, in addition to the Compound of the Disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
[0491] The term "about," as used herein, includes the recited number ± 10%. Thus, "about 10" means 9 to 11.
[0492] As used herein, the term "and / or" is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and / or" as used in a phrase such as "A and / or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and / or" as used in a phrase such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or B; A or C; B or C; A and B; A and C; B and C; A (alone); B (alone); and C (alone).
[0493] The use of the terms "a," "an," "the," and similar referents in the context of describing the disclosure (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated. Recitation of ranges of values herein merely are intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The use of any and all examples, or exemplary language, e.g., "such as," provided herein, is intended to better illustrate the disclosure and is not a limitation on the scope of thedisclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.
[0494] The word "comprising" is used in a manner consistent with its open-ended meaning, that is, to mean that a given product, composition, or process can optionally also have additional features or elements beyond those expressly described. It is understood that wherever embodiments are described with the language "comprising," otherwise analogous embodiments described in terms of "consisting of' and / or "consisting essentially of are also contemplated and within the scope of this disclosure.
[0495] Pharmaceutically acceptable salts and solvates, e.g., hydrates, of the Compounds of the Disclosure can also be used in the methods disclosed herein.
[0496] The present disclosure encompasses the preparation and use of pharmaceutically acceptable salts of Compounds of the Disclosure. Pharmaceutically acceptable salts of Compounds of the Disclosure can be prepared during the final isolation and purification of the compounds or separately by reacting the compound with a suitable acid or base. The reaction may take place in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin. Pharmaceutically acceptable salts of Compounds of the Disclosure can be acid addition salts formed with acceptable acids. Examples of acids which can be employed to form salts include inorganic acids such as nitric, boric, hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Non-limiting examples of salts of compounds of the disclosure include, but are not limited to, the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, 2-hydroxyethansulfonate, phosphate, hydrogen phosphate, acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate, camphorate, camphor sulfonate, digluconate, glycerolphosphate, hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate, maleate, ascorbate, isethionate, salicylate, methanesulfonate, mesitylenesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, paratoluenesulfonate, undecanoate, lactate, citrate, tartrate, gluconate, methanesulfonate, ethanedi sulfonate, benzene sulfonate, and p-toluenesulfonate salts. In addition, available amino groups present in the compounds of the disclosure can bequatemized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
[0497] The present disclosure encompasses the preparation and use of solvates of Compounds of the Disclosure. The term "solvate" as used herein is a combination, physical association and / or solvation of a compound of the present disclosure with a solvent molecule such as, e.g., a disolvate, monosolvate or hemisolvate, where the ratio of solvent molecule to compound of the present disclosure is about 2:1, about 1:1 or about 1:2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. Thus, "solvate" encompasses both solution-phase and isolatable solvates. Compounds of the Disclosure can be present as solvated forms with a solvent, such as water, methanol, and ethanol, and it is intended that the disclosure includes both solvated and unsolvated forms of Compounds of the Disclosure.
[0498] One type of solvate is a hydrate. A "hydrate" relates to a particular subgroup of solvates where the solvent molecule is water. Preparation of solvates is known in the art. See, for example, M. Caira et al., J. Pharmaceut. Sci., 93(3):601-611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by van Tonder et al., AAPS Pharm. Sci. Tech., 5(l):Article 12 (2004), and A.L. Bingham et al., Chem. Commun. 603-604 (2001). Atypical, non-limiting, process of preparing a solvate would involve dissolving a Compound of the Disclosure in a desired solvent (organic, water, or a mixture thereof) at temperatures above 20°C to about 25°C, then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
[0499] In light of the foregoing, any reference to Compounds of the Disclosure appearing in the present disclosure includes such compounds as well as pharmaceutically acceptable salts, hydrates, or solvates thereof.
[0500] The terms "KIT," "CD117," and "mast / stem cell growth factor receptor (SCFR)," as used herein, can be used interchangeably. The receptor tyrosine kinase protein known astyrosine-protein kinase KIT is encoded by the proto-oncogene c-KIT. The human KIT amino acid sequence is, for example, set forth in Uniprot database entry P10721.
[0501] The term "PDGFRA," as used herein, relates to platelet-derived growth factor receptor alpha. The human PDGFRA amino acid sequence is, for example, set forth in Uniprot database 5 entry Pl 6234.
[0502] The terms "gastrointestinal stromal tumor" or "GIST" as used herein refers to mesenchymal tumors located in the gastrointestinal tract (such as the stomach, the small intestine, and the large intestine) or in surrounding organs or tissues (such as the appendix, ampulla vater, rectum, omentum, anus, or the esophagus).
[0503] In the context of the present disclosure, reference is made to mutations in KIT or PDGFRA, both of which are key factors in the development and progression of a cancer comprising one or more KIT and / or PDGFRA mutations. As used herein, a "mutation" refers to an addition (insertion), deletion, or substitution of a single nucleotide at a site in a nucleic acid molecule encoding for KIT or PDGFRA, for example resulting in the onset of the disease and / or conferring resistance to a particular therapy, such as treatment with imatinib. Thus, in particular aspects, an alteration in the sequence of KIT and / or PDGFRA results in a change that affects the activity, expression, or stability of a transcript or polypeptide encoded by the sequence such that certain cellular pathways are deregulated and / or at least some resistance to therapy with kinase inhibitor drugs, such as imatinib, occurs as a result.
[0504] KIT mutations commonly found in a cancer comprising one or more KIT and / or PDGFRA mutations are KIT exon 8 mutations (extracellular (EC) domain), KIT exon 9 mutations (EC domain), KIT exon 10 mutations, KIT exon 11 mutations (juxtamembrane (JM) domain), KIT exon 13 mutations (ATP binding site on TKD, first catalytic domain), KIT exon 14 mutations (ATP binding site on tyrosine kinase domain (TKD)), KIT exon 17 mutations (intracellular (IC) domain of activation loop, second catalytic domain), and KIT exon 18 mutations (activation loop (AL)).
[0505] PDGFRA mutations commonly encountered in a cancer comprising one or more KIT and / or PDGFRA mutations are PDGFRA exon 12 mutations (JMD), PDGFRA exon 13 mutations, PDGFRA exon 14 mutations (ATP binding site TKD), PDGFRA exon 15 mutations, and PDGFRA exon 18 mutations (activation loop of the IC domain).
[0506] In some embodiments, the mutation in the cancer comprising one or more KIT and / or PDGFRA mutations to be treated is a primary mutation. The term "primary mutation," as used herein, refers to a mutation in KIT or PDGFRA. Primary mutations in KIT (mostly exon 11 or exon 9) can be treated with imatinib.
[0507] For instance, but without limitation, the primary mutation can be a KIT 8 exon mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, or a PDGFRA exon 18 mutation.
[0508] The primary mutation may also be a PDGFRA exon 18 mutation or a PDGFRA exon 12 mutation.
[0509] In the present disclosure, if reference is made to specific mutations, the affected amino acids are indicated by their one letter codes. Further, the conventional nomenclature for substitutions, deletions and insertions is used. For example, "D842V" thus means that the aspartate (D) in position 842 is replaced by a valine (V). If two target amino acids are indicated, such as "N659K / T," this means that both mutations from N659 to K as well as to T are possible.
[0510] In some embodiments, the cancer comprising one or more KIT and / or PDGFRA mutations has at least one secondary mutation. The term "secondary mutation," as used herein, refers to mutation(s) that are typically not the initiating oncogenic event in the neoplastic disease or condition, i.e. in the cancer, but instead usually emerge at a later stage of the cancer, particularly in the course of treatment with one or more drugs, such as, without limitation, one or more of imatinib, sunitinib, regorafenib, ripretinib, and avapritinib. In other words, a secondary mutation is a mutation the tumor has acquired at any stage after the primary mutation(s). Accordingly, in the context of the present disclosure, the tumor can have, in some embodiments, in addition to at least one primary mutation, as herein defined, at least one secondary mutation. The secondary mutation is essentially always a KIT or PDGFRA mutation and generally happens in the same gene as the primary mutation. Once secondary mutations in KIT occur, imatinib becomes ineffective, and second line therapy sunitinib is typically prescribed.
[0511] Any reference to "KIT inhibition," "inhibition of KIT," and the like in the present disclosure includes inhibition of mutated and / or unmutated forms KIT. Likewise, anyreference to "PDGFRA inhibition," "inhibition of PDGFRA," and the like includes inhibition of mutated and / or unmutated forms PDGFRA.
[0512] In some embodiments, the cancer comprising one or more KIT and / or PDGFRA mutations comprises a drug-resistant mutation. The term "drug-resistant mutation," as used herein, refers to mutation(s) of a tumor that render treatment of the tumor with one or more drugs, non-effective, in other words, the tumor, originally and commonly susceptible to treatment with said drug, becomes unresponsive to treatment with said drug. In the case of GIST, this means that drugs that are known to be effective, at least in a certain proportion of GIST cases, such as imatinib, sunitinib, regorafenib, ripretinib and avapritinib, become non-effective. Typically, tumor cells acquire such mutation during the course of a given treatment and thus escape the treatment regimen and can thus drive a relapse.
[0513] For instance, but without limitation, in some embodiments the tumor comprises a mutation that renders it imatinib resistant, sunitinib resistant, regorafenib resistant, ripretinib resistant and / or avapritinib resistant.
[0514] Imatinib is typically the first line drug for the treatment of GIST and CML. The term "imatinib resistant," as used herein, refers to mutation(s) of a tumor that render treatment of the tumor with imatinib or a pharmaceutically acceptable salt and solvate thereof non-effective. In other words, the tumor is or becomes unresponsive to treatment with imatinib. This can mean that common doses used for the treatment do not have the desired effect.
[0515] Sunitinib is the standard second-line treatment after imatinib failure, but in some instances can also be used as a third-line treatment. The term "sunitinib resistant," as used herein, refers to mutation(s) of a tumor that render treatment of the tumor with sunitinib or a pharmaceutically acceptable salt and solvate thereof non-effective. In other words, the tumor is unresponsive to treatment with sunitinib or a pharmaceutically acceptable salt and solvate thereof. This can mean that common doses used for the treatment do not have the desired effect.
[0516] Regorafenib is active for some secondary mutations resistant to imatinib and sunitinib and is thus commonly used as a third-line treatment after imatinib and / or sunitinib failure. The term "regorafenib resistant," as used herein, refers to mutation(s) of a tumor that render treatment of the tumor with regorafenib or a pharmaceutically acceptable salt and solvate thereof non-effective. In other words, the tumor is unresponsive to treatmentwith regorafenib or a pharmaceutically acceptable salt and solvate thereof. This can mean that common doses used for the treatment do not have the desired effect.
[0517] Ripretinib is commonly used as a fourth-line treatment after failure of imatinib, sunitinib and regorafenib. The term "ripretinib resistant," as used herein, refers to mutation(s) of a tumor that render treatment of the tumor with ripretinib or a pharmaceutically acceptable salt and solvate thereof non-effective. In other words, the tumor is unresponsive to treatment with ripretinib or a pharmaceutically acceptable salt and solvate thereof. This can mean that common doses used for the treatment do not have the desired effect.
[0518] Avapritinib is currently used in the treatment of GIST with a confirmed PDGFRA D842V mutation, which is otherwise considered as refractory to treatment, and mastocytosis. The term "avapritinib resistant," as used herein, refers to mutation(s) of a tumor that render treatment of the tumor with avapritinib or a pharmaceutically acceptable salt thereof non-effective, in other words, the tumor is unresponsive to treatment with avapritinib or a pharmaceutically acceptable salt thereof. This can mean that common doses used for the treatment no longer have the desired effect.VIII. Particular Embodiments
[0519] The present disclosure provides the following particular embodiments.
[0520] Embodiment 1. A compound having Formula (I):or a pharmaceutically acceptable salt thereof, wherein:
[0521] X is selected from the group consisting of O and S;
[0522] R1is selected from the group consisting of optionally substituted aryl and optionally substituted 5- to 10-membered heteroaryl;
[0523] R2is optionally substituted 4- to 8-membered heterocyclo; and
[0524] R3, R4a, R4b, and R5are hydrogen,
[0525] wherein the compound is selected from any one or more of the compounds of Table 1.
[0526] Embodiment 2. The compound of Embodiment 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
[0527] Embodiment 3. The compound of Embodiment 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
[0528] Embodiment 4. The compound of Embodiment 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
[0529] Embodiment 5. A pharmaceutical composition comprising the compound of any one of Embodiments 1-4, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
[0530] Embodiment 6. A method of treating a cancer comprising a KIT tyrosine kinase (KIT) mutation in a subject in need thereof, the method comprising administering a therapeutically effective amount of the compound of any one of Embodiments 1-4 to the subject.
[0531] Embodiment 7. The method of Embodiment 6, wherein the KIT mutation is a gain-of-function mutation.
[0532] Embodiment 8. The method of Embodiments 6 or 7, wherein the cancer comprising a KIT mutation is gastrointestinal stromal tumor (GIST), acute myeloid leukemia (AML), chronic myelogeneous leukemia (CML), sinonasal natural killer / T-cell lymphoma, seminoma, melanoma, or mastocytosis.
[0533] Embodiment 9. The method of Embodiment 8, wherein the cancer comprising a KIT mutation is GIST.
[0534] Embodiment 10. The method of Embodiment 9, wherein the GIST comprises a drug-resistant KIT mutation.
[0535] Embodiment 11. The method of Embodiment 10, wherein the GIST comprises an imatinib resistant mutation, sunitinib resistant mutation, regorafenib resistant mutation, ripretinib resistant mutation, avapritinib resistant mutation, or a combination thereof.
[0536] Embodiment 12. The method of any one of Embodiments 9-11, wherein the GIST further comprises a platelet-derived growth factor receptor-alpha (PDGFRA) mutation.
[0537] Embodiment 13. The method of any one of Embodiments 9-12, wherein the GIST comprises a KIT exon 8 mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, a KIT exon 18 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, a PDGFRA exon 18 mutation, or a combination thereof.
[0538] Embodiment 14. The method of any one of Embodiments 9-13, wherein the KIT mutation comprises a missense mutation, insertion mutation, a deletion mutation, or a combination thereof.
[0539] Embodiment 15. The method of any one of Embodiments 9-14, wherein the KIT mutation comprises a primary mutation.
[0540] Embodiment 16. The method of any one of Embodiments 9-15, wherein the GIST comprises: (i) a KIT exon 9 mutation selected from the group consisting of p.A502_Y503dup, p.Y503_F504insAY, andp.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from the group consisting ofK642E, V65A, and T670I; (iv) a KIT exon 17 mutation selected from the group consisting of mutations involving codons 809, 816, 820, 822, or 823; (v) a KIT exon 18 mutation selected from the group consisting of mutations involving codon 829; (vi) a PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.581S; or (vii) a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0541] Embodiment 17. The method of any one of Embodiments 9-16, wherein the GIST comprises one or more PDGFRA mutations selected from the group consisting of V598F, G605A, G652E, P653Q, V658A, N659K / T, T674R / I, E675G, Y676C, G680R / E, D842V, and I843_D846del.
[0542] Embodiment 18. The method of Embodiment 17, wherein the GIST comprises the PDGFRA mutation D842V.
[0543] Embodiment 19. The method of Embodiment 17, wherein the GIST comprises the PDGFRA mutation G680R.
[0544] Embodiment 20. The method of Embodiment 17, wherein the GIST comprises the PDGFRA mutation G652E.
[0545] Embodiment 21. The method of Embodiment 17, wherein the GIST comprises the PDGFRA mutation V658A.
[0546] Embodiment 22. The method of Embodiment 17, wherein the GIST comprises the PDGFRA mutation V658A and mutation G652E.
[0547] Embodiment 23. The method of any one of Embodiments 9-22, wherein the GIST comprises one or more KIT mutations selected from the group consisting of S476I, F522C, K642E, V654A, N655K, T670E / I, D816A / E / G / H / N / V, D820A / E / G / H / V / Y, N822I / K / Y, Y823C / D, and A829P.
[0548] Embodiment 24. The method of Embodiment 23, wherein the GIST comprises the KIT mutation T670I.
[0549] Embodiment 25. The method of Embodiment 23, wherein the GIST comprises the KIT mutation V654A.
[0550] Embodiment 26. The method of Embodiment 23, wherein the GIST comprises the KIT mutation D816A.
[0551] Embodiment 27. The method of Embodiment 23, wherein the GIST comprises the KIT mutation D820A.
[0552] Embodiment 28. The method of Embodiment 23, wherein the GIST comprises the KIT mutation N822K.
[0553] Embodiment 29. The method of Embodiment 23, wherein the GIST comprises the KIT mutation A829P.
[0554] Embodiment 30. The method of any one of Embodiments 9-29, wherein the GIST comprises at least one primary and at least one secondary mutation.
[0555] Embodiment 31. The method of Embodiment 30, wherein the GIST comprises: (i) a primary KIT exon 9 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0556] Embodiment 32. The method of Embodiment 30, wherein the GIST comprises: (i) a primary KIT exon 11 mutation; and (ii) a secondary KIT exon 13 mutation,a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0557] Embodiment 33. The method of Embodiment 30, wherein the GIST comprises: (i) a primary KIT exon 13 mutation; and (ii) a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
[0558] Embodiment 34. The method of Embodiment 30, wherein the GIST comprises: (i) a primary KIT exon 17 mutation; and (ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, or a secondary KIT exon 18 mutation.
[0559] Embodiment 35. The method of Embodiment 30, wherein the GIST comprises: (i) a primary PDGFRA exon 12 mutation; and (ii) a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, a secondary PDGFRA exon 15 mutation, or a secondary PDGFRA exon 18 mutation.
[0560] Embodiment 36. The method of Embodiment 30, wherein the GIST comprises: (i) a primary PDGFRA exon 18 mutation; and (ii) a secondary PDGFRA exon 12 mutation, a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, or a secondary PDGFRA exon 15 mutation.
[0561] Embodiment 37. The method of any one of Embodiments 9-36, wherein the GIST comprises compound mutations selected from double-in-cis mutations or triple-incis mutations.
[0562] Embodiment 38. The method of Embodiment 37, wherein the GIST comprises: (i) a primary KIT exon 9 mutation; and (ii) at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0563] Embodiment 39. The method of Embodiment 38, wherein the GIST comprises: (i) a primary KIT exon 9 mutation; and (ii) at least one acquired mutation in KIT exon 13 or KIT exon 14; and (iii) at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0564] Embodiment 40. The method of Embodiment 37, wherein the GIST comprises: (i) a primary KIT exon 11 mutation; and (ii) at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
[0565] Embodiment 41. The method of Embodiment 40, wherein the GIST comprises: (i) a primary KIT exon 11 mutation; and (ii) at least one acquired mutation in- Ill -KIT exon 13 or KIT exon 14; and (iii) at least one acquired mutation in KIT exon 17 or KIT exon 18.
[0566] Embodiment 42. The method of any one of Embodiments 9-41, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatlanib, crenolanib, ripretinib, nintedanib, ponatinib, nilotinib, axitinib, cabozantinib, pazopanib, pexidartinib, bezuclastinib, dasatinib, sorafenib, and / or avapritinib, or a pharmaceutically acceptable salt and solvate thereof.
[0567] Embodiment 43. The method of Embodiment 42, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, ripretinib and / or avapritinib.
[0568] Embodiment 44. The method of Embodiments 42 or 43, wherein the subject was previously treated with imatinib.
[0569] Embodiment 45. The method of any one of Embodiments 42-44, wherein the subject was previously treated with sunitinib.
[0570] Embodiment 46. The method of any one of Embodiments 42-45, wherein the subject was previously treated with regorafenib.
[0571] Embodiment 47. The method of any one of Embodiments 42-46, wherein the subject was previously treated with ripretinib.
[0572] Embodiment 48. The method of any one of Embodiments 42-47, wherein the subject was previously treated with avapritinib.
[0573] Embodiment 49. The method of any one of Embodiments 9-48, wherein the GIST is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of imatinib, administration of sunitinib, administration of regorafenib, administration of ripretinib and / or administration of avapritinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib, ripretinib, and / or avapritinib.
[0574] Embodiment 50. The method of any one of Embodiments 9-49, wherein the GIST is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and an optional third line administration of regorafenib or ripretinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib and / or ripretinib.
[0575] Embodiment 51. The method of Embodiment 50, wherein the GIST comprises a KIT exon 8 mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, or a KIT exon 18 mutation, wherein, the GIST comprises a KIT exon 9 mutation selected from the group consisting of: (i) p.A502_Y503dup, p.Y503_F504insAY, and p.S464L; (ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from K642E, V65A, and T670I; or (iv) a KIT exon 17 mutation selected from mutations involving codons 816, 820 or 823.
[0576] Embodiment 52. The method of any one of Embodiments 9-51, wherein the GIST is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of avapritinib, or wherein the subject has a documented intolerance to avapritinib.
[0577] Embodiment 53. The method of Embodiment 52, wherein the GIST comprises aPDGFRA exon 12 mutation, aPDGFRA exon 13 mutation, aPDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, or a PDGFRA exon 18 mutation, wherein the PDGFRA exon 12 mutation is selected from the group consisting of p.W559_R560del and p.P581S; or a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
[0578] Embodiment 54. The method of Embodiment 8, wherein the cancer comprising a KIT mutation is acute myeloid leukemia (AML), chronic myelogeneous leukemia (CML), sinonasal natural killer / T-cell lymphoma, seminoma, melanoma, or mastocytosis.
[0579] Embodiment 55. The method of Embodiment 54, wherein the cancer is acute myeloid leukemia (AML).
[0580] Embodiment 56. The method of Embodiment 54, wherein the cancer is chronic myelogeneous leukemia (CML).
[0581] Embodiment 57. The method of Embodiment 54, wherein the cancer is sinonasal natural killer / T-cell lymphoma.
[0582] Embodiment 58. The method of Embodiment 54, wherein the cancer is seminoma.
[0583] Embodiment 59. The method of Embodiment 54, wherein the cancer is melanoma.
[0584] Embodiment 60. The method of Embodiment 59, wherein the cancer is mucosal melanoma.
[0585] Embodiment 61. The method of Embodiment 59, wherein the cancer is cutaneous melanoma.
[0586] Embodiment 62. The method of Embodiment 59, wherein the cancer is acral lentiginous melanoma.
[0587] Embodiment 63. The method of Embodiment 54, wherein the cancer is mastocytosis.
[0588] Embodiment 64. The method of Embodiment 63, wherein the mastocytosis is non-advanced mastocytosis.
[0589] Embodiment 65. The method of Embodiment 64, wherein the non-advanced mastocytosis is indolent mastocytosis or systemic smoldering mastocytosis.
[0590] Embodiment 66. The method of Embodiment 63, wherein the mastocytosis is advanced mastocytosis.
[0591] Embodiment 67. The method of Embodiment 66, wherein the advanced mastocytosis is aggressive systemic mastocytosis, systemic mastocytosis with associated hematologic neoplasm, mast cell leukemia, or mast cell sarcoma.
[0592] Embodiment 68. The method of any one of Embodiments 54-67, further comprising co-administering at least one of imatinib, sunitinib, or regorafenib.
[0593] Embodiment 69. The method of any one of Embodiments 54-68, wherein the KIT mutation is an exon 8 mutation, an exon 9 mutation, an exon 11 mutation, an exon 13 mutation, an exon 17 mutation other than a D816V mutation, a D816V mutation, or a combination thereof.
[0594] Embodiment 70. The method of any one of Embodiments 6-69, wherein the subject is a human subject.
[0595] Embodiment 71. The method of any one of Embodiments 6-70, wherein the compound is for treating a cancer comprising a KIT mutation in a subject in need thereof.
[0596] Embodiment 72. The method of any one of Embodiments 6-70, wherein the compound is for preventing a cancer comprising a KIT mutation in a subject in need thereof.
[0597] Embodiment 73. The method of any one of Embodiments 6-72, further comprising administering one or more additional therapeutic agents to the subject.
[0598] Embodiment 74. The method of Embodiment 73, wherein the one or more additional therapeutic agents comprises topotecan.
[0599] Embodiment 75. The method of Embodiments 73 or 74, wherein the one or more additional therapeutic agents comprises an irinotecan drug product (IDP).
[0600] Embodiment 76. The method of Embodiment 75, wherein the IDP comprises irinotecan.
[0601] Embodiment 77. The method of Embodiment 75, wherein the IDP comprises irinotecan hydrochloride.
[0602] Embodiment 78. The method of Embodiment 75, wherein the IDP comprises irinotecan sucrosofate.
[0603] Embodiment 79. The method Embodiment 75, wherein the IDP further comprises encequidar methanesulfonate.
[0604] Embodiment 80. The method of any one of Embodiments 73-79, wherein the one or more additional therapeutic agents comprises radiotherapy.
[0605] Embodiment 81. A method of inhibiting proliferation of a cell comprising a KIT mutation in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound of Table 1 to the subject.ExamplesExample 1Synthesis of 5-[4-(l-cyanocyclopropyl)phenyl]-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 1)2M HCI / dioxane25 °C, 1 h35.5%
[0606] Step l:
[0607] (3S)-3-[(5-bromo-3-ureido-thiophene-2-carbonyl)amino]piperidine-l-carboxylate ("INT2") can be prepared as described in Example 15 (Method B) of WO 2005 / 066163.
[0608] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, eq , l-[4-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarbonitrile (135 mg, 0.503 mmol, 1.5 eq , Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq), K2CO3 (139 mg, 1.01 mmol, 3 eq in dioxane (2 mL) and H2O (0.1 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90 °C for 2 hours under N2 atmosphere. The reaction mixture was diluted with H2O (10 mL) and the mixture was extracted with EtOAc (10 mL * 3). The combined organic phase was washed with brine (10 mL * 2), dried with anhydrous Na2SC>4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-100% hexane / ethyl acetate at 35 mL / min) to give tert-butyl (3 S)-3-[[5-[4-(l - cyanocyclopropyl)phenyl]-3-ureido-thiophene-2-carbonyl]amino]piperidine-l- carboxylate (105 mg, 58.3% yield, 94.9% purity) as a yellow oil. LCMS: calc, for C26H31N5O4S1: 509.2, found: [M+H]+510.3.
[0609] Step 2:
[0610] A solution of tert-butyl (3S)-3-[[5-[4-(l-cyanocyclopropyl)phenyl]-3-ureido- thiophene-2-carbonyl]amino]piperidine-l-carboxylate (105 mg, 0.206 mmol, eq in 2M HCl / di oxane (2 mL, 4.00 mmol, 19.4 eq) was stirred at 25 °C for 1 hour. The reaction mixture was diluted with H2O (10 mL) and the mixture was adjusted to a pH of 7 with NaHCCh. The mixture was extracted with EtOAc (20 mL * 3). The combined organic phase was washed with brine (10 mL * 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: 41-WePure Biotech XP tC18 150 x 40 mm, 7 pm; mobilephase: [08-water (0.05%NH3H20 + 10 mMNH^HCChj-ACN]; gradient: 17%-57% B over 12.0 min) to give 5-[4-(l-cyanocyclopropyl)phenyl]-N-[(3S)- 3-piperidyl]-3-ureido-thiophene-2-carboxamide (30.1 mg, 35.5% yield, 99.46% purity) as a white solid. LCMS: calc, for C21H23N5O2S: 409.2, found: [M+H]+410.1. HPLC: 99.46% purity at 254 nm. 'H NMR: (400 MHz, DMSO-t / r,) 8 ppm 10.05 (br s, 1H), 8.25 (s, 1H), 7.78 (brd, J= 8.1 Hz, 1H), 7.64 (d, J= 8.5 Hz, 2H), 7.41 (d, J= 8.4 Hz, 2H), 6.63 (s, 2H), 3.83 - 3.74 (m, 1H), 2.92 (br dd, J= 2.6, 11.6 Hz, 1H), 2.78 (br d, J= 12.1 Hz, 1H), 2.45 - 2.37 (m, 2H), 1.84 - 1.76 (m, 3H), 1.61 (br dd, J= 3.8, 8.8 Hz, 1H), 1.58 - 1.54 (m, 2H), 1.52 - 1.45 (m, 1H), 1.44 - 1.34 (m, 1H).Example 2Synthesis of 5-(l,2-benzoxazol-6-yl)-A-[(35)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (Cpd. No. 2)\ NH2OH-HCI, pyridine N EtOH, 20 °c, 2 h boo 79.9% ’NH2Cpd. No.2
[0611] Step l:
[0612] A mixture of tert-butyl (35)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (300 mg, 0.671 mmol, 1 eq), 2-hydroxy-4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzaldehyde (250 mg, 1.01 mmol, 1.5 eq , K2CO3 (185 mg, 1.34 mmol, 2 eq) and Pd(dppf)C12 (49 mg, 0.0671 mmol, 0.1 eq in dioxane (6 mL) and H2O (1 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80 °C for 2 hours under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to remove to solvent. The residue was diluted with H2O (50 mL) and extracted with EtOAc (50 mL * 2). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0-100% Ethyl acetate / Hexanegradient at 35mL / min) to give tert-butyl (35)-3-[[5-(4-formyl-3-hydroxy-phenyl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate (190 mg, 58.0% yield) as a yellow solid. LCMS: calc, for C23H28N4O6S: 488.2, found: [M+H]+489.2.
[0613] Step 2:
[0614] A mixture of tert-butyl (35)-3-[[5-(4-formyl-3-hydroxy-phenyl)-3-ureido- thiophene-2-carbonyl]amino]piperidine-l-carboxylate (170 mg, 0.348 mmol, 1 eq pyridine (41 mg, 0.522 mmol, 1.5 eq and hydroxylamine;hydrochloride (36 mg, 0.522 mmol, 1.5 eq) in EtOH (4 mL) was stirred at 20 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to remove to solvent. The residue was diluted with H2O (50 mL) and extracted with EtOAc (30 mL * 2). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-100% ethyl acetate / petroleum ether gradient at 35 mL / min) to give tert-butyl (35)-3-[[5-[3-hydroxy-4- [(£)-hydroxyiminomethyl]phenyl]-3-ureido-thiophene-2-carbonyl]amino]piperidine-l- carboxylate (140 mg, 79.9% yield) as a yellow oil. LCMS: calc, for C23H29N5O6S: 503.2, found: [M+H]+504.2.
[0615] Step 3:
[0616] To a solution of PPI13 (102 mg, 0.387 mmol, 1.5 eq in DCM (6 mL) was added DDQ (88 mg, 0.387 mmol, 1.5 eq at 20 °C, The resulting mixture was stirred at 20 °C for 10 minutes. To the mixture tert-butyl (35)-3-[[5-[3-hydroxy-4-[(E)- hydroxyiminomethyl]phenyl]-3-ureido-thiophene-2-carbonyl]amino]piperidine-l- carboxylate (130 mg, 0.258 mmol, 1 eq was added. The reaction mixture was stirred at 20 °C for 10 minutes. The reaction was filtered and concentrated under reduced pressure to give a residue. The residue was diluted with H2O (50 mL) and extracted with EtOAc (30 mL * 2). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-100% ethyl acetate / petroleum ether, gradient at 35 mL / min) to give tert-butyl (35)-3-[[5-(l,2-benzoxazol-6-yl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (80 mg, 54.3% yield, 85% purity) as a yellow oil. LCMS: calc, for C23H27N5O5S: 485.2, found: [M+H]+486.2.
[0617] Step 4:
[0618] A mixture of tert-butyl (35)-3-[[5-(l,2-benzoxazol-6-yl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (70 mg, 0.123 mmol, 1 eq) in 2M HCl / dioxane (4 mL) was stirred at 20 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to remove to solvent. The residue was diluted with H2O (3 mL) and filtered to give the mixture. The residue was purified by reverse phase column (neutral condition) to give 5-(l,2-benzoxazol-6-yl)-7V-[(35)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (18.4 mg, 35.6% yield, HC1) as a yellow solid. LCMS: calc, for C18H19N5O3S: 385.1, found: [M+H]+386.2. HPLC: 98.62% purity at 254 nm. 'H NMR: (400 MHz, DMSCW) <5 ppm 9.95 (s, 1 H), 9.29 (d, J= 0.8 Hz, 1 H), 8.81 - 8.97 (m, 2 H), 8.42 (s, 1 H), 8.22 (d, J= 7.6 Hz, 1 H), 7.90 - 8.13 (m, 2 H), 7.66 - 7.69 (m, 1 H), 6.72 (s, 2 H), 4.16 - 4.20 (m, 1 H), 3.27 - 3.30 (m, 1 H), 3.17 - 3.23 (m, 1 H), 2.78 - 2.92 (m, 2 H), 1.81 - 2.00 (m, 2 H), 1.57 - 1.77 (m, 2 H).Example 3Synthesis of 5-(2,3-dihydrobenzofuran-5-yl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 3)Cpd. No.3
[0619] Step l:
[0620] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (200 mg, 0.447 mmol, 1 eq), 2-(2,3- dihydrobenzofuran-5-yl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (132 mg, 0.537 mmol, 1.2 e ) , K2CO3 (185 mg, 1.34 mmol, 3 eq) and Pd(dppf)C12 (33 mg, 0.0447 mmol,0.1 eq) in dioxane (3 mL) and H2O (0.5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90 °C for 2 hours under N2 atmosphere. The reaction mixture was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was separated, washed with brine (5 mL * 3), dried overNa2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Diehl oromethane / Methanol = 100 / 1 to 10 / 1) to give tert-butyl (3S)- 3-[[5-(2,3-dihydrobenzofuran-5-yl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l- carboxylate (130 mg, 59.8% yield) as a yellow solid. LCMS: calc, for C24H30N4O5S: 486.2, found: [M+H]+: 487.2.
[0621] Step 2:
[0622] A solution of tert-butyl (3S)-3-[[5-(2,3-dihydrobenzofuran-5-yl)-3-ureido- thiophene-2-carbonyl]amino]piperidine-l-carboxylate (130 mg, 0.267 mmol, 1 eq in 2MHCl / MeOH (1.34 mL, 2.67 mmol, 10 eq) was stirred at 25 °C for 2 hours. To the reaction mixture was added NaHCCh solution (20 mL) at 25 °C. The reaction mixture was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was separated, washed with brine (5mL * 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 55-Boston Prime C18 150 x 30 mm, 5 pm; mobile phase: [01-Water (0.225% FA)-01-MeCN]; gradient: 1%-31% B over 9.0 min) to give 5-(2,3-dihydrobenzofuran-5-yl)-N-[(3S)-3- piperidyl]-3-ureido-thiophene-2-carboxamide (70 mg, 67.1% yield, 99.84% purity) as a white solid. LCMS: calc, for C19H22N4O3S: 386.1, found: [M+H]+: 387.1. HPLC: 99.84% purity at 254 nm.1H NMR: (400 MHz, DMSO ) d ppm 10.04 (s, 1H), 8.36 (s, 1H), 8.11 (s, 1H), 7.88 (br d, J= 7.8 Hz, 1H), 7.51 (s, 1H), 7.36 (dd, J= 1.9, 8.3 Hz, 1H), 6.84 (d, J = 8.4 Hz, 1H), 6.64 (br s, 2H), 4.58 (t, J= 8.8 Hz, 2H), 3.75 (br s, 1H), 3.23 (br t, J= 8.6 Hz, 2H), 3.09 (br dd, J= 3.5, 11.9 Hz, 1H), 2.97 (br d, J= 11.8 Hz, 1H), 2.70 - 2.61 (m, 2H), 1.88 - 1.80 (m, 1H), 1.75 (br s, 1H), 1.60 - 1.50 (m, 2H).Example 4Synthesis of 5-(3-oxoisoindolin-5-yl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamidePd(dppf)Cl2, K2CO3dioxane, H2O90 °C, 2 h53.7%INT22M HCl / MeOH25 °c, 2 h23.1 %Cpd. No.4
[0623] Step l:
[0624] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (200 mg, 0.447 mmol, 1 eq 6-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)isoindolin-l-one (139 mg, 0.536 mmol, 1.2 e ), K2CO3 (185 mg, 1.34 mmol, 3 eq and Pd(dppf)C12 (33 mg, 0.0447 mmol, 0.1 eq) in dioxane (2 mL) and H2O (0.5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90 °C for 2 hours under N2 atmosphere. The reaction mixture was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was separated, washed with brine (5 mL * 3), dried overNa2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Dichloromethane / Methanol = 100 / 1 to 10 / 1) to give tert-butyl (3S)- 3-[[5-(3-oxoisoindolin-5-yl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l- carboxylate (120 mg, 53.7% yield) as a yellow oil. LCMS: calc, for C24H29N5O5S: 499.2, found: [M+H]+: 500.2.
[0625] Step 2:
[0626] A solution of tert-butyl (3S)-3-[[5-(3-oxoisoindolin-5-yl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (120 mg, 0.240 mmol, 1 eq in 2M HCl / MeOH (1.2 mL, 2.40 mmol, 10 eq was stirred at 25 °C for 2 hours. To the reaction mixture wasadded NaHCOs solution (20 mL) at 25 °C. The reaction mixture was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was separated, washed with brine (5 mL * 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 52-Welch Xtimate C18 150 x 30 mm, 5 pm; mobile phase: [01-Water (0.225% FA)-ACN]; gradient: 0% - 40% B over 10.0 min) to give 5-(3-oxoisoindolin-5-yl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene- 2-carboxamide (25 mg, 99.71% purity, FA) as a white solid. LCMS: calc, for C19H21N5O3S: 399.1, found: [M+H]+: 400.2. HPLC: 99.71% purity at 254 nm. 'H NMR: (400 MHz, DMSO-tL) 3 ppm 10.03 (br s, 1H), 8.71 (s, 1H), 8.33 (s, 2H), 8.01 - 7.92 (m, 1H), 7.87 (dd, J= 1.8, 7.9 Hz, 1H), 7.82 (s, 1H), 7.68 (d, J = 7.9 Hz, 1H), 6.67 (br s, 2H), 4.43 (s, 2H), 3.98 - 3.90 (m, 1H), 3.11 - 3.03 (m, 1H), 3.00 - 2.89 (m, 1H), 2.68 - 2.56 (m, 2H), 1.90 - 1.82 (m, 1H), 1.78 - 1.69 (m, 1H), 1.62 - 1.48 (m, 2H).Example 5Synthesis of 5-(l-methylindazol-5-yl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (Cpd. No. 5)Cpd. No. 5
[0627] Step l:
[0628] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (200 mg, 0.447 mmol, 1 eq), (1-methylindazol- 5-yl)boronic acid (94 mg, 0.537 mmol, 1.2 e ), K2CO3 (185 mg, 1.34 mmol, 3 eg) and Pd(dppf)C12 (33 mg, 0.0447 mmol, 0.1 eg) in dioxane (3 mL) and H2O (0.5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90°C for 2 hours under N2 atmosphere. The reaction mixture was partitioned between EtOAc (10 mL) andEEO (10 mL). The organic phase was separated, washed with brine (5 mL * 3), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Dichloromethane / Methanol = 100 / 1 to 10 / 1) to give tert-butyl (3S)-3-[[5-(l-methylindazol-5-yl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (150 mg, 67.3% yield) as a yellow solid. LCMS: calc, for C24H30N6O4S: 498.2, found: [M+H]+: 499.2.
[0629] Step 2:
[0630] A solution of tert-butyl (3S)-3-[[5-(l-methylindazol-5-yl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (150 mg, 0.301 mmol, 1 eq in 2M HCl / MeOH (1.5 mL, 3.01 mmol, 10 eq) was stirred at 20 °C for 1.5 hours. To the reaction mixture was added NaHCOs solution (20 mL) at 20 °C. The reaction mixture was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was separated, washed with brine (5 mL * 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 41-WePure Biotech XP tC18 150 x 40 mm, 7 pm; mobile phase: [08-water (0.05% NH3H2O + 10 mMNELjHCOs)- ACN]; gradient: 15%-65% B over 12.0 min) to give 5-(l-methylindazol-5-yl)-N-[(3S)-3- piperidyl]-3-ureido-thiophene-2-carboxamide (65 mg, 53.1% yield, 97.94% purity) as a white solid. LCMS: calc, for C19H22N6O2S: 398.2, found: [M+H]+: 399.1. HPLC: 97.94% purity at 254 nm. 'H NMR: (400 MHz, DMSO-tL) 3 ppm 10.08 (br s, 1H), 8.25 (s, 1H), 8.12 (s, 1H), 8.05 (d, J = 0.8 Hz, 1H), 7.76 - 7.64 (m, 3H), 6.63 (br s, 2H), 4.07 (s, 3H), 3.79 (br d, J= 3.6 Hz, 1H), 2.94 (br d, J= 9.6 Hz, 1H), 2.78 (br d, J= 11.9 Hz, 1H), 2.47 - 2.38 (m, 2H), 1.82 (br d, J= 8.1 Hz, 1H), 1.68 - 1.58 (m, 1H), 1.57 - 1.34 (m, 2H).Example 6Synthesis of 5-imidazo[l,2-a]pyridin-6-yl-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 6)(BPin)2. KOAcPd(dppf)Cl2 Pd(dppf)Cl2. K2CO3dioxane, H2O dioxane, H2O90 °C, 16 h 90 °C, 2 hcrude 75.4%1 2
[0631] Step l:
[0632] A mixture of 6-bromoimidazo[l,2-a]pyridine (300 mg, 1.52 mmol, 1 eq , 4,4,5- trimethyl-2-(4,4,5-trimethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (413 mg, 1.83 mmol, 1.2 eq , Pd(dppf)C12-CH2C12 (124 mg, 0.152 mmol, 0.1 eq), KOAc (448 mg, 4.57 mmol, 3 eq in dioxane (3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90 °C for 16 hours under N2 atmosphere. The reaction mixture was filtered. The filter liquor was concentrated in vacuo to give imidazo[l,2-a]pyridin-6- ylboronic acid (240 mg, crude) as a yellow oil.
[0633] Step 2:
[0634] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (120 mg, 0.268 mmol, 1 eq , imidazo[l,2- a]pyridin-6-ylboronic acid (87 mg, 0.537 mmol, 2 eq , Pd(dppf)C12 (20 mg, 0.0268 mmol, 0.1 eq , K2CO3 (111 mg, 0.805 mmol, 3 eq) in dioxane (1 mL) and H2O (0.5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90 °C for 2 hours under N2 atmosphere. The reaction mixture was diluted with H2O (10 mL) and the mixture was extracted with EtOAc (10 mL * 3). The combined organic phase was washed with brine (10 mL * 2), dried with anhydrous Na2SC>4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash®Silica Flash Column, Eluent of 0-20% DCM / MeOH at 30 mL / min) and then the residue was purified by reverse phase column (neutral condition) to give tert-butyl (3S)-3-[(5- imidazo[l,2-a]pyridin-6-yl-3-ureido-thiophene-2-carbonyl)amino]piperidine-l- carboxylate (98 mg, 75.39% yield) as a yellow solid. 'H NMR: (400 MHz, DMSO-t / r,) d ppm 10.07 (s, 1H), 9.05 (d, J= 0.8 Hz, 1H), 8.29 (s, 1H), 8.03 (s, 1H), 7.93 (br s, 1H), 7.68 - 7.60 (m, 2H), 7.43 (dd, J= 1.9, 9.4 Hz, 1H), 6.67 (s, 2H), 3.79 - 3.75 (m, 1H), 3.31 - 3.29 (m, 1H), 2.81 - 2.72 (m, 1H), 2.56 - 2.52 (m, 1H), 2.46 - 2.39 (m, 1H), 1.92 - 1.83 (m, 1H), 1.75 - 1.68 (m, 1H), 1.62 - 1.53 (m, 1H), 1.44 - 1.40 (m, 1H), 1.39 (br s, 9H).
[0635] Step 3:
[0636] A solution of tert-butyl (3S)-3-[(5-imidazo[l,2-a]pyridin-6-yl-3-ureido-thiophene- 2-carbonyl)amino]piperidine-l -carboxylate (98 mg, 0.202 mmol, 1 eq in 2M HCl / MeOH (2 mL, 4.00 mmol, 19.8 eq) was stirred at 20 °C for 1 hour. The reaction mixture was filtered. The filter liquor was concentrated in vacuo. The crude product was purified by reversed-phase column (neutral condition) to give 5-imidazo[l,2-a]pyridin-6-yl-N-[(3S)- 3-piperidyl]-3-ureido-thiophene-2-carboxamide (8.3 mg, 10.7% yield, 99.90% purity) as a white solid. LCMS: calc, for Ci8H2oN602S: 384.1, found: [M+H]+385.2. HPLC: 99.90% purity at 254 nm. 'H NMR: (400 MHz, DMSO ) d ppm 10.07 (s, 1H), 9.06 (s, 1H), 8.28 (s, 1H), 8.03 (s, 1H), 7.76 (br d, J= 8.4 Hz, 1H), 7.68 - 7.61 (m, 2H), 7.44 (dd, J= 1.9, 9.4 Hz, 1H), 6.65 (s, 2H), 3.85 - 3.79 (m, 1H), 2.98 - 2.92 (m, 1H), 2.78 (br dd, J= 2.6, 5.1 Hz, 1H), 2.58 (br d, J= 3.5 Hz, 2H), 1.86 - 1.78 (m, 1H), 1.67 - 1.60 (m, 1H), 1.56 - 1.48 (m, 1H), 1.45 - 1.37 (m, 1H).Example 7Synthesis of 5-(2-methylimidazo[l,2-b]pyridazin-6-yl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene- 2-carboxamide (Cpd. No. 7)(BPin)2, Pd(dppf)CI2-DCMKO Ac, dioxane, 95 °c, 16 h Pd(dppf)Cl2, K2C03crude dioxane, H2O90 °C, 2 h54.9%
[0637]
[0638] A mixture of 6-chloro-2-methyl-imidazo[l,2-b]pyridazine (200 mg, 1.19 mmol, 1 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2- dioxaborolane (364 mg, 1.43 mmol, 1.2 eq), Pd(dppf)C12-CH2C12 (97 mg, 0.119 mmol, O.ler?) and KOAc (351 mg, 3.58 mmol, 3eq) in dioxane (5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 95 °C for 16 hours under N2 atmosphere. The reaction mixture was filtered. The filtrate was concentrated in vacuo to give 2-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)imidazo[l,2-b]pyridazine (300 mg, crude) as a yellow oil, which was used into the next step without further purification.
[0639] Step 2:
[0640] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eq), 2-methyl-6- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)imidazo[l,2-b]pyridazine (174 mg, 0.671 mmol, 2 eq), Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq), K2CO3 (139 mg, 1.01 mmol, 3 eq) in dioxane (5 mL) and H2O (0.5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90 °C for 2 hours under N2 atmosphere. The reaction mixture was diluted with H2O (10 mL) and the mixture was extracted with EtOAc (10 mL * 3). The combined organic phase was washed with brine (10 mL * 2), dried with anhydrous Na2SC>4,filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~5% DCM / MeOH at 35 mL / min) to give tert-butyl (3S)-3-[[5-(2-methylimidazo[l,2- b]pyridazin-6-yl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate (100 mg, 54.9% yield, 91.9% purity) as a yellow oil. LCMS: calc, for C23H29N7O4S: 499.2, found: [M+H]+500.2.
[0641] Step 3:
[0642] A mixture of tert-butyl (3S)-3-[[5-(2-methylimidazo[l,2-b]pyridazin-6-yl)-3- ureido-thiophene-2-carbonyl]amino]piperidine-l -carboxylate (100 mg, 0.200 mmol, eq) in 2M HCl / MeOH (2 mL, 4.00 mmol, 20 eq) was stirred at 20 °C for 1 hour. The reaction mixture was diluted with H2O (10 mL) and the mixture was adjusted to a pH of 7 with NaHCCh. The mixture was extracted with EtOAc (20 mL * 3). The combined organic phase was washed with brine (10 mL * 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: 57-Phenomenex Gemini NX C18 150 x 30 mm, 5 pm; mobile phase: [08-water (0.05% NH3H2O + 10 mM NH4HCO3)- ACN]; gradient: 12%-52% B over 10.0 min) to give 5-(2-methylimidazo[l,2-b]pyridazin- 6-yl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (28.8 mg, 35.6% yield, 98.85% purity) as a yellow solid. LCMS: calc, for C18H21N7O2S: 399.1 found: [M+H]+400.2. HPLC: 98.85% purity at 254 nm. 'H NMR: (400 MHz, DMSO ) d ppm 10.01 (s, 1H), 8.55 (s, 1H), 8.09 - 8.01 (m, 2H), 7.93 (br d, J= 7.9 Hz, 1H), 7.66 (d, J= 9.5 Hz, 1H), 6.66 (s, 2H), 3.88 - 3.75 (m, 1H), 2.95 (br dd, J= 2.5, 10.5 Hz, 1H), 2.79 (br d, J= 12.1 Hz, 1H), 2.57 - 2.56 (m, 1H), 2.45 (br d, J= 3.6 Hz, 1H), 2.41 (s, 3H), 1.87 - 1.79 (m, 1H), 1.68 - 1.60 (m, 1H), 1.57 - 1.47 (m, 1H), 1.45 - 1.35 (m, 1H).Example 8Synthesis of 5-(l,3-benzothiazol-5-yl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (Cpd. No. 8)Cpd. No. 8
[0643] Step l:
[0644] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (200 mg, 0.447 mmol, 1 eq 5-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3-benzothiazole (140 mg, 0.537 mmol, 1.2 e ) , K2CC>3 (185 mg, 1.34 mmol, 3 eq and Pd(dppf)C12 (33 mg, 0.0447 mmol, 0.1 eq) in dioxane (2 mL) and H2O (0.5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 °C for 2 hours under N2 atmosphere. The reaction mixture was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was separated, washed with brine (5 mL * 3), dried overNa2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Diehl oromethane / Methanol = 100 / 1 to 10 / 1) to give tert-butyl (3S)- 3-[[5-(l,3-benzothiazol-5-yl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l- carboxylate (100 mg, 44.6% yield) as a yellow solid. LCMS: calc, for C23H27N5O4S2: 501.2, found: [M+H]+: 502.1.
[0645] Step 2:
[0646] A solution of tert-butyl (3S)-3-[[5-(l,3-benzothiazol-5-yl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (100 mg, 0.199 mmol, 1 eq in 2M HCl / MeOH (1 mL, 1.99 mmol, 10 eq was stirred at 25 °C for 2 hours. To the reaction mixture wasadded NaHCOs solution (20 mL) at 25 °C. The reaction mixture was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was separated, washed with brine (5 mL * 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 41-WePure Biotech XP tC18 150 x 40 mm, 7 pm; mobile phase: [01-Water (0.225% FA)-01-MeCN]; gradient: 7%-47% B over 9.0 min) to give 5-(l,3-benzothiazol-5-yl)-N-[(3S)-3-piperidyl]-3-ureido- thiophene-2-carboxamide (30 mg, 99.83% purity, FA) was obtained as a white solid. LCMS: calc, for C18H19N5O2S2: 401.1, found: [M+H]+: 402.1. HPLC: 99.83% purity at 254 nm. 'H NMR: (400 MHz, DMSO-tL) 3 ppml0.05 (br s, 1H), 9.47 (s, 1H), 8.36 (s, 2H), 8.29 - 8.24 (m, 2H), 8.04 (br d, J= 7.6 Hz, 1H), 7.77 (dd, J= 1.4, 8.4 Hz, 1H), 6.68 (br s, 2H), 4.01 (br d, J= 3.4 Hz, 1H), 3.12 (br d, J= 9.4 Hz, 1H), 2.99 (br d, J= 11.3 Hz, 1H), 2.75 - 2.58 (m, 2H), 1.85 (br s, 1H), 1.77 (br s, 1H), 1.67 - 1.51 (m, 2H).Example 9Synthesis of 5-(6-isoquinolyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamideCpd. No. 9
[0647] Step l:
[0648] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (200 mg, 0.447 mmol, 1 eq), K2CO3 (185 mg, 1.34 mmol, 3 eq), Pd(dppf)C12 (33 mg, 0.0447 mmol, 0.1 eq) and 6-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)isoquinoline (137 mg, 0.536 mmol, 1.2 eq) in dioxane (2 mL) and H2O (0.5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 °C for 2 hours under N2 atmosphere. The reaction mixture was partitionedbetween EtOAc (10 mL) and H2O (10 mL). The organic phase was separated, washed with brine (5 mL * 3), dried overNa2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiC>2, Dichloromethane / Methanol = 100 / 1 to 10 / 1) to give tert-butyl (3 S)-3-[[5-(6- isoquinolyl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate (150 mg, 67.7% yield) as a white solid. LCMS: calc, for C25H29N5O4S: 495.2, found: [M+H]+: 496.2.
[0649] Step 2:
[0650] To a solution of tert-butyl (3S)-3-[[5-(6-isoquinolyl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (150 mg, 0.303 mmol, 1 eq in 2M HCl / MeOH (1.51 mL, 1.99 mmol, 10 eq) was stirred at 25 °C for 2 hours. The reaction mixture was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was separated, washed with brine (5 mL * 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 57- Phenomenex Gemini NX C18 150 * 30 mm, 5 pm; mobile phase: [01-Water (0.225% FA)- 01-MeCN]; gradient: 0% - 30% B over 10.0 min) to give 5-(6-isoquinolyl)-N-[(3S)-3- piperidyl]-3-ureido-thiophene-2-carboxamide (30 mg, 24.8% yield, 98.62% purity) as a yellow solid. LCMS: calc, for C20H21N5O2S: 395.1, found: [M+H]+: 396.1. HPLC: 98.62% purity at 254 nm. 'H NMR: (400 MHz, DMSO-tL) d ppm 10.03 (br s, 1H), 9.32 (s, 1H), 8.54 (d, J= 5.7 Hz, 1H), 8.48 (s, 1H), 8.36 (s, 1H), 8.26 (s, 1H), 8.21 (d, J= 8.7 Hz, 1H), 8.12 (br d, J= 7.6 Hz, 1H), 7.97 - 7.90 (m, 2H), 6.71 (s, 2H), 4.02 (br d, J= 3.8 Hz, 1H), 3.13 (br d, J= 9.5 Hz, 1H), 2.99 (br d, J= 11.4 Hz, 1H), 2.78 - 2.59 (m, 2H), 1.93 - 1.71 (m, 2H), 1.67 - 1.52 (m, 2H).Example 10Synthesis of ethyl l-[4-[5-[[(3S)-3-piperidyl]carbamoyl]-4-ureido-2- thienyl]phenyl]cyclopropanecarboxylate (Cpd. No. 10) and methyl l-[4-[5-[[(3S)-3- piperidyl]carbamoyl]-4-ureido-2-thienyl]phenyl]cyclopropanecarboxylate (Cpd. No. 39)
[0651] Step l:
[0652] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eq), ethyl l-[4-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxylate (159 mg, 0.503 mmol, 1.5e ), Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq , K2CO3 (139 mg, 1.01 mmol, 3eq) in dioxane (2 mL) and H2O (0.5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90 °C for 2 hours under N2 atmosphere. The reaction mixture was diluted with H2O (10 mL) and the mixture was extracted with EtOAc (10 mL * 3). The combined organic phase was washed with brine (10 mL * 2), dried with anhydrous Na2SC>4, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-100% hexane / ethyl acetate at 35 mL / min) to give tert-butyl (3 S)-3-[[5-[4-(l - ethoxy carbonylcyclopropyl)phenyl]-3-ureido-thiophene-2-carbonyl]amino]piperidine-l- carboxylate (120 mg, 62.1% yield, 96.56% purity) as a yellow oil. LCMS: calc, for C28H36N4O6S: 556.2, found: [M+H]+557.3.
[0653] Step 2:
[0654] A solution of tert-butyl (3S)-3-[[5-[4-(l-ethoxycarbonylcyclopropyl)phenyl]-3- ureido-thiophene-2-carbonyl]amino]piperidine-l -carboxylate (120 mg, 0.216 mmol, 1 eq in 2M HCl / MeOH (2 mL, 4.00 mmol, 18.6 eq) was stirred at 25 °C for 1 hour. The reaction mixture was diluted with H2O (10 mL) and the mixture was adjusted to a pH of 7 with NaHCCh. The mixture was extracted with EtOAc (20 mL * 3). The combined organic phase was washed with brine (10 mL * 3), dried with anhydrous Na2SO4, filtered and concentrated in vacuum. The residue was purified by prep-HPLC (column: 41-WePure Biotech XP tC18 150 x 40 mm, 7 pm; mobilephase: [08-water (0.05%NH3H20 + 10 mMNH TCChj-ACN]; gradient: 24%-64% B over 12.0 min) to give ethyl l-[4-[5-[[(3S)-3-piperidyl]carbamoyl]- 4-ureido-2-thienyl]phenyl]cyclopropanecarboxylate (21.0 mg, 20.7% yield, 97.06% purity) as a white solid and methyl l-[4-[5-[[(3S)-3-piperidyl]carbamoyl]-4-ureido-2- thienyl]phenyl]cyclopropanecarboxylate (9.3 mg, 9.5% yield, 97.25% purity) as a white solid. LCMS: calc, for C23H28N4O4S (Cpd. No. 10): 456.2, found: [M+H]+457.2. HPLC: 97.06% purity at 254 nm. 'H NMR: (400 MHz, DMSO-t / r,) d ppm 10.06 (s, 1H), 8.23 (s, 1H), 7.75 (d, J= 7.6 Hz, 1H), 7.57 (d, J= 8.3 Hz, 2H), 7.41 (d, J= 8.4 Hz, 2H), 6.63 (s, 2H), 4.03 (q, J= 7.1 Hz, 2H), 3.83 - 3.71 (m, 1H), 2.96 - 2.88 (m, 1H), 2.77 (br d, J= 11.5 Hz, 1H), 2.60 - 2.53 (m, 1H), 2.40 (br d, J= 9.0 Hz, 1H), 1.84 - 1.76 (m, 1H), 1.64 - 1.57 (m, 1H), 1.53 - 1.46 (m, 3H), 1.44 - 1.35 (m, 1H), 1.24 - 1.21 (m, 2H), 1.10 (t, J= 7.1 Hz, 3H). LCMS: calc, for C22H26N4O4S (Cpd. No. 39): 442.2, found: [M+H]+443.1. HPLC: 97.25% purity at 254 nm. 'H NMR: (400 MHz, DMSO ) d ppm 10.07 (br s, 1H), 8.23 (s, 1H), 7.76 (br d, J= 8.1 Hz, 1H), 7.57 (d, J= 8.4 Hz, 2H), 7.42 (d, J= 8.4 Hz, 2H), 6.63 (s, 2H), 3.83 - 3.73 (m, 1H), 3.55 (s, 3H), 2.95 - 2.89 (m, 1H), 2.77 (br d, J= 12.4 Hz, 1H), 2.44 - 2.31 (m, 2H), 1.80 (br d, J= 7.6 Hz, 1H), 1.64 - 1.57 (m, 1H), 1.52 - 1.47 (m, 3H), 1.43 - 1.35 (m, 1H), 1.25 - 1.21 (m, 2H).Example 11Synthesis of 5-(4-morpholinophenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (Cpd. No. 11)Cpd. No. 11
[0655] Step l:
[0656] A solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eq in dioxane (5 mL) and water (1 mL) was added (4-morpholinophenyl)boronic acid (104 mg, 0.503 mmol, 1.5 eq), K2CO3 (139 mg, 1.01 mmol, 3 eq) and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq . The reaction mixture was stirred at 80 °C for 1 hour under N2. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (10 mL * 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash®Silica Flash Column, Eluent of 0-80% ethyl acetate / hexane gradient at 40 mL / min) to give tert-butyl (3S)-3-[[5-(4- morpholinophenyl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l -carboxylate (150 mg, 84.5% yield) as a yellow solid. LCMS: calc, for C26H35N5O5S: 529.2, found: [M+H- 100]+430.2.
[0657] Step 2:
[0658] A solution of tert-butyl (3S)-3-[[5-(4-morpholinophenyl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (150 mg, 0.283 mmol, 1 eq in 2MHCl / MeOH (5 mL) was stirred at 25 °C for 2 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was addition of water (10 mL). The pH of themixture was adjusted to 8 by addition of aq.Na2CC>3. The mixture was extracted with ethyl acetate (10 mL * 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 41-WePure Biotech XP tC18 150 x 40 mm, 7 pm; mobilephase: [08-water (0.05%NH3H20 + 10 mMNH4HCO3)-ACN]; gradient: 14%-54% B over 11.0 min) to give 5-(4-morpholinophenyl)-N-[(3S)-3- piperidyl]-3-ureido-thiophene-2-carboxamide (37.1 mg, 29.6% yield, 97.01% purity) as a yellow solid. LCMS: calc, for C21H27N5O3S: 429.2, found: [M+H]+430.2.
[0659] HPLC: 97.01% purity at 254 nm. 'H NMR: (400 MHz, DMSO ) d ppm 10.08 (s, 1H), 8.09 (s, 1H), 7.60 (br d, J= 7.7 Hz, 1H), 7.49 (d, J= 9.0 Hz, 2H), 7.01 (d, J= 9.0 Hz, 2H), 6.58 (br s, 2H), 3.83 - 3.70 (m, 5H), 3.20 - 3.14 (m, 4H), 3.00 - 2.86 (m, 1H), 2.78 (br d, J= 11.4 Hz, 1H), 2.45 (br d, J= 1.8 Hz, 3H), 1.90 - 1.73 (m, 1H), 1.69 - 1.57 (m, 1H), 1.56 - 1.45 (m, 1H), 1.45 - 1.32 (m, 1H).Example 12Synthesis of 5-[3-(4-methylpiperazin-l-yl)phenyl]-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 12)Pd(dppf)Cl2- K2CO3 dioxane, H2O 80 °c, 1 h 82.4%INT2
[0660] Step l:
[0661] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eq} in dioxane (5 mL) and water (1 mL) was added [3-(4-methylpiperazin-l-yl)phenyl]boronic acid (111 mg, 0.503 mmol, 1.5 eq K2CO3 (139 mg, 1.01 mmol, 3 eq and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq . The reaction mixture was stirred at 80 °C for 1 hour under N2. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (10 mL * 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residuewas purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-10% DCM / MeOH gradient at 40 mL / min) to give tert-butyl (3 S)-3- [[5-[3-(4-methylpiperazin-l-yl)phenyl]-3-ureido-thiophene-2-carbonyl]amino]piperidine- 1 -carboxylate (150 mg, 82.4% yield) as a yellow solid. LCMS: calc, for C27H38N6O4S: 542.3, found: [M+H]+543.4.
[0662] Step 2:
[0663] A solution of tert-butyl (3S)-3-[[5-[3-(4-methylpiperazin-l-yl)phenyl]-3-ureido- thiophene-2-carbonyl]amino]piperidine-l-carboxylate (150 mg, 0.276 mmol, 1 eq) in 2M HCl / MeOH (5 mL) was stirred at 25 °C for 2 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was addition of water (10 mL). The pH of the mixture was adjusted to 8 by addition of aq.Na2CO3. The mixture was extracted with ethyl acetate (10 mL * 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 55-Boston Prime C18 150 x 30 mm, 5 pm; mobile phase: [01-water (0.225% FA)-01-MeCN]; gradient: 5%-25% B over 10.0 min) to give 5-[3-(4-methylpiperazin-l-yl)phenyl]-N-[(3S)-3-piperidyl]-3- ureido-thiophene-2-carboxamide (53.5 mg, 36.0% yield, 99.40% purity, 2FA) as a yellow solid. LCMS: calc, for C22H30N6O2S: 442.2, found: [M+H]+443.3. HPLC: 99.40% purity at 254 nm. 'H NMR: (400 MHz, DMSO-r / r,) 3 ppm 10.00 (s, 1H), 8.30 (s, 2H), 8.20 (s, 1H), 8.01 (br d, J= 7.7 Hz, 1H), 7.35 - 7.22 (m, 1H), 7.08 (s, 1H), 7.04 (d, J= 7.5 Hz, 1H), 6.99 (dd, J= 1.9, 8.3 Hz, 1H), 6.64 (br s, 2H), 4.07 (br s, 1H), 3.24 - 3.17 (m, 4H), 3.17 - 3.11 (m, 1H), 3.10 - 3.00 (m, 1H), 2.81 - 2.61 (m, 2H), 2.47 (br d, J= 5.1 Hz, 4H), 2.23 (s, 3H), 1.93 - 1.70 (m, 2H), 1.60 (br d, J= 7.5 Hz, 2H).Example 13Synthesis of 5-[6-(cyclopropylmethoxy)-3-pyridyl]-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 13)Cpd. No. 13
[0664] Step l:
[0665] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eq in dioxane (5 mL) and water (1 mL) was added 2-(cyclopropylmethoxy)-5-(4, 4,5, 5-tetramethyl-l, 3,2- dioxaborolan-2-yl)pyridine (138 mg, 0.503 mmol, 1.5 e ), K2CO3 (139 mg, 1.01 mmol, 3 eq) and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq . The reaction mixture was stirred at 80 °C for 40 minutes under N2. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (10 mL * 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-65% ethyl acetate / hexane gradient at 40 mL / min) to give tert-butyl (3S)-3-[[5-[6-(cyclopropylmethoxy)-3-pyridyl]- 3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate (120 mg, 69.4% yield) as a yellow solid. LCMS: calc, for C25H33N5O5S: 515.2, found: [M+H]+516.3.
[0666] Step 2:
[0667] A solution of tert-butyl (3S)-3-[[5-[6-(cyclopropylmethoxy)-3-pyridyl]-3-ureido- thiophene-2-carbonyl]amino]piperidine-l-carboxylate (120 mg, 0.233 mmol, 1 eq in 2M HCl / MeOH (5 mL) was stirred at 25 °C for 2 hours. The mixture was concentrated underreduced pressure to give a residue. The residue was addition of water (10 mL). The pH of the mixture was adjusted to 8 by addition of aq.Na2CC>3. The mixture was extracted with ethyl acetate (10 mL * 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 57-Phenomenex Gemini NX C18 150 x 30 mm, 5 pm; mobile phase: [01-water (0.225% FA)-ACN]; gradient: 12%-52% B over 10.0 min) to give 5-[6-(cyclopropylmethoxy)-3-pyridyl]-N- [(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (27.4 mg, 25.3% yield, 99.15% purity, FA) as a yellow solid. LCMS: calc, for C20H25N5O3S: 415.2, found: [M+H]+416.2. HPLC: 99.15% purity at 254 nm. 'H NMR: (400 MHz, DMSO ) d ppm 10.03 (s, 1H), 8.40 (d, J= 2.3 Hz, 1H), 8.34 (s, 1H), 8.17 (s, 1H), 7.95 (td, J= 2.8, 5.8 Hz, 2H), 6.92 (d, J= 8.6 Hz, 1H), 6.64 (br s, 2H), 4.13 (br d, J= 7.2 Hz, 2H), 4.00 - 3.96 (m, 1H), 3.16 - 3.02 (m, 1H), 2.96 (br d, J = 11.9 Hz, 1H), 2.74 - 2.56 (m, 2H), 1.83 (br s, 1H), 1.79 - 1.66 (m, 1H), 1.64 - 1.42 (m, 2H), 1.32 - 1.16 (m, 1H), 0.66 - 0.44 (m, 2H), 0.43 - 0.21 (m, 2H).Example 14Synthesis of tert-butyl (3S)-3-[[5-[l-(2-cyano-l-cyclopentyl-ethyl)pyrazol-4-yl]-3-ureido- thiophene-2-carbonyl]amino]piperidine-l -carboxylate (Cpd. No. 14)Pd(dppf)Cl2. K2CO3dioxane, H2O80 °c, 40 min91.2%INT22M HCI / MeOH25 °C, 2 h23.0%
[0668] Step 1:
[0669] To a solution of tert-butyl (3 S)-3 -[(5 -bromo-3 -ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eq) in dioxane (5 mL) and water (1 mL) was added 3-cyclopentyl-3-[4-(4, 4,5, 5-tetramethyl-l, 3,2-di oxaborolan-2-yl)pyrazol-l-yl]propan enitrile (159 mg, 0.503 mmol, 1.5 eq), K2CO3 (139 mg, 1.01 mmol, 3 eq and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq). The reaction mixture was stirred at 80 °C for 40 minutes under N2. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL * 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash®Silica Flash Column, Eluent of 0-63% ethyl acetate / hexane, gradient at 40 mL / min) to give tert-butyl (3S)-3-[[5-[l-(2-cyano-l- cyclopentyl-ethyl)pyrazol-4-yl]-3-ureido-thiophene-2-carbonyl]amino]piperidine-l- carboxylate (170 mg, 91.2% yield) as a white solid. LCMS: calc, for C27H37N7O4S: 555.3, found: [M+H-100]+456.2.
[0670] Step 2:
[0671] A solution of tert-butyl (3S)-3-[[5-[l-(2-cyano-l-cyclopentyl-ethyl)pyrazol-4-yl]- 3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate (170 mg, 0.306 mmol, 1 eq in 2M HCl / MeOH (3 mL) was stirred at 25 °C for 2 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was addition of water (10 mL). The pH of the mixture was adjusted to 8 by addition of aq. Na2CC>3. The mixture was extracted with ethyl acetate (10 mL * 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150 * 30 mm * 4 pm; mobile phase: [08-water (0.05%NH3H20 + 10 mM NH4HCO3)-01-MeCN]; gradient: 34%-54% B over 10.0 min) to give 5-[l-(2- cyano-l-cyclopentyl-ethyl)pyrazol-4-yl]-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (32.4 mg, 23.0% yield, 98.73% purity) as a white solid. LCMS: calc, for C22H29N7O2S: 455.2, found: [M+H]+456.1. HPLC: 98.73% purity at 254 nm. 'H NMR: (400 MHz, DMSO-t ) 3 ppm 10.09 (br s, 1H), 8.34 (s, 1H), 7.97 (s, 1H), 7.82 (s, 1H), 7.59 (br d, J= 6.6 Hz, 1H), 6.60 (br s, 2H), 4.42 (dt, J= 4.7, 9.3 Hz, 1H), 3.82 - 3.71 (m, 1H), 3.22 - 3.10 (m, 2H), 2.98 - 2.84 (m, 1H), 2.76 (br d, J= 11.7 Hz, 1H), 2.47 - 2.30 (m, 3H), 1.86 - 1.71 (m, 2H), 1.67 - 1.21 (m, 9H), 1.20 - 1.06 (m, 1H).Example 15Synthesis of give tert-butyl (3S)-3-[[5-(3-cyclobutylphenyl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (Cpd. No. 15)
[0672] Step 1:
[0673] To a solution of l-bromo-3-cyclobutyl-benzene (1 g, 4.74 mmol, 1 eq in dioxane (30 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- 1,3,2-dioxaborolane (1.44 g, 5.68 mmol, 1.2 e ), KOAc (1.39 g, 14.2 mmol, 3 eq) and Pd(dppf)C12 (347 mg, 0.474 mmol, 0.1 eq . The reaction mixture was stirred at 90 °C for 2 hours under N2. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (30 mL * 3). The combined organic layers were washed with brine (40 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash®Silica Flash Column, Eluent of 0~4% ethyl acetate / hexane gradient at 50 mL / min) to give 2-(3-cyclobutylphenyl)-4,4,5,5-tetramethyl- 1,3,2-dioxaborolane (100 mg, 8.2% yield) as a yellow oil.XH NMR: (400 MHz, DMSO- d6) 6 ppm 7.54 - 7.44 (m, 2H), 7.32 (td, J= 7.5, 15.3 Hz, 2H), 3.53 (quin, J= 8.7 Hz, 1H), 2.29 (br d, J= 7.9 Hz, 2H), 2.13 - 1.92 (m, 3H), 1.86 - 1.74 (m, 1H), 1.29 (s, 12H).
[0674] Step 2:
[0675] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eg) in dioxane (5 mL) and water (1 mL) was added 2-(3-cyclobutylphenyl)-4, 4,5, 5-tetramethyl-l, 3,2-dioxaborolane (100 mg, 0.387 mmol, 1.16 eq), K2CO3 (139 mg, 1.01 mmol, 3 eq and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq). The reaction mixture was stirred at 80 °C for 1 hour under N2. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (10 mL * 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-55% ethyl acetate / hexane gradient at 40 mL / min) to give tert-butyl (3S)-3-[[5-(3-cyclobutylphenyl)-3-ureido- thiophene-2-carbonyl]amino]piperidine-l-carboxylate (130 mg, 77.8% yield) as a yellow solid. LCMS: calc, for C26H34N4O4S: 498.2, found: [M+H-100]+399.2.
[0676] Step 3:
[0677] A solution of tert-butyl (3S)-3-[[5-(3-cyclobutylphenyl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (130 mg, 0261 mmol, 1 eq in 2M HCl / MeOH (5 mL) was stirred at 25 °C for 2 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was addition of water (10 mL). The pH of the mixture was adjusted to 8 by addition of aq. Na2CC>3. The mixture was extracted with ethyl acetate (10 mL * 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 57-Phenomenex Gemini NX C18 150 x 30 mm, 5 pm; mobile phase: [01-water (0.225% FA)-ACN]; gradient: 14%-54% B over 10.0 min) to give 5-(3-cyclobutylphenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (12.1 mg, 10.4% yield, 99.63% purity, FA) as a white solid. LCMS: calc, for C21H26N4O2S: 398.2, found: [M+H]+399.2. HPLC: 99.63% purity at 254 nm. 'H NMR: (400 MHz, DMSO-t ) 3 ppm 10.03 (s, 1H), 8.36 (s, 1H), 8.24 (s, 1H), 7.96 (br d, J= 7.7 Hz, 1H), 7.51 - 7.42 (m, 2H), 7.42 - 7.36 (m, 1H), 7.26 (br d, J= 7.6 Hz, 1H), 6.64 (br s, 2H), 4.02 - 3.97 (m, 1H), 3.59 (quin, J= 8.7 Hz, 1H), 3.19 - 3.04 (m, 1H), 2.97 (br d, J = 11.5 Hz, 1H), 2.75 - 2.56 (m, 2H), 2.37 - 2.27 (m, 2H), 2.18 - 2.05 (m, 2H), 2.04 - 1.92 (m, 1H), 1.91 - 1.78 (m, 2H), 1.74 (br d, J= 7.6 Hz, 1H), 1.63 - 1.47 (m, 2H).Example 16Synthesis of 5-(3-fluorophenyl)-N-[(3S,5R)-5-methoxy-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 16)Cpd. No. 16
[0678] Step l:
[0679] To a solution of methyl 3-amino-5-bromo-thiophene-2-carboxylate (30 g, 0.127 mol, 1.0 eq), (3-fluorophenyl)boronic acid (19.56 g, 0.140 mol, 1.1 eq) in dioxane (300 mL), H2O (60 mL) were added K2CO3 (52.69 g, 0.381 mol, 3.0 eq) and Pd(dppf)C12 (4.65 g, 6.35 mmol, 0.05 eq). The mixture was stirred at 90 °C for 12 hours under N2. The mixture was filtered through Celite pad under vacuum and rinsed with ethyl acetate (150 mL x 3). The filtrate was evaporated to dryness. The residue was diluted water (200 mL) and extracted with ethyl acetate (200 mL * 3). The combined organic layer was washed with brine (150 mL * 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product, which was purified by Biotage ® combi flash (Column: 120 g Biotage ® Silica Flash column; Eluent: gradient 0~7% tetrahydrofuran in hexane; Gradient time: 20 min; Hold time: 30 min; Flow rate: 80 mL / min). Pure fractions were combined and concentrated under reduced pressure to afford methyl 3-amino-5-(3-fluorophenyl)thiophene-2-carboxylate (12.1 g, 37.7% yield) as a yellow solid. LCMS: calc, for C12H10FNO2S: 251.0, found: [M+H]+252.1.
[0680] Step 2:
[0681] To a solution of methyl 3-amino-5-(3-fluorophenyl)thiophene-2-carboxylate (16.5 g, 65.7 mmol, 1.0 eq) in CH2CI2 (170 mL) was added TEA (27.4 mL, 0.197 mol, 3 eq). The mixture was cooled to 0 °C. Then bis(trichloromethyl) carbonate (11.69 g, 39.40 mmol, 0.6 eq) was added in the mixture at 0 °C. The mixture was stirred at 0 °C for 1 hour. The mixture was quenched with 7M NHs-MeOH (40 mL). The mixture was filtered and yellow solid was triturated with MTBE (500 mL) and concentrated to afford methyl 5-(3- fluorophenyl)-3-ureido-thiophene-2-carboxylate (17 g, 36.3% yield) as a yellow solid, which was used into the next step and needed no further purification. LCMS: calc, for C13H11FN2O3S: 294.0, found: [M+H]+294.9.
[0682] Step 3:
[0683] To a solution of methyl 5-(3-fluorophenyl)-3-ureido-thiophene-2-carboxylate (6 g, 20.4 mmol, 1 eq) in CH2CI2 (60 mL) was added BBn (19 mL, 38.0 mmol, 2M in DCM, 1.86 eq) at 0 °C under N2. The mixture was warmed to 25 °C and stirred at 25 °C for 72 hours. The mixture was quenched with ice water (300 mL). The mixture was evaporated to dryness. The mixture was extracted with ethyl acetate (500 mL x 3). The combined organic layer was washed with brine (150 mL * 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product. The mixture was concentrated under reduced pressure to afford 5-(3-fluorophenyl)-3-ureido-thiophene-2-carboxylic acid (7.24 g, 63.4% yield) as a yellow solid, which was used into the next step and without further purification. LCMS: calc, for C12H9FN2O3S: 280.0, found: [M+H]+281.1. 'H NMR: (400 MHz, DMSO-t / r,) d ppm 9.29 (s, 1H), 8.43 - 8.23 (m, 1H), 7.58 - 7.44 (m, 3H), 7.33 - 7.16 (m, 1H), 6.91 - 6.66 (m, 2H).
[0684] Step 4:
[0685] To a solution of 5-(3-fluorophenyl)-3-ureido-thiophene-2-carboxylic acid (55 mg, 0.196 mmol, 1.0 eq), tert-butyl (3S,5R)-3-amino-5-methoxy-piperidine-l-carboxylate (45 mg, 0.195 mmol, 1 eq) in DMF (3 mL) were added DIEA (0.1 mL, 0.589 mmol, 3.0 eq), HOBt (29 mg, 0.216 mmol, 1.1 eq), EDCI (45 mg, 0.235 mmol, 1.2 eq). The mixture was stirred at 30 °C for 12 hours. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL * 3). The combined organic layer was washed with brine (10mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product, which was purified by Biotage ® combi flash (Column: 12 g Biotage ® Silica Flash column; Eluent: gradient 0-58% ethyl acetate in hexane; Gradient time: 16 min; Hold time: 10 min; Flow rate: 60 mL / min). Pure fractions were combined and concentrated under reduced pressure to afford tert-butyl (3S,5R)-3-[[5-(3-fluorophenyl)-3-ureido-thiophene-2- carbonyl]amino]-5-methoxy-piperidine-l-carboxylate (72 mg, 67.1% yield) as a yellow oil. LCMS: calc, for C23H29FN4O5S: 492.2, found: [M+H]+493.1.
[0686] Step 5:
[0687] A solution of tert-butyl (3S,5R)-3-[[5-(3-fluorophenyl)-3-ureido-thiophene-2- carbonyl]amino]-5-methoxy-piperidine-l-carboxylate (72 mg, 0.146 mmol, 1.0 eq) in 2M HCl / MeOH (2.2 mL, 4.39 mmol, 30 eq) was stirred at 30 °C for 1 hour. The mixture was quenched with a solution of saturated aqueous (“sat aq ”) NaHCCh (10 mL). The mixture was extracted with dichloromethane / methanol (10:1, 110 mL). The combined organic layer was washed with brine (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by prep-HPLC (Column: 40-WePure Biotech XP tC18 150 x 30 mm, 7 pm; Eluent: gradient 31%-51% acetonitrile in water (0.05% NH3H2O + 10 mM NH4HCC>3)-ACN); Gradient time: 12 min; Flow rate: 35 mL / min). Pure fractions were combined, then lyophilized to afford 5-(3-fluorophenyl)- N-[(3S,5R)-5-methoxy-3-piperidyl]-3-ureido-thiophene-2-carboxamide (10.8 mg, 18.5% yield, 98.03% purity) as a white solid. LCMS: calc, for C18H21FN4O3S: 392.1, found:[M+H]+392.8. HPLC: 98.03% purity at 254 nm. SFC: 93.5%ee. 'H NMR: (400 MHz, DMSO-tfc) 3 ppm 10.03 (br s, 1H), 8.28 (s, 1H), 7.92 (d, J= 8.0 Hz, 1H), 7.56 - 7.42 (m, 3H), 7.29 - 7.20 (m, 1H), 6.66 (br s, 2H), 3.90 - 3.74 (m, 1H), 3.27 (s, 3H), 3.20 - 3.14 (m, 1H), 3.07 - 3.00 (m, 1H), 2.88 (br dd, J= 3.3, 12.0 Hz, 1H), 2.39 - 2.31 (m, 1H), 2.24 - 2.12 (m, 2H), 1.50 - 1.30 (m, 1H).Example 17Synthesis of 5-(5-fluoro-2-methyl-phenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 17)INT2 2 Cpd. No. 17
[0688] Step l:
[0689] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1.0 eq), (5-fluoro-2- methyl-phenyl)boronic acid (62 mg, 0.402 mmol, 1.2 eq) in dioxane (5 mL), H2O (1 mL) were added K2CO3 (139 mg, 1.01 mmol, 3.0 eq) and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq). The mixture was stirred at 80 °C for 2 hours under N2. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL * 3). The combined organic layer was washed with water (5 mL * 6), brine (10 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product, which was purified by Biotage ® combi flash (Column: 20 g Biotage ® Silica Flash column; Eluent: gradient 0-60% ethyl acetate in hexane; Gradient time: 15 min; Hold time: 6 min; Flow rate: 70 mL / min). Pure fractions were combined and concentrated under reduced pressure to afford tert-butyl (3S)-3-[[5-(5-fluoro-2-methyl-phenyl)-3-ureido-thiophene-2-carbonyl]amino] piperidine- 1 -carboxylate (94 mg, 58.8% yield) as a yellow foam. LCMS: calc, for C23H29FN4O4S: 476.2, found: [M+23]+499.2.
[0690] Step 2:
[0691] A solution of tert-butyl (3S)-3-[[5-(5-fluoro-2-methyl-phenyl)-3-ureido-thiophene- 2-carbonyl]amino]piperidine-l -carboxylate (94 mg, 0.197 mmol, 1.0 eq) in 2M HCl / MeOH (3 mL, 5.92 mmol, 30 eq) was stirred at 30 °C for 1 hour. The mixture was quenched with sat aq.NaHCCh (10 mL). The mixture was extracted with dichloromethane / methanol (10:1, 110 mL). The combined organic layer was washed with brine (15 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product, which was purified by prep-HPLC (Column: 41-WePure Biotech XP tC18 150 x 40 mm, 7 pm; Eluent: gradient 0%-40% acetonitrile in water (0.225% FA);Gradient time: 12 min; Flow rate: 60 mL / min). Pure fractions were combined, then lyophilized to afford 5-(5-fluoro-2-methyl-phenyl)-N-[(3S)-3-piperidyl]-3-ureido- thiophene-2-carboxamide (44.5 mg, 53.34% yield, 99.89% purity, FA) as a white solid. LCMS: calc, for C18H21FN4O2S: 376.1, found: [M+H]+377.2. HPLC: 99.89% purity at 254 nm. 'H NMR: (400 MHz, DMSO ) d ppm 10.02 (s, 1H), 8.35 (s, 1H), 8.05 - 7.95 (m, 2H), 7.39 (dd, J= 6.2, 8.1 Hz, 1H), 7.26 - 7.14 (m, 2H), 6.64 (br d, J= 1.8 Hz, 2H), 3.99 (br s, 1H), 3.09 (br dd, J= 2.6, 11.4 Hz, 1H), 2.97 (br d, J= 12.3 Hz, 1H), 2.73 - 2.56 (m, 2H), 2.37 (s, 3H), 1.91 - 1.68 (m, 2H), 1.62 - 1.46 (m, 2H).Example 18Synthesis of 5-(3-fluoro-2-methyl-phenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 18)Cpd. No. 18
[0692] Step 1:
[0693] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1.0 eq), (3-fluoro-2- methyl-phenyl)boronic acid (62 mg, 0.402 mmol, 1.2 eq) in dioxane (5 mL), H2O (1 mL) were added K2CO3 (139 mg, 1.01 mmol, 3.0 eq) and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq). The mixture was stirred at 80 °C for 2 hours under N2. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL * 3). The combined organic layer was washed with water (5 mL * 6), brine (10 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product, which was purified by Biotage ® combi flash (Column: 20 g Biotage ® Silica Flash column; Eluent: gradient 0-55% ethyl acetate in hexane; Gradient time: 15 min; Hold time: 10 min; Flow rate: 70mL / min). Pure fractions were combined and concentrated under reduced pressure to afford tert-butyl (3S)-3-[[5-(3-fluoro-2-methyl-phenyl)-3-ureido-thiophene-2-carbonyl]amino] piperidine- 1 -carboxylate (82 mg, 51.3% yield) as a yellow oil. LCMS: calc, for C23H29FN4O4S: 476.2, found: [M+H]+477.2.
[0694] Step 2:
[0695] A solution of tert-butyl (3S)-3-[[5-(3-fluoro-2-methyl-phenyl)-3-ureido-thiophene- 2-carbonyl]amino]piperidine-l -carboxylate (82 mg, 0.172 mmol, 1.0 eq) in 2M HCl / MeOH (2.6 mL, 5.16 mmol, 30 eq) was stirred at 30 °C for 1 hour. The mixture was quenched with sat aq.NaHCCh (10 mL).The mixture was extracted with dichloromethane / methanol (10:1, 110 mL). The combined organic layer was washed with brine (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by prep-HPLC (Column: 52-Wel ch Xtimate Cl 8 150 x 30 mm, 5 pm; Eluent: gradient 4%-44% acetonitrile in water (0.225% FA); Gradient time: 10 min; Flow rate: 30 mL / min). Pure fractions were combined, then lyophilized to afford 5-(3-fluoro-2-methyl-phenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (41.4 mg, 56.9% yield, 99.89% purity, FA) as a white solid. LCMS: calc, for C18H21FN4O2S: 376.1, found: [M+H]+377.2. HPLC: 99.89% purity at 254 nm.[HNMR: (400 MHz, DMSO-t / r,) 3 ppm 10.03 (s, 1H), 8.33 (s, 1H), 8.01 - 7.94 (m, 2H), 7.32 (dd, J = 6.2, 7.7 Hz, 1H), 7.28 - 7.22 (m, 2H), 6.63 (br s, 2H), 3.98 (br d, J = 2.4 Hz, 1H), 3.08 (br d, J= 11.4 Hz, 1H), 2.95 (br d, J= 11.4 Hz, 1H), 2.70 - 2.53 (m, 2H), 2.29 (d, J= 2.0 Hz, 3H), 1.83 (br s, 1H), 1.77 - 1.69 (m, 1H), 1.61 - 1.46 (m, 2H).Example 19Synthesis of 5-(3-fluoro-2,6-dimethyl-phenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 19)
[0696] Step l:
[0697] To a solution of 3-bromo-l-fluoro-2,4-dimethyl-benzene (200 mg, 0.985 mmol, 1 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2- dioxaborolane (300 mg, 1.18 mmol, 1.2 eq) in dioxane (4 mL) were added KO Ac (290 mg, 2.95 mmol, 3.0 eq) and Pd(dppf)C12 (72 mg, 0.0985 mmol, 0.1 eq). The mixture was stirred at 90 °C for 16 hours under N2. The mixture was filtered through celite pad under vacuum and rinsed with ethyl acetate (20 mL x 3). The filtrate was evaporated to dryness. The mixture was concentrated under reduced pressure to afford 2-(3-fluoro-2,6-dimethyl- phenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (246 mg, crude) as a black brown oil, which was used into the next step and needed no further purification. LCMS: calc, for C14H20BFO2: 250.2, found: [M+H]+250.9.
[0698] Step 2:
[0699] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1.0 eq), 2-(3-fluoro-2,6- dimethyl-phenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (246 mg, 0.984 mmol, 2.93 eq) in dioxane (10 mL), H2O (2 mL) were added K2CO3 (139 mg, 1.01 mmol, 3 eq) and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq). The mixture was stirred at 80 °C for 2 hours under N2. The mixture was diluted with water (15 mL) and extracted with ethyl acetate (30mL * 3). The combined organic layer was washed with brine (20 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product, which was purified by Biotage ® combi flash (Column: 20 g Biotage ® Silica Flash column; Eluent: gradient 0-50% ethyl acetate in hexane; Gradient time: 15 min; Hold time: 5 min; Flow rate: 70 mL / min). Pure fractions were combined and concentrated under reduced pressure to afford tert-butyl (3S)-3-[[5-(3-fluoro-2,6-dimethyl-phenyl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (41 mg, 24.9% yield) as a yellow oil. LCMS: calc, for C24H31FN4O4S: 490.2, found: [M+H]+491.2.
[0700] Step 3:
[0701] A solution of tert-butyl (3S)-3-[[5-(3-fluoro-2,6-dimethyl-phenyl)-3-ureido- thiophene-2-carbonyl]amino]piperidine-l-carboxylate (41 mg, 0.0836 mmol, 1.0 eq) in 2M HCl / MeOH (1.3 mL, 2.51 mmol, 30 eq) was stirred at 30 °C for 1 hour. The mixture was quenched with sat aq.NaHCCh (10 mL). The mixture was extracted with dichloromethane / methanol (10:1, 110 mL). The combined organic layer was washed with brine (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the crude product, which was purified by prep-HPLC (Column: 41-WePure Biotech XP tC18 150 x 40 mm, 7 pm; Eluent: gradient 6%-46% acetonitrile in water (0.225% FA); Gradient time: 12 min; Flow rate: 60 mL / min). Pure fractions were combined, then lyophilized to afford 5-(3-fluoro-2,6-dimethyl-phenyl)-N-[(3S)-3-piperidyl]-3-ureido- thiophene-2-carboxamide (13.5 mg, 36.7% yield, 99.22% purity, FA) as a white solid. LCMS: calc, for C19H23FN4O2S: 390.2, found: [M+H]+391.2. HPLC: 99.22% purity at 254 nm. 'H NMR: (400 MHz, DMSO ) 3 ppm 10.08 (s, 1H), 8.31 (s, 1H), 7.90 (d, J= 7.7 Hz, 1H), 7.72 (s, 1H), 7.22 - 7.14 (m, 2H), 6.65 (s, 2H), 3.94 (br d, J= 2.4 Hz, 1H), 3.10 - 3.02 (m, 1H), 2.93 (br d, J= 12.5 Hz, 1H), 2.68 - 2.55 (m, 1H), 2.42 - 2.35 (m, 1H), 2.10 (s, 3H), 2.03 (d, J= 2.2 Hz, 3H), 1.88 - 1.81 (m, 1H), 1.74 - 1.67 (m, 1H), 1.58 - 1.45 (m, 2H).Example 20Synthesis of 5-(3-methoxyphenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (Cpd. No. 20)BTC, TEA NH3 / MeOH THF, 20 °C, 2 h 67.7%OH4 Cpd. No. 20
[0702] Step l:
[0703] To a solution of methyl 3-amino-5-bromo-thiophene-2-carboxylate (10 g, 42.4 mmol, 1 eq) in THF (100 mL) was added TEA (9 mL, 64.7 mmol, 1.53 eq) and then bis(trichloromethyl) carbonate (14 g, 47.2 mmol, 1.11 eq was added. The mixture was stirred at 20 °C for 1 hour. Then 7M NHLMeOH (19 mL, 0.133 mol, 3.14 eq) was added. The mixture was stirred at 20 °C for 1 hour. The reaction mixture was quenched by addition H2O (100 mL) at 25 °C, extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, petroleum ether / EtOAc with EtOAc from 0 ~ 60%, flow rate: 100 mL / min, 254 nm) to afford methyl 5-bromo-3- ureido-thiophene-2-carboxylate (8 g, 67.7% yield) as a white solid. LCMS: calc, for C7H7BrSN2O3: 277.9, found: [M+H]+278.9.
[0704] Step 2:
[0705] To a solution of methyl 5-bromo-3-ureido-thiophene-2-carboxylate (5.9 g, 21.1 mmol, 1 eq) in THF (60 mL) was added a solution of AlMe3and tert-butyl (3S)-3- aminopiperidine-1 -carboxylate, which preformed by the addition AlMe3(63.4 mL, 63.4 mmol, 6 eq, 2M in toluene) to a solution of tert-butyl (3 S)-3 -aminopiperidine- 1-carboxylate (12.7 g, 63.4 mmol, 3 eq) in THF (30 mL) at -70 °C for 15 minutes. Then the mixture was stirred at 20 °C for 12 hours. The reaction mixture was quenched by addition potassium sodium tartrate (50 mL) at 25 °C, extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried overNa2SC>4, filtered and concentrated under reduced pressure to give a residue. The crude product was purified by reversed-phase column (Column: SepaFlash® Sphercial Cl 8, 25 g, 40 - 60 pm, 120A; MeCN / water (0.5% NH3-H2O) with MeCN from 0 - 40%, 25 mL / min, 254 nm) to afford tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2-carbonyl)amino]piperidine-l- carboxylate (4 g, 42.3% yield) as a white solid. LCMS: calc, for CieLEsBrSlS Ch: 448.1, found: [M+H]+449.1.
[0706] Step 3:
[0707] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (200 mg, 0.447 mmol, 1 eq), (3- methoxyphenyl)boronic acid (100 mg, 0.658 mmol, 1.47 eq), Pd(PPhs)4 (50 mg, 0.0433 mmol, 0.1 eq), CS2CO3 (365 mg, 1.12 mmol, 2.51 eq) in dioxane (8 mL) andLLO (2 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90 °C for 6 hours under N2 atmosphere. The reaction mixture was quenched by addition H2O (50 mL) at 25 °C, extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 3), dried overNa2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, petroleum ether / EtOAc with EtOAc from 0 ~ 80%, flow rate: 65 mL / min, 254 nm) to afford tert-butyl (3S)-3-[[5-(3- methoxyphenyl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate (280 mg, 87.1% yield, 66% purity) as a white solid. LCMS: calc, for C23H30SN4O5: 474.2, found:[M+H]+475.2.
[0708] Step 4:
[0709] A mixture of tert-butyl (3S)-3-[[5-(3-methoxyphenyl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (280 mg, 0.390 mmol, 1 eq) in 2M HCl / dioxane (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 20 °C for 1 hour under N2 atmosphere. The mixture was added water (50 mL) and sodium bicarbonate in aqueous solution until pH ~ 7, then extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over anhydrousNa2SC>4, filtered and concentrated under reduced pressure. The crude product was purified by reversed-phase column (Column: SepaFlash® Sphercial Cl 8, 25 g, 40 - 60 pm, 120A; MeCN / water (0.5% NH3-H2O) with MeCN from 0 - 40%, 25 mL / min, 254 nm) to afford 5-(3-methoxyphenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (26.16 mg, 17.9% yield) as a white solid. LCMS: calc, for C18H22SN4O3: 374.1, found: [M+H]+375.2. HPLC: 99.16% purity at 254 nm.[HNMR: (400 MHz, DMSO ) d ppm 10.06 (s, 1 H), 8.23 (s, 1 H), 7.75 (br d, J= 7.9 Hz, 1 H), 7.29 - 7.48 (m, 1 H), 7.22 (d, J = 8.1 Hz, 1 H), 7.11 (t, J = 2.0 Hz, 1 H), 6.98 (dd, J= 8.2, 2.3 Hz, 1 H), 6.62 (br d, J= 1.8 Hz, 2 H), 3.82 (s, 3 H), 3.72 - 3.80 (m, 1 H), 2.92 (br dd, J= 11.7, 3.3 Hz, 1 H), 2.77 (br d, J= 12.3 Hz, 1 H), 2.34 - 2.49 (m, 3 H), 1.80 (br dd, J= 9.0, 4.5 Hz, 1 H), 1.58 - 1.66 (m, 1 H), 1.45 - 1.55 (m, 1 H), 1.32 - 1.43 (m, 1 H).Example 21Synthesis of 5-(2,5-difluorophenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (Cpd. No. 21)Pd(dppf)Cl2, K2CO3dioxane, H2O 80 °c, 16 h 93.1 %INT2
[0710] Step l:
[0711] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eq) in dioxane (5 mL) and water (1 mL) was added (2,5-difluorophenyl)boronic acid (79 mg, 0.503 mmol, 1.5 eq), K2CO3 (139 mg, 1.01 mmol, 3 eq and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq). The reaction mixture was stirred at 80 °C for 16 hours under N2. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL * 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-36% ethyl acetate / hexane gradient at 40 mL / min) to give tert-butyl (3S)-3-[[5-(2,5- difluorophenyl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate (150 mg,93.1% yield) as a white solid. LCMS: calc, for C22H26F2N4O4S: 480.2, found: [M+H-100]+381.0.
[0712] Step 2:
[0713] A solution of tert-butyl (3S)-3-[[5-(2,5-difluorophenyl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (150 mg, 0.312 mmol, 1 eq) in 2M HCl / MeOH (5 mL) was stirred at 20 °C for 1 hour. The mixture was concentrated under reduced pressure to give a residue. The residue was addition of water (10 mL). The pH of the mixture was adjusted to 8 by addition of aq.Na2CC>3. The mixture was extracted with ethyl acetate (10 mL * 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 57-Phenomenex Gemini NX C18 150 x 30 mm, 5 pm; mobile phase: [H2O (0.05% NH3H2O + 10 mM NH4HCO3)- ACN]; gradient: 33%-73% B over 10.0 min) to give 5-(2,5-difhiorophenyl)-N-[(3S)-3- piperidyl]-3-ureido-thiophene-2-carboxamide (10.1 mg, 8.5% yield, 99.48% purity) as a white solid. LCMS: calc, for C17H18F2N4O2S: 380.1, found: [M+H]+381.0. HPLC: 99.48% purity at 254 nm. 'H NMR: (400 MHz, DMSO-t / r,) 3 ppm 10.03 (br s, 1H), 8.37 (s, 1H), 7.88 (br d, J= 7.3 Hz, 1H), 7.57 (ddd, J= 3.1, 6.1, 9.3 Hz, 1H), 7.45 (ddd, J= 4.6, 9.2, 10.8 Hz, 1H), 7.34 - 7.25 (m, 1H), 6.65 (br s, 2H), 3.77 (br s, 1H), 2.98 - 2.86 (m, 1H), 2.85 -2.70 (m, 1H), 2.44 - 2.35 (m, 2H), 1.80 (brs, 1H), 1.72 - 1.58 (m, 1H), 1.51 (brd, J= 12.1 Hz, 1H), 1.44 - 1.28 (m, 1H).Example 22Synthesis of 5-(4-chloro-3-fluoro-phenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 22)OH
[0714] Step l:
[0715] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, l eg) in water (1 mL) and dioxane (5 mL) was added (4-chloro-3-fluoro-phenyl)boronic acid (88 mg, 0.503mmol, 1.5 eq), K2CO3 (139 mg, 1.01 mmol, 3 eq) and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq). The reaction mixture was stirred at 80 °C for 1 hour under N2. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (10 mL * 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-45% ethyl acetate / hexane gradient at 40 mL / min) to give tert-butyl (3S)-3-[[5-(4-chloro- 3-fluoro-phenyl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate(150mg, 90.0% yield) as a yellow solid. LCMS: calc, for C22H26CIFN4O4S: 496.1, found: [M+H- 100]+397.2.
[0716] Step 2:
[0717] A solution of tert-butyl (3S)-3-[[5-(4-chloro-3-fluoro-phenyl)-3-ureido-thiophene- 2-carbonyl]amino]piperidine-l -carboxylate (150 mg, 0.302 mmol, 1 eq) in 2MHCl / MeOH (3 mL) was stirred at 20 °C for 2 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was addition of water (10 mL). The pH of the mixture was adjusted to 8 by addition of aq.Na2CO3. The mixture was extracted with ethyl acetate (10 mL * 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 57-Phenomenex Gemini NX C18 150 x 30 mm, 5 pm; mobile phase: [08-water (0.05% NH3H2O + 10 mM NH4HCO3)- ACN]; gradient: 38%-78% B over 10.0 min) to give 5-(4-chloro-3-fluoro-phenyl)-N-[(3S)- 3-piperidyl]-3-ureido-thiophene-2-carboxamide (25.4 mg, 21.0% yield, 99.15% purity) as a white solid. LCMS: calc, for C17H18CIFN4O2S: 396.1, found: [M+H]+396.9.
[0718] HPLC: 99.15% purity at 254 nm. 'H NMR: (400 MHz, DMSO-t / r,) d ppm 10.01 (br s, 1H), 8.29 (s, 1H), 7.80 (br d, J= 6.8 Hz, 1H), 7.72 - 7.60 (m, 2H), 7.48 (dd, J= 1.5, 8.4 Hz, 1H), 6.64 (br s, 2H), 3.84 - 3.71 (m, 1H), 3.04 - 2.87 (m, 1H), 2.85 - 2.70 (m, 1H), 2.49 - 2.35 (m, 2H), 1.81 (br d, J= 8.4 Hz, 1H), 1.71 - 1.57 (m, 1H), 1.57 - 1.45 (m, 1H), 1.45 - 1.31 (m, 1H).Example 23Synthesis of 5-(3-chloro-5-fluoro-phenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (Cpd. No. 23)OHPd(dppf)Cl2. K2CO3dioxane, H2O 80 c, 16 h 54.0%INT2
[0719] Step l:
[0720] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eq in dioxane (5 mL) and water (1 mL) was added (3-chloro-5-fluoro-phenyl)boronic acid (88 mg, 0.503 mmol, 1.5 eq), K2CO3 (139 mg, 1.01 mmol, 3 eq) and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq). The reaction mixture was stirred at 80 °C for 16 hours under N2. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL * 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-65% ethylacetate / hexane gradient at 40 mL / min) to give tert-butyl (3 S)-3-[[5-(3- chloro-5-fluoro-phenyl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate (90 mg, 54.0% yield) as a yellow solid. LCMS: calc, for C22H26CIFN4O4S: 496.1, found:[M+H-100]+397.1.
[0721] Step 2:
[0722] A solution of tert-butyl (3S)-3-[[5-(3-chloro-5-fluoro-phenyl)-3-ureido-thiophene- 2-carbonyl]amino]piperidine-l -carboxylate (90 mg, 0.181 mmol, 1 eq) in 2M HCl / MeOH (3 mL) was stirred at 20 °C for 2 hours. The mixture was concentrated under reduced pressure to give a residue. The residue was addition of water (10 mL). The pH of the mixture was adjusted to 8 by addition of aq.Na2CC>3. The mixture was extracted with ethyl acetate (10 mL * 3) and the combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SC>4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: 41-WePure Biotech XP tC18 150 x 40 mm, 7 pm; mobile phase: [H2O (0.225% FA)-ACN]; gradient: 8%-48% B over11.0 min) to give 5-(3-chloro-5-fluoro-phenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene- 2-carboxamide (24.8 mg, 30.9% yield, 100% purity, FA) as a white solid. LCMS: calc, for C17H18CIFN4O2S: 396.1, found: [M+H]+396.9. HPLC: 100% purity at 254 nm. 'H NMR: (400 MHz, DMSO-t / r,) 3 ppm 9.97 (br s, 1H), 8.37 (s, 1H), 8.31 (s, 1H), 8.09 (br d, J= 7.7 Hz, 1H), 7.52 (d, J= 1.5 Hz, 1H), 7.51 - 7.48 (m, 1H), 7.48 - 7.44 (m, 1H), 6.69 (br s, 2H), 4.00 (br s, 1H), 3.10 (br d, J= 9.0 Hz, 1H), 2.97 (br d, J= 11.7 Hz, 1H), 2.75 - 2.57 (m, 2H), 1.85 (br s, 1H), 1.75 (br s, 1H), 1.63 - 1.48 (m, 2H).Example 24Synthesis of 5-(3-tert-butylphenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (Cpd. No. 24)
[0723] Step l:
[0724] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (200.0 mg, 0.447 mmol, 1.0 eq), (3-tert- butylphenyl)boronic acid (119 mg, 0.671 mmol, 1.5 eq) in dioxane (4.0 mL), H2O (1 mL) were added K2CO3 (185 mg, 1.34 mmol, 3 eq) and Pd(PPhs)4 (52 mg, 0.0447 mmol, 0.1 eq). The mixture was stirred at 90 °C for 16 hours under N2. The mixture was diluted with water (5.0 mL) and extracted with ethyl acetate (15 mL * 3). The combined organic layer was washed with brine (10.0 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product, which was purified by Biotage ® combi flash (Column: 12 g Biotage ® Silica Flash column; Eluent: gradient 0-49% ethyl acetate in hexane; Gradient time: 13 min; Hold time: 10 min; Flow rate: 40 mL / min). Pure fractions were combined and concentrated under reduced pressure to afford tert-butyl (3 S)-3-[[5-(3 - tert-butylphenyl)-3-ureido-thiophene-2-carbonyl]amino]piperidine-l-carboxylate (197 mg, 46.2% yield) as a yellow oil. LCMS: calc, for C26H36N4O4S: 500.2, found: [M+H]+501.3.
[0725] Step 2:
[0726] A solution of tert-butyl (3S)-3-[[5-(3-tert-butylphenyl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (197 mg, 0.207 mmol, 1.0 eq in HCl / EtOAc (4 mL, 2 M, 20 eq) was stirred at 30 °C for 2 hours. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (15 mL * 2). The aqueous phase was quenched with sat aq.NaHCCh (9.0 mL) and extracted with dichloromethane / methanol (55 mL). The combined organic layer was washed with brine (15 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product, which was purified by reversed-phase column (60% H2O in MeCN). The mixture was concentrated under reduced pressure to afford 5-(3-tert-butylphenyl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2- carboxamide (20.4 mg, 12.3% yield, 97.96% purity) as a yellow solid. LCMS: calc, for C21H28N4O2S: 400.2, found: [M+H]+401.1. HPLC: 99.60% purity at 254 nm. 'H NMR: (400 MHz, DMSO-tfc) 3 ppm 10.09 (s, 1H), 8.23 (s, 1H), 7.74 (d, J= 7.9 Hz, 1H), 7.58 (s, 1H), 7.49 - 7.38 (m, 3H), 6.61 (s, 2H), 3.85 - 3.72 (m, 1H), 2.96 - 2.88 (m, 1H), 2.77 (br d, J= 12.3 Hz, 1H), 2.46 - 2.29 (m, 3H), 1.80 (br dd, J= 2.7, 8.2 Hz, 1H), 1.65 - 1.57 (m, 1H), 1.55 - 1.45 (m, 1H), 1.44 - 1.35 (m, 1H), 1.32 (s, 9H).Example 25Synthesis of 5-(l,3-benzoxazol-5-yl)-N-[(3S)-3-piperidyl]-3-ureido-thiophene-2-carboxamide (Cpd. No. 25)
[0727] Step l:
[0728] To a solution of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (150 mg, 0.335 mmol, 1 eq), 5-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3-benzoxazole (90 mg, 0.369 mmol, 1.1 eq) in dioxane (5 mL), H2O (1 mL) were added K2CO3 (139 mg, 1.01 mmol, 3.0 eq) and Pd(dppf)C12 (25 mg, 0.0335 mmol, 0.1 eq). The mixture was stirred at 80 °C for 2 hours under N2. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (15 mL * 3). The combined organic layer was washed with water (5 mL * 8), brine (10 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crudeproduct, which was purified by Biotage ® combi flash (Column: 12 g Biotage ® Silica Flash column; Eluent: gradient 0-62% ethyl acetate in hexane; Gradient time: 15 min; Hold time: 10 min; Flow rate: 60 mL / min). Pure fractions were combined and concentrated under reduced pressure to afford tert-butyl (3S)-3-[[5-(l,3-benzoxazol-5-yl)-3-ureido-thiophene- 2-carbonyl]amino]piperidine-l -carboxylate (120 mg, 73.7% yield) as a yellow oil. LCMS: calc, for C23H27N5O5S: 485.2, found: [M+H]+486.2.
[0729] Step 2:
[0730] To a solution of tert-butyl (3S)-3-[[5-(l,3-benzoxazol-5-yl)-3-ureido-thiophene-2- carbonyl]amino]piperidine-l-carboxylate (110 mg, 0.227 mmol, 1.0 eq) in CH2CI2 (5 mL) was added ZnBn (255 mg, 1.13 mmol, 5.0 eq), the mixture was stirred at 30 °C for 16 hours. The mixture was quenched with sat aq.NaHCCh (10 mL). The mixture was extracted with dichloromethane / methanol (10:1, 110 mL). The combined organic layer was washed with brine (15 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give the crude product, which was purified by prep-HPLC (Column: 40-WePure Biotech XP tC18 150 x 30 mm, 7 pm; Eluent: gradient 10%-50% acetonitrile in water (0.05% NH3H2O + 10 mM NH4HCO3); Gradient time: 10 min; Flow rate: 30 mL / min). Pure fractions were combined, then lyophilized to afford 5-(l,3-benzoxazol-5-yl)-N-[(3S)-3- piperidyl]-3-ureido-thiophene-2-carboxamide (14.3 mg, 15.7% yield, 95.77% purity) as a yellow solid. LCMS: calc, for C18H19N5O3S: 385.1, found: [M+H]+386.2. HPLC: 95.77% purity at 254 nm. 'H NMR: (400 MHz, DMSO ) d ppm 10.07 (s, 1H), 8.83 (s, 1H), 8.28 (s, 1H), 8.00 (d, J= 1.6 Hz, 1H), 7.87 (d, J= 8.5 Hz, 1H), 7.80 - 7.66 (m, 2H), 6.63 (s, 2H), 3.85 - 3.74 (m, 1H), 2.94 (br dd, J= 2.5, 11.0 Hz, 1H), 2.82 - 2.74 (m, 1H), 2.59 - 2.52 (m, 1H), 2.44 - 2.37 (m, 1H), 1.88 - 1.76 (m, 1H), 1.70 - 1.58 (m, 1H), 1.58 - 1.32 (m, 2H).Example 26Synthesis of N-[(3S)-3-piperidyl]-5-(6-quinolyl)-3-ureido-thiophene-2-carboxamide (Cpd. No. 26)INT2 2 Cpd. No. 26
[0731] Step l:
[0732] A mixture of tert-butyl (3S)-3-[(5-bromo-3-ureido-thiophene-2- carbonyl)amino]piperidine-l -carboxylate (200 mg, 0.447 mmol, 1 eq 6-quinolylboronic acid (93 mg, 0.537 mmol, 1.2 e ), K2CO3 (185 mg, 1.34 mmol, 3 eq and cyclopentyl(diphenyl)phosphane;dichloropalladium;iron (33 mg, 0.447 mmol, 0.1 eq) in dioxane (2 mL) and H2O (0.5 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 90 °C for 2 hours under N2 atmosphere. The reaction mixture was partitioned between EtOAc (10 mL) and H2O (10 mL). The organic phase was sep...
Claims
WHAT IS CLAIMED IS:
1. A compound having Formula (I):or a pharmaceutically acceptable salt thereof, wherein:X is selected from the group consisting of O and S;R1is selected from the group consisting of optionally substituted aryl and optionally substituted 5- to 10-membered heteroaryl;R2is optionally substituted 4- to 8-membered heterocyclo; andR3, R4a, R4b, and R5are hydrogen,wherein the compound is selected from the group consisting of:
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
6. A pharmaceutical composition comprising the compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
7. A method of treating a cancer comprising a KIT tyrosine kinase (KIT) mutation in a subj ect in need thereof, the method comprising administering a therapeutically effective amount of the compound of any one of claims 1-5 to the subject.
8. The method of claim 7, wherein the KIT mutation is a gain-of-function mutation.
9. The method of claims 7 or 8, wherein the cancer comprising a KIT mutation is gastrointestinal stromal tumor (GIST), acute myeloid leukemia (AML), chronic myelogeneous leukemia (CML), sinonasal natural killer / T-cell lymphoma, seminoma, melanoma, or mastocytosis.
10. The method of claim 9, wherein the cancer comprising a KIT mutation is GIST.
11. The method of claim 10, wherein the GIST comprises a drug-resistant KIT mutation.
12. The method of claim 11, wherein the GIST comprises an imatinib resistant mutation, sunitinib resistant mutation, regorafenib resistant mutation, ripretinib resistant mutation, avapritinib resistant mutation, or a combination thereof.
13. The method of any one of claims 10-12, wherein the GIST further comprises a platelet- derived growth factor receptor-alpha (PDGFRA) mutation.
14. The method of any one of claims 10-13, wherein the GIST comprises a KIT exon 8 mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, a KIT exon 18 mutation, a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, a PDGFRA exon 18 mutation, or a combination thereof.
15. The method of any one of claims 10-14, wherein the KIT mutation comprises a missense mutation, insertion mutation, a deletion mutation, or a combination thereof.
16. The method of any one of claims 10-15, wherein the KIT mutation comprises a primary mutation.
17. The method of any one of claims 10-16, wherein the GIST comprises:(i) a KIT exon 9 mutation selected from the group consisting of p.A502_Y503dup, p.Y503_F504insAY, and p.S464L;(ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from the group consisting of K642E, V65A, and T670I;(iv) a KIT exon 17 mutation selected from the group consisting of mutations involving codons 809, 816, 820, 822, or 823;(v) a KIT exon 18 mutation selected from the group consisting of mutations involving codon 829;(vi) a PDGFRA exon 12 mutation selected from the group consisting of p.W559_R560del and p.581S; or(vii) a PDGFRA exon 18 mutation selected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
18. The method of any one of claims 10-17, wherein the GIST comprises one or more PDGFRA mutations selected from the group consisting of V598F, G605A, G652E, P653Q, V658A, N659K / T, T674R / I, E675G, Y676C, G680R / E, D842V, and I843_D846del.
19. The method of claim 18, wherein the GIST comprises the PDGFRA mutation D842V.
20. The method of claim 18, wherein the GIST comprises the PDGFRA mutation G680R.
21. The method of claim 18, wherein the GIST comprises the PDGFRA mutation G652E.
22. The method of claim 18, wherein the GIST comprises the PDGFRA mutation V658A.
23. The method of claim 18, wherein the GIST comprises the PDGFRA mutation V658A and mutation G652E.
24. The method of any one of claims 10-23, wherein the GIST comprises one or more KIT mutations selected from the group consisting of S476I, F522C, K642E, V654A, N655K, T670E / I, D816A / E / G / H / N / V, D820A / E / G / H / V / Y, N822I / K / Y, Y823C / D, and A829P.
25. The method of claim 24, wherein the GIST comprises the KIT mutation T670I.
26. The method of claim 24, wherein the GIST comprises the KIT mutation V654A.
27. The method of claim 24, wherein the GIST comprises the KIT mutation D816A.
28. The method of claim 24, wherein the GIST comprises the KIT mutation D820A.
29. The method of claim 24, wherein the GIST comprises the KIT mutation N822K.
30. The method of claim 24, wherein the GIST comprises the KIT mutation A829P.
31. The method of any one of claims 10-30, wherein the GIST comprises at least one primary and at least one secondary mutation.
32. The method of claim 31, wherein the GIST comprises:(i) a primary KIT exon 9 mutation; and(ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
33. The method of claim 31, wherein the GIST comprises:(i) a primary KIT exon 11 mutation; and(ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
34. The method of claim 31, wherein the GIST comprises:(i) a primary KIT exon 13 mutation; and(ii) a secondary KIT exon 14 mutation, a secondary KIT exon 17 mutation, or a secondary KIT exon 18 mutation.
35. The method of claim 31, wherein the GIST comprises:(i) a primary KIT exon 17 mutation; and(ii) a secondary KIT exon 13 mutation, a secondary KIT exon 14 mutation, or a secondary KIT exon 18 mutation.
36. The method of claim 31, wherein the GIST comprises:(i) a primary PDGFRA exon 12 mutation; and(ii) a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, a secondary PDGFRA exon 15 mutation, or a secondary PDGFRA exon 18 mutation.
37. The method of claim 31, wherein the GIST comprises:(i) a primary PDGFRA exon 18 mutation; and(ii) a secondary PDGFRA exon 12 mutation, a secondary PDGFRA exon 13 mutation, a secondary PDGFRA exon 14 mutation, or a secondary PDGFRA exon 15 mutation.
38. The method of any one of claims 10-37, wherein the GIST comprises compound mutations selected from double-in-cis mutations or triple-in-cis mutations.
39. The method of claim 38, wherein the GIST comprises:(i) a primary KIT exon 9 mutation; and(ii) at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
40. The method of claim 39, wherein the GIST comprises:(i) a primary KIT exon 9 mutation; and(ii) at least one acquired mutation in KIT exon 13 or KIT exon 14; and (iii) at least one acquired mutation in KIT exon 17 or KIT exon 18.
41. The method of claim 38, wherein the GIST comprises:(i) a primary KIT exon 11 mutation; and(ii) at least one acquired mutation selected from mutations in KIT exon 13, KIT exon 14, KIT exon 17, and KIT exon 18.
42. The method of claim 41, wherein the GIST comprises:(i) a primary KIT exon 11 mutation; and(ii) at least one acquired mutation in KIT exon 13 or KIT exon 14; and (iii) at least one acquired mutation in KIT exon 17 or KIT exon 18.
43. The method of any one of claims 10-42, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, lapatinib, gefitinib, erlotinib, vatlanib, crenolanib, ripretinib, nintedanib, ponatinib, nilotinib, axitinib, cabozantinib, pazopanib, pexidartinib, bezuclastinib, dasatinib, sorafenib, and / or avapritinib, or a pharmaceutically acceptable salt and solvate thereof.
44. The method of claim 43, wherein the subject was previously treated with imatinib, sunitinib, regorafenib, ripretinib and / or avapritinib.
45. The method of claims 43 or 44, wherein the subject was previously treated with imatinib.
46. The method of any one of claims 43-45, wherein the subject was previously treated with sunitinib.
47. The method of any one of claims 43-46, wherein the subject was previously treated with regorafenib.
48. The method of any one of claims 43-47, wherein the subject was previously treated with ripretinib.
49. The method of any one of claims 43-48, wherein the subject was previously treated with avapritinib.
50. The method of any one of claims 10-49, wherein the GIST is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of imatinib, administration of sunitinib, administration of regorafenib, administration of ripretinib and / or administration of avapritinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib, ripretinib, and / or avapritinib.
51. The method of any one of claims 10-50, wherein the GIST is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, a first line administration of imatinib, a second line administration of sunitinib, and an optional third line administration of regorafenib or ripretinib, or wherein the subject has a documented intolerance to one or more of imatinib, sunitinib, regorafenib and / or ripretinib.
52. The method of claim 51, wherein the GIST comprises a KIT exon 8 mutation, a KIT exon 9 mutation, a KIT exon 10 mutation, a KIT exon 11 mutation, a KIT exon 13 mutation, a KIT exon 14 mutation, a KIT exon 17 mutation, or a KIT exon 18 mutation, wherein, the GIST comprises a KIT exon 9 mutation selected from the group consisting of:(i) p.A502_Y503dup, p.Y503_F504insAY, and p.S464L;(ii) a KIT exon 11 mutation selected from the group consisting of deletions involving codons 557 / 558, deletions upstream of codons 557 / 558, deletions downstream of codons 557 / 558, and deletions affecting codons 557 / 558; (iii) a KIT exon 13 mutation selected from K642E, V65A, and T670I; or (iv) a KIT exon 17 mutation selected from mutations involving codons 816, 820 or 823.
53. The method of any one of claims 10-52, wherein the GIST is an advanced gastrointestinal stromal tumor that has progressed from, or the subject was intolerant to, administration of avapritinib, or wherein the subject has a documented intolerance to avapritinib.
54. The method of claim 53, wherein the GIST comprises a PDGFRA exon 12 mutation, a PDGFRA exon 13 mutation, a PDGFRA exon 14 mutation, a PDGFRA exon 15 mutation, or a PDGFRA exon 18 mutation, wherein the PDGFRA exon 12 mutation is selected from the group consisting of p.W559_R560del and p.P581S; or a PDGFRA exon 18 mutationselected from the group consisting of p.D842_M84del, p.D842_I843delinsV, and p.D842V.
55. The method of any one of claims 7-54, wherein the cancer comprising a KIT mutation is acute myeloid leukemia (AML), chronic myelogeneous leukemia (CML), sinonasal natural killer / T-cell lymphoma, seminoma, melanoma, or mastocytosis.
56. The method of claim 55, wherein the cancer is acute myeloid leukemia (AML).
57. The method of claim 55, wherein the cancer is chronic myelogeneous leukemia (CML).
58. The method of claim 55, wherein the cancer is sinonasal natural killer / T-cell lymphoma.
59. The method of claim 55, wherein the cancer is seminoma.
60. The method of claim 55, wherein the cancer is melanoma.
61. The method of claim 60, wherein the cancer is mucosal melanoma.
62. The method of claim 60, wherein the cancer is cutaneous melanoma.
63. The method of claim 60, wherein the cancer is acral lentiginous melanoma.
64. The method of claim 55, wherein the cancer is mastocytosis.
65. The method of claim 64, wherein the mastocytosis is non-advanced mastocytosis.
66. The method of claim 65, wherein the non-advanced mastocytosis is indolent mastocytosis or systemic smoldering mastocytosis.
67. The method of claim 64, wherein the mastocytosis is advanced mastocytosis.
68. The method of claim 67, wherein the advanced mastocytosis is aggressive systemic mastocytosis, systemic mastocytosis with associated hematologic neoplasm, mast cell leukemia, or mast cell sarcoma.
69. The method of any one of claims 55-68, further comprising co-administering at least one ofimatinib, sunitinib, or regorafenib.
70. The method of any one of claims 55-59, wherein the KIT mutation is an exon 8 mutation, an exon 9 mutation, an exon 11 mutation, an exon 13 mutation, an exon 17 mutation other than a D816V mutation, a D816V mutation, or a combination thereof.
71. The method of any one of claims 7-70, wherein the subject is a human subject.
72. The method of any one of claims 7-71, wherein the compound is for treating a cancer comprising a KIT mutation in a subject in need thereof.
73. The method of any one of claims 7-71, wherein the compound is for preventing a cancer comprising a KIT mutation in a subject in need thereof.
74. The method of any one of claims 7-73, further comprising administering one or more additional therapeutic agents to the subject.
75. The method of claim 74, wherein the one or more additional therapeutic agents comprises topotecan.
76. The method of claim 74, wherein the one or more additional therapeutic agents comprises an irinotecan drug product (IDP).
77. The method of claim 76, wherein the IDP comprises irinotecan.
78. The method of claim 76, wherein the IDP comprises irinotecan hydrochloride.
79. The method of claim 76, wherein the IDP comprises irinotecan sucrosofate.
80. The method claim 76, wherein the IDP further comprises encequidar methanesulfonate.
81. The method of claim 74, wherein the one or more additional therapeutic agents comprises radiotherapy.
82. A method of inhibiting proliferation of a cell comprising a KIT mutation in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound of any one of claims 1-5 to the subject.
